

1           IN THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS  
 2                           COUNTY DEPARTMENT, LAW DIVISION

3	- - - - -	X
4	BOARD OF EDUCATION OF THE	:
5	CITY OF CHICAGO,	:
6		:
7	Plaintiffs,	: NO. 92 L 9934
8		:
9	vs.	: DEPOSITION OF:
10		:
11	A, C AND S, INC., et al.,	: DR. ARTHUR M. LANGER
12		:
13	Defendants.	:
14	- - - - -	X
15	EVANSTON COMMUNITY CONSOLIDATED:	:
16	SCHOOL DISTRICT NO. 65, et al.,	:
17		:
18	Plaintiffs,	: NO. 92 L 9933
19		:
20	vs.	:
21		:
22	A, C AND S, INC., et al.,	:
23		:
24	Defendants.	:
25	- - - - -	X

1           TRANSCRIPT of the Examination Under Oath  
2           of the witness called, in the above-captioned  
3           matter, said deposition being taken pursuant to  
4           Federal Rules of Civil Procedure by and before  
5           BERNADETTE H. MASTRANGELO, a Certified Shorthand  
6           Reporter and Notary Public of the State of New  
7           York, at the law offices of WILSON, ELSER,  
8           MOSKOWITZ, EDELMAN & DICKER, ESQS., 150 East  
9           42nd Street, New York, New York, on Wednesday,  
10          May 31, 1995, commencing at 10:00 a.m.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

## 1       A P P E A R A N C E S:

2               GREITZER & LOCKS, ESQS.,  
3               1500 Walnut Street  
4               22nd Floor  
5               Philadelphia, Pennsylvania 19102  
6               BY: JONATHAN W. MILLER, ESQ.,  
7               Attorneys for the Plaintiffs.

8               STICH, ANGELL, KREIDLER & MUTH, ESQS.,  
9               The Crossings, Suite 120  
10              250 Second Avenue South  
11              Minneapolis, Minnesota 55401  
12              BY: ROBERT D. BROWNSON, ESQ.,  
13              Attorneys for the Defendant, Asbestospray  
14              Corp.

15              PEPPER, HAMILTON & SCHEETZ, ESQS.,  
16              3000 Two Logan Square  
17              Eighteenth & Arch Streets  
18              Philadelphia, Pennsylvania 19103-2799  
19              BY: SUSAN A. KING, ESQ.,  
20              Attorneys for the Defendant, Pfizer Inc.

21              MORGAN, LEWIS & BOCKIUS, ESQS.,  
22              2000 One Logan Square  
23              Philadelphia, Pennsylvania 19103-6993  
24              BY: DENNIS J. VALENZA, ESQ.,  
25              Attorneys for the Defendant, United States  
                Gypsum & Company.

                W.R. GRACE & CO.,  
                One Town Center Road  
                Boca Raton, Florida 33486-1010  
                BY: RICHARD A. SENFTLEBEN, ESQ.,  
                Attorneys for the Defendant, W.R. Grace & Co.

                BURKE, WEAVER & PRELL  
                Xerox Centre  
                55 West Monroe Street  
                Chicago, Illinois 60603  
                BY: DANIEL C. COLE, ESQ.,  
                Attorneys for the Defendant, Union Carbide.

                HAYTHE & CURLEY, ESQS.,  
                237 Park Avenue  
                New York, New York 10017  
                BY: CLINTON B. FISHER, ESQ.,  
                Attorneys for the Defendant, T & N plc.

                \* \* \*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

I N D E X

WITNESS	DIRECT	CROSS	REDIRECT	RECROSS
DR. ARTHUR M. LANGER				
By: Mr. Miller				5

E X H I B I T S

IDENT.	DESCRIPTION	PAGE
P-1	Curriculum vitae	14
P-2	Expert witness disclosure	55
P-3	One-page document	98
P-4	Diagram sheet	116
P-5	Cover letter	116
P-6	Report by Dr. Langer	163

REQUESTS FOR INFORMATION	PAGE
Electron micrograph data sheets	123
Air sampling for work sites	139

1       D R.   A R T H U R   M.   L A N G E R, doing  
2               business at Bedford Avenue and Avenue H,  
3               Brooklyn, New York, having been duly  
4               sworn, testified as follows:

5

6       DIRECT EXAMINATION BY MR. MILLER:

7               Q.     Dr. Langer, good morning. My name  
8               is Jonathan Miller. I'm an attorney with the  
9               firm of Greitzer & Locks in Philadelphia. It's  
10              important that you hear and understand  
11              everything that I say today. If you do not hear  
12              me or do not understand me, please stop me and I  
13              will be happy to repeat my question.

14                               Do you understand that, sir?

15       A.     Yes.

16              Q.     I represent two of the three  
17              plaintiffs, and they've consolidated the  
18              asbestos case pending in Chicago. I represent  
19              the Board of Education of the City of Chicago  
20              and a number of suburban district captions,  
21              generally under the title of Evanston.

22                               Do you understand that, sir?

23       A.     Yes.

24              Q.     I understand that you have been retained,  
25              you are an expert consultant for Asbestospray in

DR. LANGER - Direct

1 this case, is that correct?

2 A. Yes.

3 Q. You are also an expert consultant  
4 for another defendant named Conwed in this case,  
5 is that correct?

6 A. Yes.

7 Q. It's my understanding that your  
8 testimony today will focus on your being  
9 consulted by Asbestospray, and so it will  
10 include Asbestospray-specific questions, as well  
11 as general questions about your view, but I will  
12 not go into any Conwed specific questions.

13 MR. MILLER: Is that your  
14 understanding, also?

15 MR. BROWNSON: Jon, so we're clear,  
16 Dr. Langer was obtained by Conwed. As you  
17 know, Conwed is a defendant in District  
18 2007, 211 cases which are being handled by  
19 Elaine Siegel.

20 MR. MILLER: That is another reason  
21 why I am not going to ask anything about  
22 Conwed. Conwed is not a defendant in whom I  
23 have interest. I understand there's a  
24 future date for your deposition with  
25 Ms. Siegel that will focus on Conwed.

DR. LANGER - Direct

1 MR. BROWNSON: Specifically, we made  
2 those arrangements with her.

3 BY MR. MILLER:

4 Q. Doctor, how many times have you  
5 testified in an asbestos property damage  
6 deposition?

7 A. I don't know, maybe a half dozen or so.

8 Q. Have you ever testified in a trial  
9 in an asbestos property damage case?

10 A. Yes.

11 Q. How many times?

12 A. I testified in the West Virginia property  
13 damage case, I may have testified in one other  
14 case, but I'm not sure, maybe several other  
15 cases.

16 Q. At least one of the asbestos  
17 property damage depositions you gave was in a  
18 case for Robert Sweeney on behalf of the  
19 plaintiff, is that correct, sir?

20 A. Yes, that's correct.

21 Q. Aside from that, have all your other  
22 asbestos property damage depositions and trial  
23 testimonies been as an expert consultant by a  
24 defendant?

25 A. That could be true, yes.

DR. LANGER - Direct

1 Q. Approximately, how many times have  
2 you testified in depositions involving asbestos  
3 personal injury cases?

4 A. Several dozen, probably.

5 Q. How many times have you testified at  
6 trials involving asbestos personal injury cases?

7 A. Maybe one dozen, maybe more.

8 Q. How would you divide those  
9 testimonies between an expert consultant by the  
10 plaintiff and expert consultant by the  
11 defendant, sir?

12 A. These are only testimony, correct?

13 Q. Both deposition and trials.

14 A. Just testimony, you're talking testimony,  
15 not consultant?

16 Q. Exactly, just testimony, precisely  
17 right.

18 A. That's an evolution. At the very  
19 beginning, I represented plaintiffs only. Then  
20 an equal number of plaintiffs and defendants;  
21 and as of late, it's mostly defendants.

22 Q. Have you ever testified before the  
23 EPA?

24 A. Yes. Well, I'm just trying to think if  
25 EPA's ever held hearings, which one would

DR. LANGER - Direct

1 testify. Have I? Indirectly.

2 Q. I'm not talking here about the times  
3 that you were a reviewer.

4 A. No, no, I understand the question.

5 Q. Have you ever done such direct  
6 testimony with regard to asbestos?

7 A. Yes, that would be before a committee  
8 hearing on the advisability of passing the Toxic  
9 Substances Control Act. It would be Senator  
10 Tunney's (phonetic) committee.

11 Q. What year was that, sir, that you  
12 testified?

13 A. Could be 1973 or thereabouts.

14 Q. What was the general subject of your  
15 testimony?

16 A. Well, the sources of fiber which may enter  
17 into the environment.

18 Q. You were still --

19 A. I'm sorry, that's all right. Ask your  
20 question.

21 Q. You were still at Mount Sinai at  
22 that time?

23 A. Yes.

24 Q. Were you testifying on behalf of any  
25 particular group?

DR. LANGER - Direct

1 A. No.

2 Q. That's the only time you've  
3 testified directly or indirectly regarding the  
4 EPA, is that correct, sir?

5 A. Well, this is my recall, but there may  
6 have been other instances in which testimony was  
7 then used by the Environmental Protection  
8 Agency, such as testimony before OSHA.

9 Q. How many times have you testified  
10 before OSHA with regard to asbestos?

11 A. I think three times, two or three times,  
12 something like that.

13 Q. Please tell me the years and the  
14 subject matter of each one.

15 A. Well, the foremost that is easy to recall  
16 is the last piece of testimony which focused  
17 on -- well, what was the year? The years 19 --  
18 1991 or thereabouts, '90, '91.

19 Q. It concerned what, sir?

20 A. It concerned the subject of whether or not  
21 OSHA should remove cleavage fragments from the  
22 asbestos standard.

23 Q. Your position was, in summary, what?

24 A. Cleavage fragments were different from  
25 asbestos fibers. Experimental data indicated

DR. LANGER - Direct

1 that they had a much, much reduced  
2 carcinogenicity, and they should be removed from  
3 the asbestos standard.

4 Q. Did OSHA so remove them?

5 A. Yes.

6 Q. Was that in the 1994 regulations?

7 A. Which?

8 Q. The asbestos regulations that came  
9 out in August of 1994?

10 A. Well, the -- yeah. I mean, all of these  
11 are published in the Federal Register. These  
12 are all public documents. You can read them  
13 yourself and find out what the outcome was, but  
14 they did effectively remove cleavage fragments  
15 from the standard.

16 Q. 1990 testimony, were you testifying  
17 on behalf of any organization?

18 A. I was testifying on behalf of my own  
19 laboratory. We had provided data which were  
20 collected during the support from the Vanderbilt  
21 Tagging Company, but we represented ourselves.

22 When I say "we," that's Langer, Nolan  
23 who testified. He's the associate director of  
24 my crew, and John Addison from the Institute of  
25 Occupational Medicine in Edinburgh.

DR. LANGER - Direct

1 Q. Is this the second time you  
2 testified before OSHA?

3 A. Yes, that would be the hearings held in  
4 19, I think, 84.

5 Q. Have those hearings led up to the 1986  
6 OSHA asbestos regulations?

7 A. Yes.

8 Q. What was the general subject of your  
9 testimony in those hearings?

10 A. Well, I wrote a document which was  
11 submitted as supporting a documentation  
12 concerning the nature of asbestos fibers and  
13 whether or not certain materials should be  
14 included in the standards.

15 Q. Was that testimony on behalf of any  
16 organization?

17 A. No. Actually, it was on behalf of the  
18 Department of Labor. We were asked to -- we, my  
19 colleagues and I at Mount Sinai, were asked to  
20 generate a number of documents which were to be  
21 used as the underpinning support for OSHA  
22 asbestos regulations.

23 Q. Is there a possibility of a third  
24 time you testified before OSHA?

25 A. I seem to recollect that in the late '70s

DR. LANGER - Direct

1 I appeared before one of the hearing committees  
2 with Irving Selikoff.

3 Q. Do you remember the general subject  
4 of that testimony?

5 A. No, I think it was general mineralogy.  
6 That was my expertise, and that was why I was  
7 present. I appeared with Irving Selikoff. That  
8 was my expertise, mineralogy.

9 Q. Okay. Are there any other Federal  
10 government organizations that you have appeared  
11 before in giving testimony before, sir?

12 A. Here in the United States?

13 Q. Yes, sir.

14 A. Yes, I appeared before the Consumer  
15 Products Safety Commission.

16 Q. What year was that?

17 A. 1989, perhaps, 1990, something like that.

18 Q. What was the general subject of your  
19 testimony then?

20 A. I appeared as an expert for the Consumer  
21 Product Safety Commission. The issue at that  
22 time was a carbonate place, and in whether or  
23 not this material was contaminated with asbestos  
24 fiber.

25 Q. So, that's the only time you

DR. LANGER - Direct

1 appeared before them?

2 A. Yes.

3 Q. Any other Federal government  
4 testimony appearances in this country that you  
5 can recall at this time?

6 A. I can't recall.

7 Q. Have you ever testified before any  
8 State or local legislature or municipal or  
9 governing bodies in Illinois?

10 A. In Illinois?

11 Q. Yes, sir.

12 A. No.

13 MR. MILLER: Okay. Exhibit 1,  
14 please.

15 (P-1, Curriculum Vitae, received and  
16 marked for Identification.)

17 Q. Dr. Langer, marked as Exhibit 1 is  
18 a copy of your CV. This copy of your CV has  
19 materials going up through 1994, has numbered  
20 pages through page 43, and then additional pages  
21 called funding source.

22 Is this the most up-to-date copy of  
23 your CV, sir?

24 A. Well, it's reasonably up-to-date, yes.

25 Q. Please tell me if there are any

DR. LANGER - Direct

1 items that should be added to it in any of the  
2 categories.

3 A. As an example, I attended a conference at  
4 Pennsylvania State University last week and  
5 presented a paper on modification of chrysotile  
6 fiber and biological activity. It was called a  
7 Goldschmidt Conference. It was held under the  
8 auspices of the Mineralogical Society of the  
9 American -- the Mineralogical Society of  
10 America, and the Geochemical Society, among  
11 others.

12 Q. Anything else which should be added  
13 to Exhibit 1?

14 A. I don't know. I would have to examine it  
15 in detail.

16 Q. How about in terms of peer-reviewed  
17 articles, are there any that have appeared more  
18 recently than your last one, which is on Page  
19 16, and it's your New York City article with Dr.  
20 Wilson, et al.?

21 A. No. I don't think so.

22 Q. Okay. Are there any more recent  
23 publications under symposium proceedings?

24 A. I think that is current. It looks  
25 current.

DR. LANGER - Direct

1 Q. Are there other publications and  
2 published abstracts?

3 A. No, we have two abstracts that were  
4 published in proceedings of the Goldschmidt  
5 Conference, and we have a paper which has been  
6 submitted to -- as soon-to-be-published text on  
7 Occupational Environmental Medicine, a chapter  
8 in the book.

9 Q. What is your chapter on, sir?

10 A. It's on mineralogy, the nature, the  
11 materials to which workers are exposed in the  
12 workplace.

13 Q. Who's the editor on that book?

14 A. Phillip Harber, from Los Angeles.

15 Q. Do you know which publishing company  
16 will be publishing the book?

17 A. Not offhand.

18 Q. Do you know how soon it will be  
19 published?

20 A. I think publication is about as imminent,  
21 as they say.

22 Q. Good.

23 Do you have any other peer-  
24 reviewed articles or other types of publications  
25 in which publication is imminent, namely, before

DR. LANGER - Direct

1       October?

2       A.     No.

3           Q.     On Page 30, you have a list of  
4       manuscripts and preparation.

5                   Are they still in preparation or --

6       A.     Preparation changes with time because  
7       there is the famous item, crocidolite paper,  
8       that's on the back burner because I don't have  
9       time to do it. The tremolite dust is exactly  
10      the same. It's just the data there. The fibers  
11      in human lungs of an exposed worker, that is all  
12      done, and that has to be written up. The  
13      surface mechanisms and the anion transport  
14      paper, that is up to Nolan to write up. He has  
15      pretty much a draft worked out.

16                   Basically these papers are in  
17      preparation, meaning the data are in the  
18      laboratory and they are in the process of being  
19      written up.

20                   Yes, they're all pretty much  
21      manuscripts and preparation -- work in preparation.

22           Q.     The last two manuscripts in  
23      preparation are on the top of Page 31, and they  
24      both concern asbestos bodies.

25      A.     Correct.

DR. LANGER - Direct

1 Q. If I were to ask you your general  
2 opinions about asbestos bodies, particularly as  
3 indices in the disease risk, would you be able  
4 to tell me even though the manuscripts are not  
5 published?

6 MR. BROWNSON: That's a yes or no  
7 question.

8 A. Would I be willing?

9 Q. Would you tell me your opinions?

10 A. Only if you're decent to me today; yes, of  
11 course.

12 Q. What are your opinions, Doctor,  
13 about asbestos bodies as indices of disease  
14 risk?

15 MR. BROWNSON: Well, this is a vague  
16 and general question, and I object to it  
17 on that basis, but to the extent you can  
18 answer, go ahead.

19 A. The asbestos body has been used as a  
20 marker of exposure, as an early marker of  
21 exposure. It has -- the asbestos body has  
22 evolved in time in terms of nomenclature and  
23 specificity. The asbestos body, depending on  
24 occupation, is an index of exposure to fibers,  
25 generally, and on the basis of my work,

DR. LANGER - Direct

1 following various groups of individuals, there  
2 is a quantitative and proportional trend which  
3 indicates that among workers that are intimately  
4 involved with asbestos-containing products,  
5 their asbestos body concentration tends to be  
6 high, and the prevalence among that population  
7 tends to be universal. Meaning, an insulation  
8 worker who works in cramped spaces exposed to  
9 aerosols of asbestos-containing products, all  
10 asbestos workers have what we call asbestos  
11 bodies in pulmonary tissues, and concentrations  
12 tend to be very high.

13 My data showed that the shipyard  
14 worker population tends to be lower in  
15 prevalence, meaning, only 75 or 80 percent of  
16 shipyard workers have what appear to be asbestos  
17 bodies in their pulmonary tissues, and that the  
18 concentrations of these are very much less than  
19 present -- are present if the insulation worker  
20 that is followed by a group that we call  
21 construction workers, that I called construction  
22 workers, in which the prevalence, again,  
23 decreases, and numerically, the quantities  
24 decrease.

25 This is followed by a number of

DR. LANGER - Direct

1 other occupations which deal with automotive  
2 trades, mechanics, brake maintenance and repair  
3 workers, and this is followed by white-collar  
4 workers, in general, and then followed by  
5 white-collar housewives who have never been  
6 engaged in work outside of their own home,  
7 followed by neonatal deaths.

8 So, there is discontinuum, and the  
9 asbestos body is, according to our technique,  
10 and the technique, of course, was light  
11 microscopy and the certain volume of tissue  
12 waves analyzed according to a certain  
13 technique. So, the asbestos body is a rough  
14 index of "exposure," and, of course, there's all  
15 these other embellishments, meaning that there  
16 are variables and confounders and so on and so  
17 forth.

18 Q. Did you find asbestos bodies in the  
19 cases of neonatal deaths?

20 A. No.

21 Q. Did you find asbestos bodies in the  
22 case of the white-collar housewife who never  
23 worked outside the home?

24 A. Approximately 30 percent of these women  
25 had what appeared to be asbestos bodies in their

DR. LANGER - Direct

1 tissues. They tended to occur numerically,  
2 according to our protocol, maybe one or two  
3 asbestos bodies per unit volume of tissue.

4 Q. Did you find asbestos bodies in  
5 white-collar workers?

6 A. Approximately 40, 45 percent. Again,  
7 there were very few, maybe one or two or three.

8 Q. Have you reached any conclusions  
9 from this body data that you just summarized?

10 MR. BROWNSON: Again, I'll object to  
11 the form of the question as vague, but go  
12 ahead.

13 A. What have I concluded? I have concluded  
14 that the asbestos body is a gross index of  
15 exposure to mineral fiber, that shipyard workers  
16 and construction workers appear to be exposed to  
17 higher levels of fiber than others in the  
18 working populations in the United States.  
19 Whether or not risk can be determined on the  
20 basis of asbestos bodies is more problematic and  
21 I'm not sure it's possible.

22 Q. If you do not find asbestos bodies  
23 in the lungs of the person who has died, can you  
24 then conclude that that person did not have an  
25 asbestos-related disease?

DR. LANGER - Direct

1 A. You're talking to me as a mineralogist,  
2 not as a pathologist?

3 Q. Based on your experience, either in  
4 mineralogy or if you wish to opine on pathology,  
5 let me know.

6 MR. BROWNSON: I'll state for the  
7 record that we're not going to opine about  
8 pathology because he's not a pathologist.

9 Q. Well, limited to mineralogy, if  
10 you're comfortable to, then?

11 A. Sure.

12 Q. Do you know the question, sir?

13 A. Not only do I know the question, I know  
14 the answer.

15 Q. May I have the answer, please?

16 A. As you know, there is a spectrum of  
17 "asbestos diseases." The mesotheliomas,  
18 meaning the sites, the multiple sites in which  
19 mesothelioma occurs, lung cancer, and cancer of  
20 other sites, and, of course, asbestosis.

21 Now, there are some who believe that  
22 the asbestos body is a necessary marker for each  
23 and every one of those diseases. I, personally,  
24 believe that one should look for uncoated fibers  
25 rather than asbestos bodies. In that sense, the

DR. LANGER - Direct

1 asbestos body is a more -- I guess the right  
2 word is a more coarse index of exposure.

3 Q. Are you aware of any person who had  
4 mesothelioma, who, upon appropriate examination,  
5 was not found to have had uncoated fibers in  
6 their body?

7 MR. BROWNSON: I'll object to the  
8 form of the question.

9 Are you talking about his  
10 examination or --

11 Q. I'll start with your examination.

12 A. My experience?

13 Q. Yes, sir, your experience.

14 A. Have I ever found a mesothelioma without  
15 asbestos fiber in the pulmonary tissues?

16 Q. Yes.

17 A. Yes.

18 Q. How many times did that happen?

19 A. We're talking about asbestos. This means  
20 even below what I would anticipate as  
21 background?

22 Q. Yes, sir.

23 A. Perhaps twice.

24 Q. Okay. Did you reach any conclusion  
25 regarding the cause of the mesothelioma in those

DR. LANGER - Direct

1 two cases?

2 A. Other than unrelated to asbestos, no.

3 Q. Going back to your CV, on Page 3 you  
4 state that you were a fellow with the Collegium  
5 Ramazzini, and elected a fellow in 1983?

6 A. Correct.

7 Q. What is the Collegium Ramazzini,  
8 sir?

9 A. Collegium Ramazzini was an organization  
10 which came into being through the efforts of  
11 Irving Selikoff and a number of other  
12 individuals, and came about because of the  
13 perceived time lag between research in areas  
14 affecting occupational health, "the publication  
15 of seminal papers," put that in quotes, in the  
16 peer-reviewed literature and the implementation  
17 of those data to ameliorate conditions which  
18 might have been dangerous in the workplace.

19 There was a perceived need to bring  
20 together scientists from around the world  
21 working on these peculiar problems and to use  
22 these new findings to better understand problems  
23 of the workplace and to bring about change in  
24 perceived hazards.

25 Q. When was the Collegium formed?

DR. LANGER - Direct

1 A. You mean, when was it incorporated?

2 Q. Yes, sir.

3 A. I don't really know. I'm thinking out  
4 loud. That's a good question to ask Shelly  
5 Samuels. Perhaps 1981, '82, something like  
6 that. It's about that time.

7 Q. Have you been a member since it was  
8 incorporated?

9 A. Yes.

10 Q. After you left Mount Sinai, which  
11 was in 1988, is that correct, Doctor?

12 A. Correct.

13 Q. Have you kept up with Collegium  
14 Ramazzini in terms of doing anything with regard  
15 to it?

16 A. No.

17 Q. Did you attend the conference known  
18 as the Third Wave, here in New York City?

19 A. No.

20 Q. Why not?

21 A. I don't know.

22 Q. Were you invited?

23 A. No.

24 Q. Did you ask somebody if you could  
25 go?

DR. LANGER - Direct

1 A. No.

2 Q. Did you know that you could attend  
3 simply by paying an admission fee?

4 A. That, I'm certain of.

5 Oh, that tickles me.

6 Q. The general subjects discussed at  
7 that conference appear to me, as a mere layman,  
8 to have had some relevance to work that you have  
9 done for many years, and I wondered, given that,  
10 why you didn't attend.

11 A. I can't for the life of me think why. I  
12 could have been out of town that week.

13 When was it, anyway?

14 It was sometime in 1991. I really  
15 do believe I had commitments elsewhere, as a  
16 matter of fact.

17 MR. FISHER: June 1991.

18 Q. Doctor, I've handed you a book which  
19 is titled: "The Third Wave Of Asbestos Disease:  
20 Exposure To Asbestos In Place Public Health  
21 Control," published by the New York Academy of  
22 Sciences in 1991.

23 Have you ever had an occasion to  
24 review this book?

25 A. To review it?

DR. LANGER - Direct

1 Q. To read any of the papers in it?

2 MR. BROWNSON: You mean, as a peer  
3 reviewer?

4 Q. No, to read it.

5 A. Oh, have I read some papers in it?

6 Q. Yes, sir.

7 A. Yes, of course.

8 Q. Okay. Do you have any opinions  
9 about the usefulness in your work of any of the  
10 papers that were represented in here?

11 MR. BROWNSON: Well, again, that's a  
12 general and vague question. I'll object  
13 to the form of the question on that basis,  
14 but it's a thick book.

15 Are those papers useful in your  
16 work, is that the question?

17 MR. MILLER: I think so.

18 A. Well, I have to translate what you mean by  
19 "useful."

20 Do I occasionally cite papers that  
21 are in that volume? Yes.

22 Q. Okay. Which papers, if you recall,  
23 have you cited in this volume?

24 A. Do you want to go through the volume with  
25 me?

DR. LANGER - Direct

1 Q. Yes, sir, just the table of contents  
2 would be sufficient, I think.

3 A. You want to know what I've read in here or  
4 what I cited, what I've quoted?

5 MR. BROWNSON: Well, let's get the  
6 question in mind.

7 THE WITNESS: Well, let's start  
8 with --

9 MR. BROWNSON: Whoa, let's hear the  
10 question.

11 Are you asking him papers he has  
12 cited in his publications?

13 MR. MILLER: Yes.

14 MR. BROWNSON: That seems to be the  
15 question.

16 Q. That's correct.

17 A. Which of the papers that I, myself, have  
18 read that I've cited and found of interest?

19 Well, the very first paper, the one  
20 by Selikoff and Seidman on "Asbestos-associated  
21 deaths among insulation workers in the United  
22 States and Canada," that has the most recent  
23 data on the national survey. Very interesting.

24 I've read the paper on the  
25 "Carcinogenicity of chrysotile asbestos:

DR. LANGER - Direct

1 evidence from cohort studies." A paper by  
2 Dement. That has some interesting chrysotile  
3 commentary in it and other interesting features.

4 The third paper I have quoted, this  
5 is the paper by Kohyama and Suzuki, "The  
6 analysis of asbestos fibers in lung parenchyma."  
7 That's also of interest.

8 I've also read the fourth paper,  
9 which is Ron Dodson's paper, and colleagues, "A  
10 comparison of asbestos burden in lung parenchyma."

11 I've read this paper, the fifth  
12 paper, as well, which is Baker's paper, on the  
13 "Limitations in drawing etiologic inferences  
14 based on measurement of asbestos fibers from  
15 lung tissue." I've read that, too.

16 MR. BROWNSON: Wait a minute. Now,  
17 you're asking as to papers you read. I  
18 think the question was papers you cited.

19 MR. MILLER: I appreciate the way  
20 the doctor is doing it. It's making time  
21 shorter. I wish he'd continue that way.

22 MR. BROWNSON: The only thing I was  
23 going to say is let's continue with the  
24 answer to the question of papers you've  
25 cited in your publications, and if you want

DR. LANGER - Direct

1 to note whether you've read it from  
2 something or not, I think you can do that,  
3 that's fine. I don't want to get the  
4 answer confused with the question.

5 MR. MILLER: I appreciate that the doctor  
6 is being very clear, as he always is in  
7 his answers, about which he has read, and  
8 in addition to which of those he has read,  
9 he has also cited, and I wish he would  
10 continue that same way. I think that's  
11 good.

12 MR. BROWNSON: Okay, fine. I want  
13 to make clear as to what we're doing  
14 here.

15 A. I will state which papers I've read and,  
16 for example, the Kohyama paper, the Dodson  
17 paper, the Baker paper are referenced in the  
18 manuscript that I'm generating now on asbestos  
19 fibers in 83 cases in the United States.

20 The Dose-Response papers,  
21 Nicholson's papers on "Comparative dose-response  
22 relationships with asbestos fiber types," I've  
23 read that. I haven't quoted anywhere as yet.

24 I've read Murray Finkelstein's paper  
25 on exposure response relationship with

DR. LANGER - Direct

1       mesothelioma among the cement workers in  
2       Canada.

3                   I've read the paper on the  
4       radiographic abnormalities by Christine  
5       Oliver and colleagues. I've read that but I  
6       haven't quoted it anywhere.

7                   I've read the paper by Sluis-Cremer,  
8       "Asbestos disease at low exposure after long  
9       residence times." I haven't quoted that anywhere,  
10      either.

11                  I've read Friedrich Potts' paper,  
12      "The neoplastic findings in experimental  
13      asbestos studies," which is very interesting,  
14      but I haven't used that as yet.

15                  I've read Suzuki's paper of  
16      "Comparability of mesothelioma in humans and in  
17      experimental animal studies." I have not quoted  
18      that, as well.

19                  The experimental studies, I've read  
20      the study of Raymond Begin, "The asbestosis in  
21      sheep."

22                  I've read Marie-Claude Jaurand's  
23      papers, "The observations of carcinogenicity of  
24      asbestos fibers."

25                  I have read Landrigan's paper on the

DR. LANGER - Direct

1 children at risk. I haven't quoted that anywhere  
2 as yet.

3 I've read Mancuso's paper on  
4 "Mesotheliomas among railroad workers."

5 I've read Jacques Ruttner's paper,  
6 "Mesothelioma in Swiss railroad workers."

7 I've read this paper by Seidman and  
8 Selikoff. Lou Joubert as a single part, I don't  
9 know why.

10 "Mortality experience and family  
11 contacts of asbestos factory workers," I've read  
12 that, as well.

13 I read "Asbestos in lungs of  
14 children." This, again, comes out of Ron  
15 Dodson's group. It's an interesting paper. I  
16 don't know what it means, though.

17 I've read the paper, "Pleural  
18 plaques in the general population," Hillerdal's  
19 paper. I haven't used that in any paper.

20 I've read the paper by Boutin, and  
21 "Pleural effects of environmental asbestos  
22 pollution in Corsica."

23 I've read David Lilienfeld's paper,  
24 "Asbestos-associated pleural mesothelioma in  
25 school teachers." I haven't used that in

DR. LANGER - Direct

1 anything.

2 I've read Jack Harington's paper on  
3 "The carcinogenicity of chrysotile asbestos."

4 I've read John Davis' paper on  
5 "Variations in the carcinogenicity of  
6 tremolite."

7 I've read Bruce Case's paper on  
8 "Health effects of tremolite: Now and in the  
9 future." I haven't used that, as well.

10 I have read "Asbestos exposure from  
11 activities in buildings with asbestos-containing  
12 materials," by Keyes and Jim Millette.

13 I read the "Mineral fiber contents  
14 of lung tissue in patients with environmental  
15 exposures." That's the paper by Roggli and  
16 Longo. I haven't used those.

17 I read the paper by Christine Oliver  
18 on maintenance workers.

19 I've read the paper by Levin and  
20 Selikoff on radiological abnormalities.

21 I think I reviewed John Balmes'  
22 paper. The original paper was submitted to the  
23 Peer Review Journal, so I did not review it  
24 here.

25 I read Henry Anderson's paper on

DR. LANGER - Direct

1       "**Mesothelioma** among employees with likely  
2       contact with in-place asbestos-containing  
3       building materials."

4                   I have just about looked at every  
5       paper in here. I mean, whether I've read them  
6       all in detail or not, is more problematic, but  
7       those are the ones that I've read or looked  
8       over.

9           Q.       Thank you, Doctor.

10                   Do you have a general opinion about  
11       the breadth or scope of the people who submitted  
12       papers that are in the Third Wave?

13                   MR. BROWNSON: I'll object to the  
14       form of the question.

15                   What do you mean, "the breadth or  
16       scope of the people"?

17           Q.       Do you believe that the people who  
18       submitted papers are all plaintiff-oriented  
19       experts in asbestos-oriented litigation?

20       A.       I have no idea.

21           Q.       Do you respect the scientific work  
22       of some, at least, of the people who submitted  
23       papers in the Third Wave?

24       A.       Sure.

25           Q.       Is it fair to say that you respect

DR. LANGER - Direct

1 the scientific work of those people whose papers  
2 you have just said you cited in your own work?

3 A. That doesn't necessarily follow.

4 Q. Who are the people whom you just  
5 mentioned as having read, and in some cases  
6 cited whose work you respect?

7 If you would like the book back to  
8 look at the index again.

9 MR. BROWNSON: I'm going to object  
10 to the form of the question. If you're  
11 asking him does he -- first of all, I  
12 object to the form of the use of the term  
13 "respect."

14 Secondly, when you say "respect the  
15 work," you're not limiting it to the work  
16 which comprises those papers. So I think  
17 the form of the question is objectionable.

18 That being said, you can attempt to  
19 answer the question.

20 A. Well, one of my concerns is that it's --  
21 when you say "respect," there are words written  
22 on Page 1, accepts or rejects. It's one on Page 1  
23 that reads the data, how old the data derived  
24 are, these data, robust data, are these data  
25 weak data, are there conclusions in keeping with

DR. LANGER - Direct

1 the data presented, is this a contribution to  
2 the field, is it just a rehash of old materials,  
3 and so on and so forth. I mean, you could read  
4 papers and read them different ways.

5 Do I respect the people? I mean,  
6 some people I respect, some I don't respect, but  
7 you have to take each individual contribution  
8 and read it with a fresh eye.

9 Selikoff -- I cannot think of any  
10 group in the world that has reproduced the work  
11 that Selikoff, Hammond, Seidman, et al.,  
12 produced in terms of the insulation workers.  
13 They stand on -- without peer, or peers, sure,  
14 wonderful work, great work.

15 Q. Are there any other papers in this  
16 Third Wave that you would say are contributions  
17 to the field?

18 A. Well, I happen to like the paper by  
19 Kohyama and Suzuki, because it is the first work  
20 to come out of Mount Sinai that shows that  
21 insulation workers were exposed to crocidolite.  
22 I thought that was first-rate.

23 There are others like that. I've  
24 considered John Harington -- Jack Harington as  
25 one of the more brilliant and insightful

DR. LANGER - Direct

1 investigators in the field. I mean, there are  
2 lots of people out there.

3 Q. Doctor, are you familiar with a book  
4 called the "The Identification and Control of  
5 Environmental & Occupation Diseases, Asbestos  
6 and Cancer," edited by Ira Mehlman and Arthur  
7 Upton. I'm showing you the book now.

8 A. No.

9 Q. Do you know anything at all about  
10 this book?

11 A. No. Can I look at it?

12 Q. Certainly.

13 A. Oh, my goodness, this has finally come  
14 out. Isn't that something. This was in the  
15 works for about 10 years.

16 Q. Are you familiar with some of the  
17 papers in that on a pre-publication basis?  
18 You're looking at a picture of Dr. Selikoff. I  
19 don't mean to interrupt you.

20 A. Quite a guy.

21 I'm sorry, what was that question  
22 pending?

23 Q. Are you familiar with any of the  
24 papers that appeared in this book on a  
25 pre-publication basis?

DR. LANGER - Direct

1 A. No.

2 MR. MILLER: Off the record.

3 (Whereupon a discussion is held off  
4 the record.)

5 Q. Dr. Langer, moving on with your CV,  
6 reference Page 5, that you worked with the EPA in  
7 the Orange, Purple and Blue Books.

8 Did you have any connection with the  
9 Green Book?

10 A. No. Neither Green Book -- either Green  
11 Book.

12 Q. I am speaking about what I believe  
13 you had called the second Green Book.

14 A. 1990?

15 Q. Yes, sir.

16 A. No.

17 Q. Okay. Why not?

18 A. Why not what?

19 Q. Why didn't you have a connection  
20 with the Green Book, given that you had a  
21 connection with three prior rainbow books that  
22 in some ways led up to it?

23 A. No one asked me.

24 Q. How would you describe your  
25 contribution or your status with the three prior

DR. LANGER - Direct

1 books as the peer-reviewing consultants or what  
2 would you use for either one of them?

3 A. Both, basically.

4 Q. Each of the three books?

5 A. Each of the three books.

6 The Orange Book, I wrote a section  
7 in one of the appendices with Arthur Rohl and  
8 Ann Weill (phonetic). Arthur Rohl and I were at  
9 Mount Sinai at the time, Ann Weill at the  
10 University of Maryland. And we wrote on the  
11 identification and characterization of asbestos  
12 in bulk asbestos-containing products found in  
13 buildings. We wrote that section.

14 I also reviewed part of the document  
15 which meant read over certain sections, and I  
16 was asked in the Purple Book, in the Blue Book,  
17 I was one of the committee members when we put  
18 these documents together.

19 Q. On Page 9 of your CV, under the  
20 heading "Consultants," it refers to you being a  
21 consultant for Safe Building Alliance, asbestos in  
22 buildings, 1987.

23 Was that the symposium held at  
24 Harvard University, sir?

25 A. No.

DR. LANGER - Direct

1 Q. What was that consulting about,  
2 please?

3 A. I met with John Welch, in Washington.  
4 John Welch, he was the president of the Safe  
5 Building Alliance, and we discussed certain  
6 problems that they perceived with  
7 asbestos-containing materials in buildings.

8 Q. Did you write any document for the  
9 SBA?

10 A. No.

11 Q. Do you know if your views were  
12 reflected in any SBA publication?

13 A. There probably are, but when you say my  
14 views, they are not so unique as to be easily  
15 recognizable as having my imprimatur;  
16 many people think the way I do, concerning  
17 asbestos products in buildings.

18 Q. Okay. Who were some of those people  
19 whom you would say think the way you do  
20 concerning asbestos products in buildings?

21 MR. BROWNSON: Now, there's a vague  
22 and general question, but I'm assuming it  
23 will lead to --

24 MR. MILLER: Assuming I'm responding  
25 exactly to what he said.

DR. LANGER - Direct

1 MR. BROWNSON: I'm sure you are.  
2 I'm objecting to the form of the question,  
3 and we'll proceed from there.

4 THE WITNESS: I'm sorry?

5 MR. BROWNSON: Go ahead, proceed,  
6 and tell us who the people are who think  
7 as you do.

8 A. As an example, the generic paper which  
9 appeared in Science; Mossman, Gee, Corn, Bignon,  
10 others like that.

11 Q. Can you think of the names of any  
12 others at this time?

13 A. Who, what, who think the way I do?

14 Q. Yes, sir.

15 MR. BROWNSON: I assume you're  
16 limiting the question to researchers in  
17 the field and not men on the street?

18 MR. MILLER: I'm limiting it to any  
19 way that Dr. Langer meant it, though I  
20 assume he meant the researchers in the  
21 field as opposed to the average dumb  
22 lawyer on the street.

23 A. Not so dumb.

24 Those in the field, if we were to  
25 approach this problem as it should be

DR. LANGER - Direct

1       approached, the Mossman article, or articles,  
2       because there was another article which appeared  
3       in, I guess, the New England Journal of  
4       Medicine, Mossman & Gee, they are responsible  
5       for bringing to the United States that which  
6       already existed elsewhere in other countries.

7             Q.       That is what, sir?

8       A.       That is that low-level exposure to mineral  
9       fiber, such as fibers in buildings, represents a  
10      very small risk of developing the asbestos  
11      diseases.

12                    Now, when we talk about the  
13      individuals who would support this, I would  
14      think that the following individuals in, let's  
15      say Europe, Richard Doll, Julian Peto, Chris  
16      Whamel, Allan Gibbs, Jean Bignon, Molly  
17      Newhouse, Lorenzo Simonato.

18                    I served on a committee with John  
19      Gillson, and of course, Gillson passed  
20      away, for the regenerated document in Hanover,  
21      Germany, for the international program for  
22      chemical safety on asbestos fibers in the  
23      ambient environment, and presented really a  
24      European view of the importance, or lack of  
25      importance of fibers in the ambient

DR. LANGER - Direct

1 environment.

2 There are a number of others in  
3 Europe. The general consensus among the  
4 scientists working in the field was that the  
5 focus on asbestos in buildings in North America  
6 was misplaced. The others who also feel this  
7 way presented their views for the Ontario Royal  
8 Commission. That is part of the Dupres report  
9 on fibers and buildings in Ontario.

10 Q. I'm familiar with a report that was  
11 done at the Ontario Royal Commission. I am not  
12 used to the Dupres report.

13 Is there only one Ontario report?

14 A. Yes. Stefan Dupres is the senior  
15 committee member.

16 Q. Okay.

17 A. Stefan.

18 MR. BROWNSON: Be careful, try not  
19 to talk when Jonathan's talking because  
20 our reporter here does not like that.

21 MR. MILLER: I was equally at fault.

22 Q. Doctor, who in the United States  
23 feels this way, the way you just described the  
24 certain Europeans, and now certain people who  
25 took part in the Ontario Commission field in the

DR. LANGER - Direct

1 asbestos in buildings?

2 MR. BROWNSON: Again, I'm posing an  
3 objection. I assume you're referring to  
4 researchers in the field?

5 MR. MILLER: Of course.

6 A. Brook Mossman, Morton Corn, Bernard Gee,  
7 certainly the people who work with me, Robert  
8 Nolan, Marvin Kuschner, Richard Wilson, Jack  
9 Spengler. A number of others have been at the  
10 Harvard School of Public Health.

11 Robert Sawyer, I'm thinking Jerry  
12 Kliaman as a pathologist. I believe he also  
13 supports this view. There are others, and I  
14 don't know why I'm blocking them, but there are  
15 many others who support this.

16 Q. Doctor, we started this particular  
17 part of the discussion by starting with your  
18 reference to people who think the way you do  
19 about asbestos in buildings.

20 Will you please tell us, summarize  
21 for me how you feel or believe, how you think  
22 about asbestos in buildings?

23 A. I don't think about it. One of my  
24 opinions concerning asbestos in buildings is --  
25 you want to know all of my opinions or just

DR. LANGER - Direct

1 general, just a little brush stroke?

2 Q. If you could summarize your opinions  
3 in asbestos in buildings, that would be good,  
4 sir.

5 A. Asbestos in presence in buildings are in a  
6 number of forms. Each of these forms serve some  
7 function and purpose. Some of these functions  
8 and purposes are very important. The presence  
9 of asbestos-containing products in buildings  
10 need not indicate the presence of asbestos fiber  
11 in the air.

12 The levels of fibers found in  
13 buildings, now many hundreds of buildings and  
14 thousands of air samples, have demonstrated that  
15 in the very large majority of these buildings,  
16 the fiber levels in air, if found in air, the  
17 fiber levels, even using the most pessimistic  
18 risk model, represents de minimis risks to  
19 building occupants. I think that's a reasonable,  
20 short summary.

21 Q. What is that de minimus risk using a  
22 pessimistic risk model?

23 MR. BROWNSON: Before you answer the  
24 question, I'm going to object, but I  
25 just -- since we're about to take our

DR. LANGER - Direct

1 break, I'll incur the wrath of Judge Ito  
2 and make a speaking objection, but what I  
3 wanted to say, Jonathan --

4 MR. MILLER: -- Thank you. I'll accept  
5 that.

6 MR. BROWNSON: -- Jonathan, is that you  
7 know we've identified Richard Wilson as  
8 our expert on risk assessments in this  
9 case and generally with respect to Chicago  
10 buildings, so he's going to testify about  
11 that area and I have no objection to you  
12 getting into that a little bit with  
13 Dr. Langer, but in terms of moving his  
14 deposition with what he's going to testify  
15 about, that's not the area that he's  
16 talking about in this case.

17 Q. I appreciate it, Doctor.

18 Very briefly, what is the de minimis  
19 risk to building occupants using the most  
20 pessimistic risk model?

21 A. Using the fiber levels found in the air,  
22 it would range from one in a million plus or  
23 minus in order of magnitude, one in 100,000, one  
24 in 10 million.

25 Q. By "building occupants," you mean

DR. LANGER - Direct

1 passive building occupants, is that correct?

2 A. Yes, correctomundo.

3 MR. MILLER: Thank you.


4 Break?

5 MR. BROWNSON: Sure.

6 (Whereupon a brief recess was taken  
7 at 11:00 a.m.)

8 (Whereupon the proceedings resumed  
9 at 11:10 a.m.)

10 BY MR. MILLER:

11 Q. Doctor, on Page 36 of your CV, you  
12 state at the very bottom that you gave an  
13 invited seminar and lecture to the Armstrong  
14 Defense Group in Memphis, Tennessee. That it   
15 was called the "Asbestos Saga and the Star Wars  
16 Trilogy: The Empire Strikes Back." It was  
17 given in 1991.

18 Which, if any, asbestos tests were  
19 part of the Armstrong Defense Group?

20 A. I have no idea.

21 Q. Okay. Did it concern vinyl asbestos  
22 tile as opposed to other types of asbestos in  
23 buildings, if you recall?

24 A. I believe so, yes.

25 Q. Why did you choose such a catchy

DR. LANGER - Direct

1 name, aside from the fact that it's obviously a  
2 catchy name, for your talk?

3 A. I thought people might come. It's hard  
4 speaking in an empty room, the reverberations  
5 are deafening.

6 Q. What did you mean when you said,  
7 "The Empire Strikes Back"?

8 A. 1991, what was the date of that  
9 presentation?

10 Q. Thursday, April 25th, 1991.

11 A. The asbestos in buildings passion play was  
12 being played out in North American courtrooms,  
13 and the only group, "recognizable group," put  
14 that in quotes, which could not embrace any of  
15 the concepts and principles of low-level  
16 exposures, was the group at Mount Sinai which  
17 was then under the leadership of Phil  
18 Landrigan. The more North Americans brought the  
19 issue of low-level exposure and its low-level  
20 risk to the attention of administrators in  
21 certain government agencies, the more the Mount  
22 Sinai group resisted.

23 In fact, there was some speculation  
24 that the Mount Sinai group had not acted in the  
25 best interests of the community by actions and

DR. LANGER - Direct

1 by words.

2 Q. What do you mean by that, sir?

3 A. Just that I've spoken sentences, and it  
4 means just that.

5 Q. How have they not acted in the best  
6 interest of the community?

7 A. I believe that if one reads a data set,  
8 that is how delicately I phrase this, a data  
9 set which runs contrary to your beliefs and one  
10 attacks ad hominem, rather than the data, that,  
11 to me, is not serving the best interests of the  
12 scientific community.

13 So if a young woman publishes a paper  
14 which someone at Mount Sinai finds offensive  
15 because they don't like the conclusions, one  
16 should present data and the data will speak for  
17 themselves. One should not proceed to attack  
18 this person as an individual, it serves no  
19 purpose.

20 Q. Are you referring specifically to  
21 the paper by Mossman, et al., and Science?

22 A. You can use that as an illustration.

23 Q. Do you believe she was attacked  
24 ad hominem?

25 A. Yes.

DR. LANGER - Direct

1 Q. There were certain letters that were  
2 published in, I think Science, and maybe  
3 elsewhere, as follow-ups to the Science article,  
4 and I believe one of them was by Dr. Nicholson,  
5 at least. Are these the documents to which you  
6 were referring that she was attacked ad hominem, or  
7 something outside that?

8 A. Outside that.

9 Q. What is there outside those  
10 published letters that you're referring to, sir?

11 A. This is hearsay of people present at  
12 meetings at Mount Sinai.

13 Q. Who was it? Who did this attack,  
14 according to your source of interest?

15 MR. BROWNSON: To the extent if you  
16 know.

17 A. To the extent that I know, this is all  
18 hearsay, and it's unfair because some of the  
19 principals are no longer living.

20 Q. By that, you're referring to Dr.  
21 Selikoff?

22 A. He was one, yes.

23 Q. Do you believe he was one who  
24 unfairly attacked directly Ms. Mossman?

25 A. Yes.

DR. LANGER - Direct

1 Q. Excuse me, Dr. Mossman.

2 Who else?

3 A. Who else what?

4 Q. Who else attacked her, do you  
5 believe?

6 A. You would have to depose Jack Harington to  
7 find out details, since he was present at some  
8 of these meetings.

9 Q. Now, when you were referring to the  
10 empire striking back, who, in your mind, in  
11 1991, was the empire?

12 A. Who constituted membership in the empire?

13 Q. Yes, sir.

14 A. Well, the center of the empire was at  
15 Mount Sinai, of course.

16 Q. Do you remember anything you said at  
17 that particular discussion in 1991 before the  
18 Armstrong Defense Group, other than what you  
19 have already referred to here today?

20 A. I don't think I mentioned this -- well,  
21 what I've spoken about today.

22 Q. What did you tell the Armstrong  
23 Defense Group in 1991?

24 A. Actually, I outlined what was known in the  
25 field, I outlined what was known in Europe, I

DR. LANGER - Direct

1 outlined what was brought over to the United  
2 States, and I outlined what the perceived  
3 response was from Mount Sinai.

4 Q. Anything further than that that you  
5 recall?

6 A. About what?

7 Q. What you told the Armstrong Defense  
8 Group?

9 A. Well, I don't remember everything, of  
10 course not.

11 Q. Okay.

12 A. Since it was more spontaneity than  
13 pre-thought.

14 Q. I'd like to ask you a couple  
15 questions about the projects for which you have  
16 provided a very nice graph at the back of your  
17 CV under "funding sources."

18 Starting with the most recent one first,  
19 sir, on the last page, there's a project at the  
20 Ecaterinburg workshop, project chrysotile.  
21 You're co-investigator for The Asbestos Institute  
22 and the W.R. Grace Company.

23 What was that all about, sir?

24 A. About five years ago, Favel Kogan wrote a  
25 paper which was published -- actually a

DR. LANGER - Direct

1       commentary which was published in the American  
2       Journal of Industrial Medicine on the occurrence  
3       of mesotheliomas in chrysotile-exposed workers  
4       in Katerinsburg. It used to be Verdslosk, and  
5       I'll spell Katerinsburg later.

6                 The commentary was of interest to me  
7       because its wording suggested there were more  
8       mesotheliomas there than reported among the  
9       miners and millers from Canada. I wrote to  
10      Kogan and we communicated, and through a mutual  
11      colleague, we were able to obtain tissue blocks  
12      from Kogan, obtained from individuals who died  
13      with asbestosis, and we began a joint -- and we  
14      arranged with certain individuals in the Russian  
15      federation, we arranged to participate jointly  
16      in a study of tissues obtained from certain  
17      kinds of workmen.

18                We are presently obtaining tissues  
19      from individuals who succumb with mesothelioma,  
20      which interestingly, more mesotheliomas occur  
21      outside this region than inside the region, occur  
22      from other areas in the Russian federation.

23                Q.     Will this someday be a published  
24      article?

25                A.     It certainly will.

DR. LANGER - Direct

1 Q. Do you have any tentative conclusion  
2 you have reached based on your research thus  
3 far?

4 MR. BROWNSON: Well, I'll object to  
5 the form of the question. Again, it's  
6 broad and it's vague and requires  
7 speculation, but go ahead.

8 A. You just want to hear two basic  
9 conclusions, let's say?

10 Q. If you reached them, sir, yes.

11 A. The first conclusion is that they have a  
12 lot of the dust in their lungs, high  
13 concentrations of chrysotile, no tremolite.

14 Q. You're referring to dust in the  
15 lungs of these people that died from asbestosis  
16 or --

17 A. Yes.

18 Q. Are there any who died from  
19 mesothelioma?

20 A. Not yet.

21 Q. Okay. Is the Katerinsburg a  
22 chrysotile mine?

23 A. Katerinsburg is the major city which is  
24 east of the Ural Mountains. It is the jumping-  
25 off point to a small town of approximately 60

DR. LANGER - Direct


1 kilometers to the northeast called Asbestos,  
2 like asbestos, Quebec. Basically, this is  
3 asbestos and this is where the largest pits are  
4 located.

5 Q. Have you concluded that the chrysotile  
6 mine in Asbestos does not have tremolite as a  
7 contaminant or that, whatever word you would  
8 like to use in it?

9 A. No.

10 Q. Do you know if it does have  
11 tremolite in it?

12 A. No.

13 Q. Turning to the prior page that I  
14 guess is Page 48, there's another project funded   
15 by the W.R. Grace Company, titled "Asbestos in  
16 the lungs of exposed workers," starting March of  
17 '93, going to the present.

18 What is that project all about?

19 A. That's part of the Katerinsburg project.

20 MR. MILLER: Exhibit 2, please.

21 (P-2, Expert witness disclosure,  
22 received and marked for Identification.)

23 BY MR. MILLER:

24 Q. Doctor, I've had marked as Exhibit  
25 2, an expert witness disclosure in this case

DR. LANGER - Direct

1 given by the defendant Asbestospray. I believe  
2 this is similar to some expert witness  
3 disclosures I have seen in the past, and I hope  
4 I will not have to spend too much time on it.

5 Have you seen this before, sir?

6 A. Yes.

7 Q. Can you tell me if, in the last five  
8 years, you can think of any particular area of  
9 your testimony where your views have been  
10 significantly changed?

11 MR. BROWNSON: I'm going to object  
12 to the form of the question, but are you  
13 speaking here to see if we can at least --  
14 so I understand, your testimony expressed  
15 in this disclosure?

16 MR. MILLER: Exactly.

17 MR. BROWNSON: If you look at the  
18 areas in that disclosure, the question  
19 is: Have your views changed in any of  
20 those areas in the last five years, as I  
21 understand it?

22 MR. MILLER: Yes.

23 MR. BROWNSON: I still object to the  
24 question, but go ahead.

25 A. You want to do this line by line or just

DR. LANGER - Direct

1 topic by topic?

2 Let's do it topic by topic. I see  
3 you are shaking your head to the topic by  
4 topic.

5 The testimony in the first  
6 paragraph, he will testify there's been a great  
7 deal of confusion in the medical and scientific  
8 literature concerning the term "asbestos" and  
9 that it is often improperly defined.

10 Well, there seems to be a little  
11 less confusion now since OSHA has taken cleavage  
12 fragments out of the asbestos standard. Okay.

13 Q. What is the nature of fiber release  
14 from asbestos fireproofing?

15 A. That's rather broad and generic.

16 Q. Well, that's something that you're  
17 going to testify to in exactly those words. I'm  
18 interested in what you're going to say about  
19 it.

20 A. It depends on whether Mr. Brownson asks me.

21 Q. Tell the jury, in your opinion,  
22 whether or not fibers are released in  
23 asbestos-containing fireproofing, and if so,  
24 under what circumstances?

25 A. I have not examined all asbestos-containing

DR. LANGER - Direct

1 fireproofing. Asbestos-containing fireproofings  
2 have a range of compositions, asbestos-containing  
3 fireproofings have a range of agents that are  
4 called binders.

5 I, personally, have examined many  
6 structures which were sprayed with a cementitious  
7 material. For example, Asbestospray formulation  
8 T, which is an amosite-containing material.  
9 These applications have existed in construction  
10 for the past 30 years or more. The buildings  
11 that have vibrated with mechanical stresses have  
12 been subject to large noises, have had bombs go  
13 off in their basements -- no, that's not  
14 asbestos, I'm thinking of the World Trade  
15 Center.

16 Materials are in place. The fiber  
17 levels found in the area of these structures are  
18 either not detectable below a certain volume, or  
19 when fibers are detected, they suggest, given  
20 various risk models available to us, the risks  
21 vary between one in 100,000 and one in a  
22 million, that these fireproofings function  
23 according to their specifications, and that they  
24 present a little or no risk to occupants of  
25 buildings.

DR. LANGER - Direct

1 Q. When you say "occupants of  
2 buildings," you were referring, again, to what  
3 you call passive occupants?

4 A. Or C1 occupants, as we referred to them in  
5 the AGI report.

6 Q. Do you have any opinion about risk  
7 to other categories of building occupants other  
8 than the C1 categories as referred to in the  
9 HEIAR report?

10 MR. BROWNSON: Well, again, I'll  
11 object to the question in that Dr. Langer  
12 is not going to testify for Asbestospray  
13 in this case about risk, as he previously  
14 stated, but go ahead and answer.

15 A. Again, it's a broad question because there  
16 are any number of activities that could be  
17 performed inside of a building or by maintenance  
18 workers. If a material is sprayed on a surface,  
19 on a decking, on cementitious material that's  
20 behind a suspended ceiling, would people who  
21 sweep the floors be at any greater risk than  
22 people sitting in a room? The fiber levels  
23 would be identical and the risks would be  
24 identical, as well. The risks would approach  
25 zero. Others might change lightbulbs. If the

DR. LANGER - Direct

1 lightbulb is below the suspending tile  
2 ceilings, they constitute zero risk. If there's  
3 someone who pulls cables above a suspended tile  
4 ceiling, it depends on the integrity of the  
5 material whether or not there are any activities  
6 that have dislodged the spraying application.

7 So there are any number of scenarios.  
8 I mean, I'm not saying it approaches an infinite  
9 number, but N is a very large number, and one  
10 has to specify a kind of worker and an activity  
11 and the circumstances under which this person  
12 performs these activities and the nature of the  
13 installation of which these are carried out. I  
14 mean, there's no way to really do it other than  
15 with some specificity associated with them.

16 Q. One of the suggestions or  
17 recommendations of the HEIAR was that research  
18 should be accomplished on these other than C1  
19 building occupants.

20 Do you believe that that research or  
21 any has been done, sir?

22 A. Yes, a great deal of it's been done. Not  
23 all of it, but a great deal.

24 Q. Would you please cite for me certain  
25 articles or other reports on which you rely,

DR. LANGER - Direct

1 particularly for the conclusions you just gave  
2 about people who sweep floors are not at  
3 different levels, people who change lightbulbs  
4 may not be at different levels, et cetera?

5 A. The HEI had a meeting in Boston, the  
6 proceedings of which was published in Applied  
7 Occupational Environmental Hygiene in November  
8 of 1994. There's a number of interesting papers  
9 in here which I am now reading.

10 Q. That means you have not read them  
11 yet, sir?

12 A. No, I haven't finished.

13 Q. Okay.

14 A. I know this is hard to believe, but it's  
15 true.

16 Q. Okay.

17 A. The title of the conference was called  
18 "Proceedings of Operations and Maintenance  
19 Programs in buildings containing asbestos,"  
20 subtitled "Workshop organized by the Health  
21 Effects Institute in asbestos research."  
22 Editors are Morton Lippmann, John Samet, and  
23 Rashi Shaikh.

24 There's a number of papers that were  
25 presented, interesting papers, with data

DR. LANGER - Direct

1 touching on the issues of maintenance workers in  
2 buildings, and whether or not they are exposed  
3 to fiber and various settings.

4 Q. Are those your own handwritten notes  
5 in that volume of the journal, sir?

6 A. Yes.

7 Q. Can you tell me which articles, I'm  
8 sorry?

9 A. Yes.

10 Q. I mean, can you tell me which  
11 articles you have read, thus far, that you found  
12 to be a particular interest or value to you and  
13 your opinions?

14 A. You mean, the articles pertaining to  
15 asbestos? There are some very interesting ones  
16 in here on mortality among construction laborers,  
17 if you're interested.

18 Q. I mean only asbestos?

19 A. Only asbestos, thus far, Millette's paper  
20 on TEM, transmission electron microscopy,  
21 "Analysis of asbestos structures," and his  
22 microvac technique and so on.

23 An interesting paper by Rashi Shaikh  
24 and colleagues on fiber levels found in  
25 buildings with maintenance activities.

DR. LANGER - Direct

1                   There are a number of others that I  
2                   started to read but put down because I haven't  
3                   had time to really focus on these things.

4                   Q.       What is your opinion about the value  
5                   of surface dust sampling for asbestos?

6                   A.       Not much.

7                   Q.       Why is that, sir?

8                   A.       Well, it doesn't tell you anything,  
9                   basically. It tells you that you have asbestos  
10                  in some settled dust. It doesn't tell you the  
11                  nature of the original size distribution. It  
12                  doesn't tell you anything about the respirability  
13                  of the fibers. It doesn't tell you about the  
14                  nature of the fibers in the air. It tells you  
15                  that it used to be in place A, it's now in place  
16                  B, and we find it there, and people generate  
17                  these very large numbers which are generally  
18                  misleading, and they have very little biological  
19                  relevance.

20                  Q.       When you speak about people generating  
21                  these large numbers, they are generally in terms  
22                  of structures per cubic something?

23                  A.       Area.

24                  Q.       Some area?

25                  A.       Correct.

DR. LANGER - Direct

1 Q. Do you know, if the information were  
2 analyzed in terms of weight, if that would have  
3 more relevance for the issues you're concerned  
4 with?

5 A. Worse.

6 Q. Why?

7 A. Weight doesn't tell you anything except  
8 weight.

9 Let's say that -- let's use an  
10 example. A fiber has just fallen off the  
11 ceiling. The fiber dimension is 10 microns in  
12 diameter, and it is a millimeter in length, and  
13 the weight is 100 micrograms. Let's say it  
14 falls to this table, someone comes in and does a  
15 dust assay, and say there's 100 micrograms of  
16 dust on this table. My question is 100  
17 micrograms of what? What are the dimensions of  
18 the fibers?

19 Now, I just told you it was a single  
20 fiber, but let's say we were to calculate on the  
21 basis of a preparation technique which alters  
22 the size distribution. We grind it up. We  
23 sonicate it. We do a lot -- we manipulate this,  
24 so instead of that one particle, we now have  
25 100,000, and that 100 micrograms now represents

DR. LANGER - Direct

1 100,000 fibers.

2 Now, that carries a different  
3 meaning to you in terms of hazard and risk than  
4 that single fiber. So you have to know  
5 something about size distribution in order to  
6 come to some understanding of risk.

7 So mass is awful, don't bother using  
8 that because then mass may be, in part, the  
9 matrix materials, it could be mixed with vitreous  
10 fiber, could be mixed with a cementing agent,  
11 Portland Cement, it could be mixed with bentonite  
12 clay, whatever.

13 So mass means nothing. Well, it  
14 means something, but it doesn't tell you very  
15 much, and when one looks at the microvac  
16 techniques and sonication and the alteration of  
17 size distribution, it is misleading. So it's  
18 worse than telling you very little, it's  
19 actually misleading.

20 Q. Would your opinion regarding the  
21 utility or usefulness of surface dust sampling  
22 vary depending upon the method by which the dust  
23 is taken off the surface?

24 A. Taken off of the surface?

25 Q. Yes, sir, microvac as opposed to

DR. LANGER - Direct

1       scraping as opposed to any of the different  
2       techniques?

3       A.     No, no, no, the artifact is not in  
4       removing from the surface so much as in the  
5       preparation of the material for examination by  
6       electron microscopy, that's the problem.

7             Q.     The way it is removed from the  
8       surface is not something which would enter into  
9       your judgment or surface dust sampling in  
10      general?

11      A.     I don't think -- in general, that's too  
12      much of a problem.

13             MR. BROWNSON: Try to wait until the  
14      question is done.

15             THE WITNESS: I know, I'm getting  
16      antsy. I have to apologize.

17             Q.     Would your opinion about utility of  
18      dust sampling change if the preparation were  
19      done by direct preparation as opposed to  
20      indirect preparation?

21      A.     Better.

22             Q.     Okay. How is it better?

23      A.     A direct preparation would be a  
24      preparation in which the material in its state  
25      on the surface is not altered when examined by

DR. LANGER - Direct

1 transmission electron microscopy; that would be  
2 better, yes.

3 Q. Do you think it still has some  
4 limits?

5 A. It depends on the nature of the matrix.

6 Q. Explain.

7 A. Well, do the fibers stick out? Can you  
8 see a whole fiber? Is this particle respirable?  
9 If a fiber is sticking out, is it coated with  
10 some of the matrix materials?

11 It's more meaningful, but there are  
12 always interesting questions that come up. I'm  
13 not dismissing it, of course. Merely, I'm  
14 saying if you remove it from the surface and you  
15 prepare it so that there's no artifact introduced  
16 in terms of size distribution, that's better.

17 Q. Is one of the disadvantages of  
18 direct preparation that it could hide the  
19 asbestos fibers in other material?

20 A. That's possible.

21 Q. Are there any other disadvantages to  
22 direct preparation that you can think of?

23 A. The major disadvantage is that these  
24 clumps are so large that you can't see  
25 anything. So this material is broken down so

DR. LANGER - Direct

1       you can see what's there. That's one of the  
2       reasons people went into the indirect method;  
3       that the direct method, that was just so much  
4       junk there, you couldn't see through it.

5             Q.     Any other disadvantages you can  
6       think of at this time, sir?

7       A.     Well, no. There are probably others I  
8       just can't think of.

9             Q.     Have you, by any chance, read the  
10      book by Millette called "Settled Asbestos Dust  
11      Sampling & Analysis"?

12      A.     No, I have not.

13                    Jim Millette is such a handsome  
14      devil.

15             Q.     Well, I've seen pictures of you,  
16      Doctor, that flatter you.

17      A.     Aren't you nice to say that.

18             Q.     Doctor, you said that at one point  
19      recently in your testimony that you had examined  
20      various types of cementitious fireproofing.

21                    What other types of fireproofing,  
22      cementitious or not, have you, personally,  
23      examined?

24                    MR. BROWNSON: I'm going to not  
25      interpose an objection to the question,

DR. LANGER - Direct

1 per se, but just state that Dr. Langer is  
2 here to talk about his examination of  
3 various asbestos fireproofings. While  
4 other examinations he may have done will  
5 be of interest, and you're certainly  
6 welcome to question him, we're not going  
7 to ask him at trial.

8 MR. MILLER: Thank you.

9 A. I don't know whether I'm going to give  
10 this back to you. It's very interesting. I'm  
11 only kidding.

12 Q. Doctor, it only costs about \$70 and  
13 some of the money goes --

14 A. Only \$70, well...

15 Q. What is your current -- while we're  
16 speaking, what is your fee for expert  
17 consultation?

18 A. Well, it depends. \$225 an hour, general  
19 background work; \$275 an hour for a deposition;  
20 and usually \$325 an hour for trial testimony.

21 Q. It has not gone up in a number of  
22 years?

23 A. Indeed, it is the same.

24 Q. Very good. I'm going to be --

25 A. How good that is, I don't know.

DR. LANGER - Direct

1 Q. What other asbestos-containing  
2 fireproofings have you, personally, examined?

3 MR. BROWNSON: Other than asbestos?

4 A. You mean, over my career?

5 Q. Yes, sir.

6 A. Holy mackerel, I think about all of them.  
7 I've looked at specimens of Kafco blaze shield,  
8 I've looked at a number of products from W.R.  
9 Grace, I've looked at material -- this is just  
10 fireproofing, correct?

11 Q. Yes, sir.

12 A. I would say on the average at Mount Sinai  
13 we would examine a half a dozen to a dozen  
14 specimens submitted to the laboratory weekly  
15 over a period of several years.

16 Q. Using the EPA definition of  
17 friability, do you believe that all the  
18 fireproofings which you've examined, including  
19 those specifically which you named here, are  
20 friable?

21 A. You mean, the definition, crumbled or  
22 easily crumbled?

23 Q. By hand pressure.

24 A. By hand pressure?

25 Q. Yes, sir.

DR. LANGER - Direct

1 A. When you say all of the products, you mean  
2 blaze shield?

3 Q. Let's start there.

4 Is that friable?

5 A. I have to have the specimen in front of  
6 me.

7 Q. How about the Asbestospray type T?

8 A. That's fairly cementitious, especially  
9 when tamped.

10 Q. Would you say that is not friable?

11 A. I said generally not friable.

12 Q. How about Grace Monokote-3?

13 A. I would have to see it in front of me, and  
14 I just don't recall. I've looked at them, but  
15 when you talk about friability, that requires a  
16 specimen in front of you.

17 Q. Are there any others you can recall  
18 now without having a specimen in front of you?

19 A. Actually --

20 MR. BROWNSON: The question is: Can  
21 you recall if any others are friable or can  
22 you recall seeing any others?

23 Q. If any others are friable?

24 A. I'm sorry, now I'm confused.

25 Q. Can you recall if any other

DR. LANGER - Direct

1 fireproofings that you have had personal  
2 experience in, are, in your opinion, friable?

3 You understand the EPA definition?

4 A. Well, there were some that I examined at  
5 Mount Sinai that under the definitions would be  
6 considered friable.

7 Q. Do you recall the names?

8 A. I can't recall.

9 Q. Okay.

10 A. These are just fireproofings, we're not  
11 talking about decorative?

12 Q. Just fireproofings, sir.

13 A. Okay.

14 Q. You gave a definition or your  
15 opinion of risk a little while ago, and that  
16 definition or your opinion of risk was based  
17 upon air levels, is that correct, sir?

18 A. In part.

19 Q. Was it based on anything other than  
20 air levels?

21 A. Well, of course.

22 Q. What?

23 A. Well, the air level is only one aspect of  
24 risk assessment, the other involves the  
25 response. There's a dose and there's a

DR. LANGER - Direct

1 response, and the response models, which are  
2 used by various agencies.

3 Q. Was your opinion regarding risk  
4 based at all upon the actual condition of any of  
5 the asbestos-containing materials in any of the  
6 plaintiff's buildings?

7 A. I don't understand the question, I'm  
8 sorry.

9 Q. Do you know the actual condition  
10 today of any of the asbestos-containing  
11 materials in any of the plaintiff's buildings?

12 MR. BROWNSON: We're speaking of the  
13 Chicago buildings?

14 Q. Yes, this case.

15 A. I've seen photographs of the application  
16 of Asbestospray in some of these buildings'  
17 photographs.

18 Q. Aside from the photographs, do you  
19 have any additional information regarding the  
20 actual condition of any of the  
21 asbestos-containing materials in these  
22 buildings?

23 A. Yes.

24 Q. What is that?

25 A. Some of the documents that I've read of

DR. LANGER - Direct

1 the individuals who inspected these facilities.

2 Q. Aside from the inspection reports  
3 and the photographs, do you have any further  
4 information regarding the actual condition of  
5 the materials in the buildings today?

6 A. You mean, like a videotape or something?

7 Q. For example, fireproofing?

8 A. Fireproofing, no, I don't believe so.

9 Q. Do you have some knowledge about the  
10 types of asbestos-containing materials in the  
11 Chicago and Evanston plaintiffs' buildings other  
12 than fireproofing?

13 A. Yes.

14 Q. What is that, what type?

15 A. As you know, I'm also representing Conwed,  
16 a manufacturer of a ceiling tile. Those  
17 materials are present in some of the buildings.

18 Q. I will not be asking you questions  
19 specifically about Conwed.

20 Other than the Conwed specific  
21 information, do you have any additional  
22 information?

23 A. Other than that which I read, meaning that  
24 other experts examine materials and carry out  
25 what is commonly referred to as product ID;

DR. LANGER - Direct

1 other than that, I have no firsthand  
2 information, correct.

3 Q. Did the information you received  
4 through photographs you mentioned and the  
5 inspection reports that you mentioned form some  
6 part of the basis for your opinion about risk in  
7 the buildings?

8 A. In part.

9 Q. Was the information that you saw and  
10 you've described, thus far, namely, the  
11 photographs and the inspection reports, aside  
12 from the Conwed, which I'm not going to ask you  
13 about, but other stuff you saw regarding our  
14 building, was that Asbestospray-specific, to the  
15 best of your knowledge; in other words, it was  
16 in buildings where Asbestospray products were  
17 alleged to have been?

18 A. Yes, that's right. There are three  
19 buildings there we're talking about, correct.

20 Q. In what document could I find the  
21 most up-to-date statement that the EPA's published  
22 on asbestos in buildings, if there is such one  
23 document?

24 A. Yes, there is. What is that document  
25 called? You say asbestos in buildings or

DR. LANGER - Direct

1 asbestos in schools?

2 Q. I said in buildings.

3 A. Asbestos, I have two recent EPA documents,  
4 one published in June of '91, which is called  
5 "Asbestos in schools, evaluation of asbestos  
6 hazard emergency response act, a summary report;  
7 and in January of '92, a U.S. EPA document  
8 called "Communicating about risk, EPA, and  
9 asbestos in schools."

10 Q. Is there anything more recent than  
11 those two documents, more generally referring to  
12 buildings?

13 A. You know, there is one and I've been  
14 trying to get it and I can't get it.

15 Q. What is that, sir?

16 A. There is a most recent document, it  
17 postdates the second Green book, and it  
18 postdates many of the statements that you hear  
19 about it's safer to leave it in place than to  
20 take it out, so on and so forth.

21 There is another document which I  
22 have not been able to get as yet, but it's my  
23 understanding that it's floating around at the  
24 Environmental Protection Agency. It might be a  
25 draft of a document rather than a final report.

DR. LANGER - Direct

1 Q. Can you give any further or a more  
2 clear description of what the document might be?

3 A. I wish I could.

4 Q. Does it concern generally asbestos  
5 in buildings, as you understand it?

6 A. That's my understanding, yes.

7 Q. It has not been published yet in any  
8 form, to the best of your knowledge?

9 A. Apparently so, correct.

10 Q. Doctor, do you have any AHERA  
11 certifications?

12 A. No.

13 Q. Do you have any certification from  
14 any Illinois Department of Public Health or  
15 other governing bodies concerning asbestos?

16 A. No.

17 Q. You are not a certified industrial  
18 hygienist, is that correct?

19 A. Correct.

20 Q. Would you call yourself an  
21 industrial hygienist?

22 A. No.

23 Q. Okay. Given that, would you please,  
24 in some summary form, tell me why you believe  
25 you have the expertise to testify as stated in

DR. LANGER - Direct

1 Exhibit 2 concerning proper responses to  
2 asbestos in buildings including, but not limited  
3 to, the necessity of removal, the advisability  
4 of removal, and operations and maintenance of  
5 asbestos in buildings?

6 MR. BROWNSON: Well, I object to the  
7 form of the question, but go ahead, you  
8 can answer.

9 A. I object to the form of that question,  
10 myself.

11 Do you want to ask part of it, what  
12 makes me think I can advise people about  
13 anything, is what you're asking me?

14 Q. Advise people specifically, and  
15 what, if anything, should they do about asbestos  
16 in buildings?

17 A. I'm one of those people who believes that  
18 advice of an expert is best when from an expert  
19 who knows a lot about a subject area. I'm not  
20 saying that an industrial hygienist -- a  
21 hygienist tells you one part of the problem, but  
22 expertise requires some understanding of what is  
23 asbestos; what are the fiber types; what are the  
24 risks associated with the different fiber types;  
25 what is known about those responses; what is

DR. LANGER - Direct

1 known about fiber levels in the industry; what  
2 are the implications of cigarette smoking in  
3 asbestos risk; how much fiber is in the air; how  
4 do we ever get these models that the EPA uses.  
5 And in their hazard analysis, what do these  
6 models mean; what is it based on; what is  
7 epidemiological studies; what are the fiber  
8 levels; how do you measure the fiber levels;  
9 what do you use in electron microscopy; why do  
10 you use an electron microscope rather than a  
11 light microscope; what are the fiber levels;  
12 what are your interpretations and meaning of  
13 these data.

14 Now, if you find me an industrial  
15 hygienist in the United States who can answer  
16 all of those questions and give you a reasonable  
17 dissertation on each of these, then I will back  
18 out of the litigation, meaning, that there's  
19 someone out there who really knows something.

20 On the other hand, one doesn't have  
21 to be an industrial hygienist to gauge  
22 situations where there may or may not be a  
23 risk. In fact, one doesn't need all the tickets  
24 in certain instances, but you have to have some  
25 broad-based knowledge.

DR. LANGER - Direct

1 Q. Do you believe that a medical doctor  
2 would be more qualified than you with your  
3 qualifications to give advice to a building  
4 owner about what, if anything, they should do  
5 about asbestos in buildings?

6 MR. BROWNSON: I'll object.

7 A. It depends on the doctor.

8 Q. Are there some doctors whose names  
9 come to mind who you think would be at least as  
10 well qualified as you to give advice to building  
11 owners regarding asbestos in buildings?

12 MR. VALENZA: Objection.

13 MR. BROWNSON: I'm going to object  
14 to the form of the question, and I'll tell  
15 you specifically why, which may help you  
16 understand the objection.

17 Dr. Langer will be asked in this  
18 case to give testimony as to what  
19 response, perhaps, will be asked, what  
20 response would be appropriate in the three  
21 Chicago buildings which are at issue with  
22 respect to Asbestospray, and I don't know  
23 what doctors may or may not have reviewed  
24 the data he's reviewed with respect to  
25 those buildings, and therefore, I think

DR. LANGER - Direct

1 the question is objectionable on that  
2 ground.

3 MR. MILLER: I appreciate that. Let  
4 me change my question slightly.

5 Q. If a medical doctor were to review  
6 the same data that you reviewed regarding the  
7 three Chicago buildings, is there any particular  
8 medical doctor whose name comes to mind who you  
9 think would be at least as well qualified as you  
10 to give advice to building owners regarding  
11 what, if anything, to do about the asbestos in  
12 those buildings?

13 A. Very, very complex and compound question.

14 First, you're asking: Is there a  
15 medical doctor who's as qualified as I am in my  
16 field? Nay, not so.

17 Are there medical doctors who know a  
18 great deal more in pulmonology than I do? Sure.

19 Are there doctors who are certified  
20 to be readers who can read chest x-rays? Sure.  
21 Sure, there are many physicians who are better  
22 qualified in the medical field.

23 Now, talking overall asbestos field,  
24 that's more problematic now.

25 Are there physicians who could read

DR. LANGER - Direct

1 the data and come to the same conclusion as I would  
2 come to, qualifications aside? Yes, there are  
3 physicians who would come to the same general  
4 conclusion as I.

5 Q. When you refer to your field, were  
6 you referring to what you subsequently call the  
7 overall asbestos field?

8 A. I think so, yes.

9 Q. Who, in your field, namely, the  
10 overall asbestos field, do you believe is as  
11 qualified or perhaps even more qualified than  
12 you to give advice to a building owner if  
13 they were to review the same information you  
14 were to review? And this is advice concerning  
15 what, if anything, to do about asbestos in  
16 buildings.

17 A. Well, I don't normally give advice to  
18 people on what you do in buildings. All I could  
19 do is present the problem to them and they make  
20 their own decisions.

21 That's not the question. The  
22 question is: Are there individuals who -- well,  
23 there are people who do it to a greater or  
24 lesser extent.

25 Q. Who, among the people who do it in

DR. LANGER - Direct

1 your field, do you believe, if any, are as  
2 qualified as you or more so to give either the  
3 advice or the information that you give to  
4 people?

5 A. Well, there are a number of people who  
6 give the information to building owners. I  
7 think Roger Morris, as an architect, is very  
8 well qualified to render advice and opinions to  
9 building owners and operators. I think that  
10 Morton Corn, who is an industrial hygienist or  
11 engineer, is qualified to render advice to  
12 various people. I think Richard Lee, who's a  
13 physicist, is qualified to render opinions and  
14 advice to people.

15 The people have slightly different  
16 areas of focus in slightly different percentages  
17 in areas of expertise. I mean, there are lots  
18 of people who are not physicians, like myself,  
19 who you can categorize as basic scientists, who  
20 give advice, and the advice comes from a  
21 slightly different perspective.

22 Are they as qualified in my field?  
23 I don't think so. In their field, yes, they're  
24 as qualified as one could be qualified, yeah.

25 Q. It's fair to call your field, then,

DR. LANGER - Direct

1 that of a basic scientist, is that right?

2 A. That's fair enough.

3 Q. Who else, specifically in your  
4 field, would you believe is a basic scientist  
5 who is as qualified as you, or perhaps more so,  
6 to give advice to a building owner regarding  
7 what should be done, if anything, about asbestos  
8 in buildings?

9 MR. BROWNSON: I'll interpose the  
10 same objection, but again, the original  
11 question was based upon the data he's  
12 reviewed here?

13 MR. MILLER: Right, and I will amend  
14 it.

15 Q. To me, if they were able to look at  
16 the same data you looked at, who do you think,  
17 as a basic scientist, would be as qualified as  
18 you?

19 A. Well, Richard Wilson.

20 Q. Anyone else whose name comes to  
21 mind, sir?

22 A. I'm thinking.

23 Q. I'm sorry.

24 A. Maybe Richard Lee, Robert Nolan.

25 You're talking just about basic

DR. LANGER - Direct

1       scientists now?

2               Q.     Yes.

3       A.     Who are in the field, who have a feeling  
4       for all these data and what they mean?

5               Q.     Yes.

6       A.     Malcolm Ross.

7               Q.     Where is Malcolm Ross, sir?

8       A.     He is just retired from the United States  
9       Geological Survey. He's in Virginia.

10              Q.     To your knowledge, is he now in the  
11       business or expertise of giving advice to building  
12       owners about asbestos?

13       A.     No.

14              Q.     I interrupted you, I'm sorry.

15                      Were there any other names that you  
16       had in mind?

17       A.     I'm thinking. Well, there are others who  
18       are epidemiologists who are interested in risk  
19       analysis. There's Janet Hugh and Philip  
20       Enterline of Pittsburgh. I'm sure there are many  
21       others, but I just can't recall.

22                      MR. MILLER: Off the record.

23                              (Whereupon a discussion is held off  
24       the record.)

25                              (Whereupon a luncheon recess was taken

1 at 12:00 p.m.)

2 (Whereupon the proceedings resumed

3 at 12:55 p.m.)

4 \* \* \*

5

6

7 A F T E R N O O N S E S S I O N

8

9 DIRECT EXAMINATION BY MR. MILLER CONTINUED:

10 Q. Doctor, before lunch, you referred  
11 to the physicist Richard Lee.

12 Is that the same Dr. Lee who does  
13 product identification in this case, he's in  
14 Pittsburgh, at ETC, or are you referring to  
15 somebody else?

16 A. I'm referring to the Richard Lee who is  
17 the president of the Lee, I guess, and  
18 Associates in Monroeville, Pennsylvania.

19 Q. That's the same person?

20 A. Oh, yes.

21 Q. That's exactly?

22 A. Oh, yes, yes.

23 Q. Thank you.

24 You have been consulted by

25 Asbestospray in this case.

DR. LANGER - Direct

1           Is it your understanding that they  
2           are alleged to have an asbestos-containing  
3           product in three schools in Chicago in this  
4           case?

5           A.     There are three buildings.

6           Q.     Three buildings, that you think?

7           A.     There are three buildings, one is the  
8           South Shore High School, one is the Leif Ericson  
9           School, and the other is the District 2 Offices.

10          Q.     What is your advice to the building  
11          owners as to what, if anything, she should do  
12          about the asbestos-containing Asbestospray,  
13          allegedly Asbestospray material in those  
14          buildings?

15          A.     No one's asked me for my advice.

16          Q.     I'm asking you.

17          A.     What would I advise them to do?

18          Q.     Yes, sir, this is a hypothetical  
19          question.

20          A.     This is a hypothetical. Well, based on  
21          the surveys which have been completed, based  
22          upon the description of the utilization of the  
23          spaces, based on a description of where this  
24          material occurs in relation and regard to the  
25          spaces in which people work and are educated,

DR. LANGER - Direct

1 given the purpose which it serves and given the  
2 experiences, and given the air data which have  
3 been obtained in other circumstances, in other  
4 structures, my advice would be to leave the  
5 material in place.

6 Q. Do you know what type of asbestos is  
7 alleged to be in the fireproofing in those three  
8 buildings?

9 A. Yes, the formulation approximates  
10 Asbestospray T, which is an amosite-containing  
11 formulation.

12 Q. Have you seen the formula for  
13 Asbestospray T?

14 A. Pardon?

15 Q. Have you seen the formula for  
16 Asbestospray T?

17 A. I have. It's been reported to me. I have  
18 notes and it is my understanding that it is a  
19 formulation consisting of approximately 25  
20 percent amosite fiber, approximately 60 percent  
21 vitreous fiber, a wool of some kind,  
22 approximately seven and a half percent Portland  
23 cement, and approximately seven and a half  
24 percent bentonite clay.

25 Q. Do you have any reason to believe

DR. LANGER - Direct

1 that any of the information that you have that  
2 the material in any of those three buildings is  
3 not Asbestospray T?

4 A. Do I have information that it is not?

5 Q. Yes, sir.

6 A. You mean, do I have an understanding that  
7 it is not, or do I have some impression that the  
8 assays performed are limited or provide me with  
9 some reason to be skeptical that this is  
10 Asbestospray, is that what you're asking me?

11 Q. Yes.

12 A. Yes.

13 Q. What is that?

14 A. I have looked at some of the assays from,  
15 I guess, Dr. Longo's group, MVA -- no, excuse  
16 me, that's not MVA -- Longo's group, and it is  
17 the assays, as presented, are similar to the  
18 Asbestospray formulation, but the assays have  
19 limited -- the assays described certain  
20 materials as being present in amounts which are  
21 similar to Asbestospray products, and I'm not at  
22 all certain that the interchanging of bentonite  
23 and montmorillonite.

24 So, there are certain characteristics  
25 of the assay which are not -- haven't fulfilled

DR. LANGER - Direct

1 my own requirements for a proper product ID. I  
2 would have preferred to have seen a bulk x-ray  
3 diffraction tracing. I would have preferred to  
4 have seen other kinds of data presented in order  
5 to come to the conclusion this is Asbestospray  
6 T.

7 Q. Thank you, Doctor.

8 MR. BROWNSON: For the record, as  
9 you know, Dr. Langer is not being  
10 presented as a witness on this question,  
11 although you might find his comments  
12 interesting.

13 MR. MILLER: I always find the  
14 doctor's comments interesting.

15 MR. BROWNSON: Off the record for  
16 one moment.

17 (Whereupon a discussion was held off  
18 the record.)

19 BY MR. MILLER:

20 Q. Doctor, one of the bases for your  
21 advice to the building, I understand the three  
22 buildings, was where the material occurs?

23 A. Correct.

24 Q. Does the material occur above some  
25 type of suspended ceiling in these buildings?

DR. LANGER - Direct

1 A. Yes, it is my understanding from the  
2 description in one of the schools in which there  
3 is a suspended ceiling in a pool area, maybe the  
4 pool area wasn't opened and the pool area wasn't  
5 used, but there are areas described in which the  
6 spray product is present above a suspended tile  
7 ceiling. I would have to check the details.

8 Q. Do you believe that the owner  
9 should, even though the owner is keeping  
10 material in place, have some sort of operations  
11 and maintenance program with regard to that  
12 material?

13 A. Well, if they're not using the room, no.  
14 If it's above a suspended tile ceiling, other  
15 than you might do some air sampling once in a  
16 while under the ceiling, no, I wouldn't  
17 recommend any extensive kind of O and M program,  
18 no.

19 Q. Is any of the air sampling that you  
20 have seen thus far, air sampling, taken above  
21 the suspended ceiling in these buildings?

22 A. No.

23 Q. Do you have any information as to  
24 how often maintenance or custodial persons in  
25 the course of their normal duties must gain

DR. LANGER - Direct

1 access above the suspended ceilings in these  
2 buildings?

3 A. The inference drawn from the description  
4 of what exists above the ceiling with the  
5 existing services indicates that they would have  
6 very little, if any, need to go above these  
7 tiles.

8 Q. If they should have any need to go  
9 above tiles, would you recommend any form of  
10 protective clothing or other practices that they  
11 should follow in there above the ceiling?

12 MR. BROWNSON: Just so we're clear  
13 on the question, you're speaking of  
14 buildings that he's examined and talking  
15 about, you're not making this a more  
16 general question?

17 MR. MILLER: I'm speaking about the  
18 buildings in this case that you are  
19 referring to that have the alleged  
20 Asbestospray type T above some form of  
21 suspended ceiling.

22 A. If it makes the workers feel better, then  
23 they should wear some kind of respirator, an  
24 approved respirator, dust respirator for fibrous  
25 dust.

DR. LANGER - Direct

1 Q. Do you believe there's any  
2 health-related reason as to why they should have  
3 any type of precaution, whether it's a  
4 respirator or anything else when they go above  
5 ceilings in these particular buildings or  
6 buildings where there is alleged Asbestospray  
7 type T above ceilings?

8 A. A health reason, specifically?

9 Q. Yes.

10 A. Are they at risk, is what you're asking  
11 me?

12 Q. Yes.

13 A. Or are you asking me are they at risk?

14 Q. Yes.

15 A. If there's a risk, it is a very small  
16 risk. If the risk exists, it is a very small  
17 risk.

18 Q. Could you quantify that risk?

19 A. Well, I've stated for the record that I  
20 know of no air data taken above those tile  
21 ceilings, so I don't know that.

22 You can give me another  
23 hypothetical.

24 Q. Given the present state of your  
25 knowledge, which includes no air data, would you

DR. LANGER - Direct

1 recommend that any type of precautionary  
2 measures be taken by custodians or maintenance  
3 personnel if they must access above the ceiling  
4 in the same building or buildings that we're  
5 talking about?

6 A. The absence of data invites extrapolation.  
7 The extrapolation would include a worst-case  
8 scenario. I would recommend the use of a  
9 respirator.

10 Q. Okay. Would you recommend that the  
11 maintenance or custodial personnel who are going  
12 above the ceiling in the same buildings we've  
13 been talking about take care not to in any way  
14 contact the fireproofing itself?

15 A. Of course.

16 Q. Okay. Do you have any knowledge as  
17 to whether there is any debris or dust or other  
18 portions of the fireproofing that has fallen  
19 from the fireproofing and is currently on the  
20 top side of the suspended ceiling in the same  
21 buildings we've been talking about?

22 A. According to my recollection and an  
23 inspection carried out by Don Hunter, there was  
24 some debris on top of the tile ceilings, and I'm  
25 thinking that there was debris, also, in a power

DR. LANGER - Direct

1 plant, which came about for other reasons.

2 Q. Assuming that that debris, in fact,  
3 did come from the asbestos-containing material,  
4 do you have any recommendation as to what, if  
5 anything, should be done with that debris?

6 A. You mean, other than place it in some kind  
7 of a bag and take it away?

8 Q. Well, that's the first thing.

9 Should you leave it there, put it in  
10 a bag, take it out, or what?

11 A. That would depend on the situation. I  
12 mean, you might leave it there.

13 Why would you want to move it?

14 Q. If a maintenance personnel or  
15 custodian has to go above the ceiling to do some  
16 work above the ceiling, sticking his or her head  
17 above of the ceiling, and all around there's  
18 some debris, do you think in that situation the  
19 debris from the fireproofing should be cleaned  
20 up?

21 MR. VALENZA: Objection.

22 A. I still don't know. One needs an air  
23 measurement of the fibers in the air. The fact  
24 of the matter is we can have a box of asbestos  
25 on this table, the question is: Does it produce

DR. LANGER - Direct

1 any hazard or associated or attendant risk by  
2 its presence? Are there other factors that come  
3 into play here?

4 So, its mere existence is no prima  
5 facie evidence that it hasn't existed and  
6 recommendations thus follow.

7 Q. Do you believe that  
8 asbestos-containing dust or debris on a surface  
9 can be re-entrained into the air?

10 A. Could be, sure.

11 Q. Do you have opinions as to what  
12 types of activity would re-entrain  
13 asbestos-containing dust surfaces into the air?

14 MR. BROWNSON: Object to the form of  
15 the question.

16 Are we speaking again of these three  
17 buildings or --

18 Q. More generally, but if you care to  
19 limit it, I don't care, Doctor. My question was  
20 more general.

21 A. The only data I have seen are data  
22 involved or generated on clean-up activities,  
23 such as sweeping, specifically dry sweeping, and  
24 fibers can be re-entrained for short periods of  
25 time.

DR. LANGER - Direct

1 Q. Therefore, would you recommend, going  
2 back to the three Asbestospray buildings, that if  
3 a custodian were going above the suspended  
4 ceiling, that that custodian not dry-sweep, or  
5 in any other way, similar way, push around the  
6 debris from the fireproofing?

7 MR. BROWNSON: I'll object to the  
8 form of the question.

9 A. Pushing around is different, of course.  
10 Should he sweep the top of that tile? No, I  
11 wouldn't recommend it. I wouldn't recommend  
12 anyone going up there and sweeping the debris on  
13 top of the tiles.

14 Q. Would you recommend that it would be  
15 a prudent health measure for a custodian going  
16 above the ceiling in the same buildings we've  
17 been talking about to use some sort of water  
18 spray to spray down the debris to help stop any  
19 possible re-entrainment?

20 A. I'm not so sure.

21 Q. Why not?

22 A. Once you get water above the tiles and the  
23 limited amount of air circulation above those  
24 tiles, you might begin to harbor certain  
25 organisms in dangerous environment molds, for

DR. LANGER - Direct

1       example; so I'm not certain that would be an  
2       efficacious method.

3               Now, you've begged the question, is  
4       there a health risk? You have to measure fibers  
5       in the air.

6               MR. MILLER: Mark this 3, please.

7               (P-3, one-page document, received  
8       and marked for Identification.)

9               Q.     Doctor, I've had marked as Exhibit  
10       3, a single page document which is headed the  
11       following words: "Dr. Langer will rely on the  
12       following materials in this case." This came  
13       from a pleading filed by Asbestospray.

14               Does this document, in fact,  
15       summarize the specific materials in which you  
16       expect to rely for your testimony in this case?

17       A.     May I read them?

18               Q.     Of course. I assumed you had seen  
19       them before, I apologize.

20       A.     No, that's all right.

21               I think that I have seen this report  
22       before, yes. I have read reports of Longo,  
23       Millette and Hatfield. I have read the  
24       deposition transcript in this matter. I have  
25       looked at the product ID reports, and we've

DR. LANGER - Direct

1 already discussed some of my reservations.

2 Air sampling data, yes, I've seen  
3 those. Most of these instances, dust samples,  
4 I've seen those.

5 Photographs in buildings, yes, air  
6 sampling data. We are in the process of  
7 completing those.

8 As a matter of fact, documents  
9 pertaining to Sprayed Mineral Fibers, yes, I've  
10 read those.

11 Air consultants and other parties,  
12 yes, I have those.

13 Proceedings of Harvard, yes, I've  
14 read those.

15 Spengler and colleagues on the  
16 "Summary of Symposium," yes. I've read that.

17 The Health Effects Institute, yes,  
18 I've read that.

19 Wilson, Langer, yes, I've even seen  
20 that paper, too, yes. I've seen all of these.

21 Q. Thank you.

22 Are there any building-specific  
23 documents that are not on this list on which --  
24 or which you have seen -- let's start with that,  
25 relating to our building, the three buildings at

DR. LANGER - Direct

1 issue.

2 A. I have. I am now completing review of  
3 documents from Conwed, so there may be other  
4 buildings.

5 Q. Putting aside Conwed, again --

6 A. Oh, you mean this particular or three  
7 little litigations grouped into big ones?

8 Q. Fairly big.

9 A. No.

10 Q. I'd like to go quickly through as  
11 many of these references as we can.

12 Number 1: Reports of William Longo,  
13 Jim Millette, and William Hatfield, are they  
14 product identification reports?

15 A. Well, generally so. I mean, you're asking  
16 me the questions. Let me see if I can give you  
17 something more specific.

18 Q. Do you have with you the actual  
19 reports that you looked at?

20 A. No, no, no.

21 Okay. Go ahead and ask me the  
22 question. I can give you the specifics.

23 I've seen a report in a letter of  
24 November 9th, 1992, MAS to Mr. Tucker, Counsel,  
25 concerning samples analyzed in the District 2

DR. LANGER - Direct

1 Office. Material is identified as Asbestospray T.

2 I've looked at the TEM reports.

3 I have looked at the report from law  
4 engineering. This is Hatfield's report of  
5 November 16th, 1994, concerning settled dust.

6 I have looked at Hunter's  
7 Environmental Survey, 10 to 11 November, 1994.

8 Air sampling data. Those are the  
9 data I have looked at for the District 2 Offices  
10 in Kenwood.

11 I have also looked at a report in a  
12 letter of July 6th, 1993, Dr. Longo to  
13 Mr. Tucker, concerning identification of the  
14 specimens, some of his TEM reports. Interesting.

15 I have the Hunter, Incorporated  
16 Environmental Assay, 9 through 10, November of  
17 '94.

18 MR. BROWNSON: Which building is  
19 this that we're speaking of?

20 A. This is the Leif Ericson building -- I'm  
21 sorry, this is Leif Ericson, also known as Leif  
22 the Lucky.

23 Then it's Glenbrook South High  
24 School, Glenbrook. We're not interested in  
25 them.

DR. LANGER - Direct

1 How about South Shore High School?

2 Q. Let's stop right there.

3 We said earlier, and Mr. Brownson  
4 said that there were three buildings in Chicago.  
5 You also mentioned Glenbrook South and  
6 Hawthorne.

7 Are they under the Evanston, Heading?

8 MR. BROWNSON: Yes, you can question  
9 all you want about that. We have not had  
10 to look for those specifically because  
11 those are the ones that -- where there  
12 have been removal already, so air sampling  
13 has not been analyzed there.

14 Q. Very simple: Have you looked at  
15 Glenbrook South or Hawthorne, Doctor?

16 A. I have looked at some documents.

17 Q. You have?

18 A. Yes. Many of these reports contain data  
19 from different buildings, so if you read Report  
20 A, it may have some on Hawthorne and South Shore  
21 for reasons which escape me; but nonetheless,  
22 this is the reality.

23 Q. The air sampling you see relates to  
24 South Shore, Leif Ericson and District 2 Offices?

25 A. Yes.

DR. LANGER - Direct

1 Q. Air sampling from Glenbrook or  
2 Hawthorne, is that correct?

3 A. May not be correct at all, no.

4 I have some data that I've looked  
5 at.

6 MR. BROWNSON: Just to help you out,  
7 we did not have him analyze air sampling  
8 from those two schools because, as you  
9 know, its materials have been removed.  
10 So, whether he has seen some in one of  
11 these Longo reports, I don't know.

12 Q. I apologize, Doctor, I interrupted  
13 you. You were telling us the documents you've  
14 seen, and I wish you would finish the recitation.

15 A. I've seen documents from the South Shore  
16 High School. This is a Longo report to Mr.  
17 Tucker. It's dated January 1st, 1993. It  
18 consists of a bulk assay of what these materials  
19 are, its formulation. It consists of a TEM  
20 assay of different components.

21 There is also a report from Hunter  
22 Environmental, a survey done on the 14th and  
23 15th of November, 1994.

24 There is also, for some reason --  
25 oh, as I said, sometimes there are reports with

DR. LANGER - Direct

1 different schools. Here is a report that had  
2 Webster Elementary and South Shore High School  
3 as part of the same report.

4 The South Shore High School, there  
5 is an assay by polarized light microscopy what  
6 the bulk material is. There are a number of  
7 settled dust assays.

8 There are South Shore air samples  
9 analyzed by the NIOSH, OSHA technique using  
10 phase contrast microscopy. These were  
11 undertaken by McCrone and air data from South  
12 Shore.

13 Q. You earlier talked about your  
14 general opinions about dust sampling results.

15 Is there anything in addition about  
16 the specific dust sampling that you looked at  
17 here that you feel is worthy of comments or do  
18 all your prior comments fairly cover what you  
19 say about the dust sampling that you see here?

20 A. Well, that's an awfully broad question.

21 What is it that you would like me to  
22 do? You want me to take a single specimen or  
23 single report and just "sally forth," as we  
24 say?

25 Q. Please, I would appreciate it.

DR. LANGER - Direct

1 A. Okay. Let's take a look at the Leif  
2 Ericson report here, a report from Longo's group  
3 to Mr. Tucker, five samples analyzed as a bulk  
4 material.

5 What is this stuff, basically, is  
6 the question?

7 MR. BROWNSON: Wait a minute.

8 MR. MILLER: Dust sampling is what  
9 I'm talking about.

10 MR. BROWNSON: The question is  
11 settled dust?

12 MR. MILLER: Surface dust or settled  
13 dust.

14 Thank you.

15 A. Okay. Let's stay with the District 2 --  
16 let's do District 2, and let's look at a report  
17 dated November 16th, 1994, which consists of a  
18 dust sample log from Hatfield which is sent to  
19 materials analysis, whatever, Longo's group, and  
20 Longo produces an assay and sends this assay to  
21 someone on -- well, that doesn't matter.

22 The material is collected by  
23 Hatfield and sent to Longo. Longo receives it  
24 November 21st, which is five days later.

25 There are three dust samples. There's

DR. LANGER - Direct

1 a certain area which has been microvaced, and  
2 these materials are processed and a number of  
3 objects are counted and given in asbestos  
4 structures per square centimeter.

5 Of the 102 objects which are  
6 described as amosite, only one of these 102  
7 objects have any diffraction data available,  
8 which is not included in that assay.

9 Now, of the 1.6 million, only  
10 770,000, approximately one half are greater than  
11 five microns in length, which I'm interested in  
12 because this relates to risk analysis and the  
13 OSHA data sheets that we use.

14 Now, the values given, concerning  
15 the distance between the ceiling and the top of  
16 the tile, from the data given, I have  
17 recalculated, based on 30 years, 365 days a  
18 year, 24 hours a day, 60 minutes as a continuum  
19 that the fibers falling, if these were  
20 individual fibers, those greater than five  
21 microns in length, that a concentration per  
22 cubic centimeter of air should have been  
23 approximately 0.3 fibers per CC, 3/10 of a fiber  
24 per CC. It was a continuum over that 30-year  
25 period. Failure began day one, and it has never

DR. LANGER - Direct

1 changed.

2 Now, if you look at the air data,  
3 this is too high by three orders of magnitude,  
4 so obviously, one cannot reconcile the settled  
5 dust data with the fiber levels found in the air  
6 of buildings.

7 So, the fact of the matter is you  
8 can find "stuff" on the top of a surface, but it  
9 begs the question: How did it get there? Was  
10 it ever in the air to begin with? Other than  
11 traversing point A to point B, were there ever  
12 any fibers in the air? The fact you find fibers  
13 on the settled surface, what does it mean in  
14 terms of risk to building occupants, that begs  
15 the question.

16 So just based on raw data, based on  
17 the fact that there are a certain number of  
18 fibers found, and given the circumstances that  
19 it's landed on top of this surface, you cannot  
20 reconcile fiber numbers with fiber levels found  
21 in buildings, that is the bottom line.

22 Q. Is it your conclusion that the  
23 figures found by Dr. Longo mean nothing in terms  
24 of risk to building occupants?

25 MR. BROWNSON: With respect to

DR. LANGER - Direct

1 settled dust?

2 MR. MILLER: I'm asking the  
3 question.

4 A. No, of course not. I didn't say nothing.  
5 Every piece of data has some meaning. The fact  
6 of the matter is: I'm interested in risk  
7 calculation and I'm interested in fiber levels  
8 in the air.

9 Now, tell me whether this pertains  
10 to fiber levels in the air. Based on what this  
11 technique involves, and based on what is  
12 presented to us, I don't think that you can rely  
13 on these data to form any conclusion regarding  
14 risk to building occupants.

15 Do they have meaning? Yeah, I  
16 suppose they have meaning. It means that it  
17 went from there to here. I'm pointing up and  
18 I'm pointing down. It went from there to here,  
19 but it carries no other significance without  
20 other data. One has to measure fiber levels in  
21 the air.

22 Q. You indicated that your calculations  
23 include the distance between, I guess, the  
24 fireproofing above and the sample below.

25 How far was that distance, sir?

DR. LANGER - Direct

1       A.     The distance that I used in this  
2       calculation was 10 centimeters.

3           Q.     Okay. Are you willing to conclude  
4       that the amosite found in the dust sample, 10  
5       centimeters below the amosite containing  
6       fireproofing, came from the fireproofing?

7       A.     Might have.

8           Q.     Is there any place else that you can  
9       realistically think that it came from?

10       A.     Well, let's say you have a maintenance guy  
11       who's going to go up into the ceiling and he's  
12       just come from the boiler room and he did a  
13       repair job in the boiler room.

14                   Is it possible that the jacket he's  
15       wearing will be contaminated with stuff from the  
16       boiler room? That's a possibility, but let's be  
17       reasonable here. You look at the material on  
18       top of the ceiling tile and you look at the  
19       material in the ceiling, and you should  
20       characterize it on the basis of fiber type,  
21       fiber chemistry, size distribution. You come to  
22       a better understanding as to whether this stuff  
23       on top of a ceiling tile really came from the  
24       ceiling.

25                   Let's say it did. Is there any

DR. LANGER - Direct

1 other way of getting it -- people talk so much  
2 about maintenance workers knocking this stuff  
3 around, it could have come from any number of  
4 sources.

5 Do I believe that that's it?

6 No, I think if you can find  
7 something on top of the ceiling tile, it  
8 probably came from whatever is sprayed on top.  
9 That's just sensible.

10 Q. You indicated that the diffraction  
11 information was not written down on a report  
12 that you saw.

13 A. It was not provided.

14 Q. Not provided.

15 Do you believe that a light  
16 microscope report should always have optical  
17 diffraction information written down?

18 MR. VALENZA: Objection.

19 A. You mean, TEM report, a transmission? You  
20 mean light microscopy?

21 Q. I did say light.

22 A. You did say light.

23 Well, what is diffraction?

24 Q. That's only for -- I'll rephrase my  
25 question.

DR. LANGER - Direct

1 Do you believe that a light  
2 microscopic report should always have written  
3 down on it optical qualities of the  
4 asbestos-containing material, such as indices  
5 and refraction?

6 MR. VALENZA: Objection.

7 A. It depends.

8 Q. On what?

9 A. See, if someone gave me a sample and I  
10 said there was amosite there, I think there's a  
11 pretty good chance there was amosite there. If  
12 there's someone that's just been trained in the  
13 laboratory, let's say, a big laboratory, as in a  
14 laboratory, and someone got three weeks training  
15 how to identify asbestos, then I'd like to see  
16 most of the characteristics written out, yes.

17 Is it necessary to do that?

18 Generally so.

19 In many of the reports there's an  
20 index of refraction given parallel to the fiber  
21 bundle and right angles to the fiber bundle and  
22 some optical characteristics which indicate and  
23 support the otherwise visual observation that  
24 this stuff is an amosite, crocidolite or  
25 chrysotile. So, generally so, you'd like a

DR. LANGER - Direct

1 little bit of quantitative information.

2 Q. You did some calculations to come up  
3 with a .3 fibers per CC level on a piece of  
4 paper in front of you, is that correct?

5 A. Yes.

6 MR. SENFTLEBEN: Objection. I  
7 thought he said .03, but I stand  
8 corrected.

9 Q. I thought it was 0.33.

10 A. Let's say it's .03, what does it matter?

11 Q. What does it matter?

12 A. It doesn't matter. Calculations could be  
13 off.

14 MR. BROWNSON: Wait for a second.

15 Q. Now, would you have any objection if  
16 I made that piece of paper an exhibit, Doctor?

17 A. Would I object to it?

18 Q. Yes.

19 You can certainly have a copy of it  
20 or we can take a copy.

21 MR. MILLER: I'd like that to be  
22 Exhibit 4.

23 MR. BROWNSON: Let's mark it as an  
24 exhibit.

25 MR. MILLER: We'll do it after a

DR. LANGER - Direct

1 break. Good.

2 Q. Then this will be the next exhibit.

3 A. I assumed a ceiling height of 10 feet -- I  
4 misspoke. Ten feet would yield a fiber level of  
5 0.01. Ten centimeters, it would be 0.3, but this  
6 is written down and so you may copy it.

7 MR. BROWNSON: We'll make that as  
8 Exhibit 4.

9 Q. If you assume the ceiling height of  
10 10 feet, does that mean that the dust sample was  
11 not taken above a suspended ceiling; rather, it  
12 had to be taken below a suspended ceiling?

13 A. Correct. Let's say you found it on a  
14 floor, in a carpet, whatever.

15 Q. Given that circumstance, Doctor,  
16 namely, you have the asbestos amosite-containing  
17 fireproofing separated by a suspended ceiling  
18 from the normal occupancy area, and somewhere  
19 down on the floor of the occupancy area the  
20 sample is taken. So you have about a 10-foot  
21 distance and you find the 107 or 102 amosite  
22 fibers in that dust sample.

23 Do you still believe that the  
24 amosite in that sample probably came from the  
25 fireproofing 10 feet above it?

DR. LANGER - Direct

1 MR. BROWNSON: I'm just interposing  
2 an objection to the form of the question  
3 because it really is hypothetical, it's  
4 not fact, but you can answer it.

5 A. May I answer it as a hypothetical?

6 Q. You can answer as a hypothetical.  
7 It's how you are looking at it, but hypothetical  
8 is fine.

9 A. The more, as the physicians would say, the  
10 more proximal this sample is to the source, the  
11 more you are secure in your conclusion.

12 The more distal this is, like if you  
13 find it on a floor under some surface embedded  
14 in the carpet, there the issue of tracking dust  
15 in a building is raised, and it could come from  
16 any number of sources. So, the closer you are  
17 to that source, the more likely it came from  
18 that source.

19 Q. Given the hypothetical I gave you,  
20 to what degree of certainty would you say that  
21 the amosite on the floor came from the  
22 fireproofing 10 feet above?

23 A. I have no idea, I've never been in the  
24 building.

25 Q. Okay. If you had a dust sample

DR. LANGER - Direct

1 taken on a ledge that's about two feet below the  
2 surface of a ceiling, and the ceiling, itself,  
3 was asbestos-containing, and the ceiling has  
4 chrysotile and you have chrysotile dust samples  
5 taken a couple feet below that level, this is  
6 all in a normal occupying area of a building,  
7 like a hallway, say --

8 A. Right.

9 Q. -- would you be willing to make any  
10 conclusion regarding the source of the chrysotile  
11 in the dust sample being the material two feet  
12 above it?

13 MR. VALENZA: Objection.

14 MR. BROWNSON: I will object to the  
15 form of the question as an improper  
16 hypothetical, but go ahead. Improper in  
17 the sense that I don't think it fits any  
18 of the facts that we're dealing with here.

19 Q. Okay. You may answer.

20 A. Chrysotile is more problematic. Obviously  
21 it comes from a greater number of sources, and  
22 there are those who believe that it is -- there  
23 are many other sources of chrysotile fiber.  
24 Amosite is more restricted in consumer products,  
25 meaning products found outside of a boiler room

DR. LANGER - Direct

1 or power plants. So there's only a limited  
2 number of sources, whereas chrysotile, you enter  
3 into a "where did it come from" kind of thing.

4 MR. MILLER: The next exhibit  
5 number, please.

6 (P-4, diagram sheet, received and  
7 marked for Identification.)

8 (P-5, cover letter, dated May 26,  
9 1995, received and marked for  
10 Identification.)

11 Q. Doctor, I've handed you Exhibit 5,  
12 which is a cover letter from Lynnae Waskosky,  
13 dated May 26, 1995, to Dan Albers. There are  
14 attached reports that are, I believe, reports  
15 prepared by you.

16 Are all the attached reports  
17 prepared by you?

18 A. No.

19 Q. Did you prepare any of them?

20 A. These reports were prepared by Dr. Nolan  
21 of my laboratory.

22 Q. Do you have any idea why Ms.  
23 Waskosky would say in the letter that the  
24 reports were prepared by Dr. Arthur Langer?

25 A. Well, she's a paralegal at Mr. Brownson's

DR. LANGER - Direct

1 law firm, and I suppose she assumed that.

2 Q. Okay. Now, did Dr. Nolan do his  
3 work under your direction and supervision and  
4 control?

5 A. I received the samples. The samples were  
6 prepared by my laboratory, by our laboratory  
7 technician, and I asked Bob Nolan, who has 15  
8 years' experience in this field, to scan the  
9 grids.

10 Q. Okay. Now, it appears to me that  
11 the work is not completed, is that correct?

12 A. As we sit here today, no, we're still  
13 working on this.

14 Q. Well, this provides a bit of a  
15 problem, since I'm supposed to ask you opinions;  
16 since your work isn't completed, it may be hard  
17 to ask you about opinions.

18 MR. MILLER: Mr. Brownson, what do  
19 you think we should do about this problem?

20 MR. BROWNSON: Work not completed  
21 largely because of the fact, as you know,  
22 our second round of sampling was just done  
23 less than a month ago.

24 My solution is, and has been, that  
25 you can ask him all you want about the

DR. LANGER - Direct

1 work that's been completed. As soon as  
2 the additional analysis from the recent  
3 sampling is completed, you'll get it. If  
4 you want to ask him about that, you're  
5 welcome to do it.

6 MR. MILLER: Okay.

7 MR. BROWNSON: I suspect that you  
8 can ask him enough questions today  
9 concerning the technique and such that  
10 when you see the additional data, it  
11 probably will not involve a lot of  
12 additional questions, but maybe it will,  
13 that's up to you.

14 Q. Let's look at the first page, HES  
15 identification number refers to Hunter  
16 Environmental Services, sir.

17 A. Which school are you in?

18 Q. The first page, as I have, table  
19 one, it should be the same that you have.

20 A. Description of sites and types of second  
21 air monitoring in South Shore High School.

22 Q. Right.

23 A. HES, Hunter Environmental -- yes.

24 Q. Do you have back-up data from them  
25 detailing the dates, the times, the exact

DR. LANGER - Direct

1 location, that type of information?

2 A. Yes, of course.

3 MR. MILLER: Has that information  
4 been provided to us, Mr. Brownson?

5 MR. BROWNSON: Yes, if you look at  
6 this previous exhibit, which I think was  
7 3.

8 MR. MILLER: It was provided. I'll  
9 take your word for it.

10 MR. BROWNSON: I'm trying to look  
11 here very quickly, which I don't see it on  
12 that exhibit. It was provided. It was  
13 the Hunter report.

14 MR. MILLER: Okay. Fair enough.

15 Q. Doctor, I'll ask you a few more  
16 general questions to see if you can give me that  
17 information.

18 Were these samples all taken during  
19 normal school hours, according to your  
20 understanding, Dr. Langer?

21 A. I don't recall. I would have to reread  
22 Hunter's report. I think so, but I'm not  
23 certain.

24 Q. For the samples taken into the  
25 specific building, were they all taken on the

DR. LANGER - Direct

1 same day except, of course, for the reference to  
2 second-day air monitoring, which I assume would  
3 be taken on a different day?

4 A. I think they were taken over two days, if  
5 I'm correct.

6 Q. Okay. Getting down to the bottom  
7 line of these, let's see, the sixth page of the  
8 report, as I count them, is: "Table 2: Results  
9 of the analysis of the membrane filters by  
10 transmission electron microscopy for asbestos in  
11 Leif Ericson Elementary School."

12 Do you have that page, sir?

13 A. Yes.

14 Q. The columns that are towards the  
15 right center are headed "Chrysotile asbestos  
16 fibers detected."

17 Do you see that?

18 A. Yes.

19 Q. Some columns simply have asbestos  
20 fibers detected.

21 Was there a distinction or reason  
22 why some columns on some pages use the word  
23 "chrysotile," and others do not?

24 A. No, I don't know.

25 Q. If the amphibole fibers were

DR. LANGER - Direct

1 detected in this specific school we are looking  
2 at, which has a heading of only chrysotile  
3 asbestos fibers, would there be some indication  
4 of amphiboles or should there be?

5 A. Normally, we indicate asbestos fibers  
6 detected, and if an asbestos fiber is detected,  
7 then we note which asbestos fiber type.

8 So we made reports before in which  
9 we indicated it was either chrysotile or amosite.  
10 We never found any crocidolite in the air, nor  
11 have we found any other fiber by either amosite  
12 or chrysotile. Why that says chrysotile, I'm  
13 not certain, other than the fact that this was  
14 awfully rushed when we made this report.

15 Everything that takes time is the actual  
16 scanning, of course.

17 Q. As I look through these reports and  
18 I look at the columns where it's either  
19 chrysotile or just asbestos fibers detected,  
20 where there is a numerical result, it is always  
21 zero.

22 Is that how you read it, also?

23 A. No.

24 Q. Where do you see fibers detected,  
25 sir?

DR. LANGER - Direct

1 A. Well --

2 Q. Asbestos fibers detected?

3 A. Well, asbestos fibers detected, there were  
4 no asbestos fibers detected. I think you were  
5 referring to the airborne concentration. It's  
6 never referred to as zero, of course, less than  
7 a certain limit of detection based on the amount  
8 of air actually scanned on the filter, the  
9 amount of particulates deposited from air  
10 scanned.

11 Q. Thus far, Dr. Nolan has found no  
12 asbestos fibers whatsoever in those that he has  
13 reported results on, is that correct?

14 A. These are as reported, correct.

15 Q. Do you have any back-up data of any  
16 typewritten data regarding these air samples  
17 that have not been presented?

18 A. What do you mean, the scientific data?

19 Q. Any type of spectra charts, any --  
20 you broadly included Dr. Nolan when you did  
21 these air samples, were there documents prepared  
22 that we don't have?

23 A. Well, I don't know what you can prepare if  
24 you don't see the asbestos fibers. That's what  
25 you're counting. You don't just count the

DR. LANGER - Direct

1       particulates or photograph particulates, what  
2       you do is look for fibers.

3               Q.     You don't have, for example,  
4       electron micrograph data sets of some sort?

5       A.     You mean, an actual printout of the grid  
6       shown in the various areas scanned?

7               Q.     Among other things, yes.

8       A.     I don't have those with me.

9               Q.     Okay.

10      A.     Since the project is not finished as yet,  
11      normally those are a part of a file and they're  
12      kept in one place.

13              Q.     Would they normally be turned over  
14      to your clients when the project is done?

15      A.     Sure.

16                      MR. MILLER:   Okay.  I would  
17      appreciate, of course, receiving  
18      everything.

19                      MR. BROWNSON:  Right, you'll get all  
20      that.

21                      MR. MILLER:   Okay.

22              Q.     Let's move on a little bit, sir.

23                      Do you have with you the photographs  
24      that you looked at of the three buildings?

25      A.     No.

DR. LANGER - Direct

1 Q. Category 8 says that you will rely  
2 on documents pertaining to Asbestospray and/or  
3 Spray Mineral Fibers Manufacturing Association.

4 Is it all right with you if I call  
5 it SMFMA for short?

6 A. No, I would say it's most certainly not  
7 correct.

8 Q. Not correct?

9 A. No. I want you to call them anything else  
10 but that. As a matter of fact, you mean the  
11 sprayed mineral fiber, whatever?

12 Q. Manufacturing Association, SMFMA?

13 A. Can't we agree on some other term?

14 Q. What would you prefer?

15 You're serious?

16 A. Sprayed Fiber Association.

17 Q. Okay. Sprayed Fiber Association,  
18 Doctor.

19 I'm looking at what's been given to  
20 me. I believe it's supposed to be Exhibit A.  
21 It's a fairly thick pile of papers, generically,  
22 about Asbestospray or Sprayed Mineral  
23 Manufacturers. I don't see anything in here  
24 dealing specifically with this case.

25 Tell me how this is going to support

DR. LANGER - Direct

1 your opinions, this Exhibit A information.

2 A. What opinions are there? Those that are  
3 going to be objected to are going to be supported?

4 Are we talking the Sprayed Mineral  
5 Fiber Association? Then they will help me. If  
6 you're going to ask me about Mr. Herbert Levine,  
7 who is president of the company, these will help  
8 me. If we are interested in whether this  
9 organization participated in asbestos research  
10 at Mount Sinai, these documents will help me.  
11 If you're going to suggest to me that this  
12 organization was a nefarious organization with  
13 suppressed data and injured workers, then these  
14 data will support me in my opinions.

15 Q. Doctor, it's obvious that the large  
16 number of documents in there could be relevant  
17 for many different issues.

18 A. Exactly correct.

19 Q. The point is, though, that it has  
20 been presented to me by Mr. Brownson as material  
21 on which you will specifically rely, so I think  
22 it's fair to ask you: What is this type of  
23 information which in some way is generically  
24 different than everything else we've talked  
25 about today?

DR. LANGER - Direct

1 A. Correct.

2 Q. How do you expect this to be  
3 relevant to what you expect your direct  
4 testimony to be? I don't mean relevant in a  
5 legal sense, where does it fit in so I get a  
6 fair shot to ask you a question without looking  
7 through hours -- to go through page by page?

8 MR. BROWNSON: I can probably move  
9 that along.

10 MR. MILLER: Appreciate it.

11 MR. BROWNSON: Dr. Nolan had certain  
12 contact with Herbert Levine, who is  
13 president of Sprayed Mineral Fibers  
14 Manufacturing Association. Dr. Nolan  
15 worked at Mount Sinai and --

16 THE WITNESS: You misspoke.

17 MR. BROWNSON: I meant Dr. Langer.

18 MR. MILLER: That's right, you did  
19 say that.

20 MR. BROWNSON: To some extent you  
21 can appreciate that we don't know what the  
22 evidence may be on various theories with  
23 respect to liabilities against Asbestospray,  
24 but to the extent that any of the claims  
25 involved analyzing conducting Asbestospray

DR. LANGER - Direct

1           during the years the material was applied  
2           in these buildings, we may ask Dr. Langer  
3           to respond to that in terms of what he knows  
4           about the activities in Asbestospray during  
5           those years, and that's why he's reviewed  
6           this.

7           MR. MILLER: Thank you.

8           BY MR. MILLER:

9           Q.     Can you, in summary, tell me what  
10          you would tell the jury if you were asked: What  
11          do you know about Dr. Levine --

12          A.     Mr. Levine.

13          Q.     -- Mr. Levine, and his activity  
14          about asbestos during the years covered by these  
15          documents?

16          A.     That's a fair question.

17                 Mr. Levine frequently came to Mount  
18          Sinai to discuss issues of asbestos and its  
19          health effects. He frequently met with Irving  
20          Selikoff. Mr. Levine, through his organization,  
21          Sprayed Mineral Fiber Manufacturer's  
22          Association, contributed to some of the ongoing  
23          projects at Mount Sinai. Mr. Levine generously  
24          gave of his time, he generously gave of his  
25          knowledge in the field, he provided investigators

DR. LANGER - Direct

1 in our laboratory with information concerning  
2 ongoing spray activities, and allowed members of  
3 our research group to visit sites and to perform  
4 air sampling exercises.

5 He was forthcoming. He participated  
6 in several of our early courses on asbestosis at  
7 Mount Sinai. I found him to be reliable and  
8 honest and open, generous with his resources,  
9 and a refreshing individual in terms of a  
10 representative of asbestos concerning the late  
11 1960's, early 1970's.

12 Q. Doctor, before we broke, you made a  
13 comment that Dr. -- excuse me -- Mr. Levine was  
14 refreshing, I think, in terms of people in this  
15 issue at that time.

16 Whom did you contrast Mr. Levine to?  
17 You said he was refreshing. Refreshing in terms  
18 of comparison to X?

19 A. Well, let's invoke one of the great demons  
20 of modern industry. A lawyer, by training,  
21 called Vandiver Brown, who is quoted or is  
22 reported to have said, "The less said about  
23 this, the better, in terms of diseases," so on  
24 and so forth, that would be one side of the  
25 fulcrum; and on the other side is Herb Levine,

DR. LANGER - Direct

1 who is willing, able, open and generous with  
2 resources, as I have said.

3 Q. Okay. When did you first get this  
4 pile of documents which is supposed to be No. 8  
5 as listed on this Exhibit 3?

6 A. I don't remember. Several months ago, I'm  
7 sure.

8 Q. You agree with me that these  
9 documents are not in chronological order? Do  
10 you agree with that?

11 A. I don't remember, but I put mine in  
12 chronological order.

13 Q. Did you notice whether or not there  
14 were documents which appeared to be missing  
15 because Bates stamp numbers would jump from one  
16 document to another?

17 A. Well, there are some documents that didn't  
18 belong in there, actually, which I pulled out,  
19 so that might account for it. This enterprise  
20 is carried out by someone who is going to take  
21 the 5 o'clock train home or something.  
22 Hopefully, the documents are put into some order  
23 that make them useful, but it doesn't always  
24 happen that way. So you have to look at a box  
25 of documents, see what's there, and do your own

DR. LANGER - Direct

1 kind of recategorizing, if that's a word, and  
2 this has to be done.

3 Are there documents missing? I  
4 don't know. I haven't thought about looking. I  
5 mean, are there jumps from 1967 through 1971? I  
6 didn't notice any, but there may be.

7 Q. How do you know that you're getting  
8 the complete story about what happened with the  
9 Sprayed Mineral Fibers Association, Mr. Levine,  
10 in those years regarding your concerning  
11 interest and testing for asbestos?

12 How do you know those documents are  
13 complete?

14 A. I'm glad you asked me that question  
15 because this is something I volunteered with  
16 Mr. Brownson not too long ago.

17 That is, I was there at Mount Sinai  
18 at that particular time, and I was involved in  
19 most of those activities, and I had an  
20 impression as to what Mr. Levine's contribution  
21 was, and these documents reinforced my  
22 previously-held opinions and high regard for  
23 him.

24 Q. Was there any other asbestos  
25 manufacturer at that time whose representatives

DR. LANGER - Direct

1 or general policies struck you as favorably as  
2 Mr. Levine obviously has?

3 MR. VALENZA: Objection.

4 MR. BROWNSON: I'll object to the  
5 characterization of "asbestos  
6 manufacturer." He didn't manufacture  
7 asbestos, he manufactured products.

8 Subject to that objection, go ahead.

9 A. My interaction with manufacturers? Let's  
10 say Johns-Manville was considerable at that time  
11 and we were involved in certain joint studies  
12 with the Johns-Manville Corporation, and I found  
13 them to be generally helpful and open, generally  
14 so.

15 Q. Did you have any contact during that  
16 time with representatives of U.S. Gypsum?

17 A. I don't think so, no.

18 Q. Did you have any contact with  
19 representatives of W.R. Grace during that time?

20 A. I don't think so. You mean, in the late  
21 '60s, early '70s?

22 Q. Yes.

23 A. I don't think so. I mean, I may have. I  
24 may have misspoke. Is there someone who contacted  
25 me, who wrote me a letter or called me on the

DR. LANGER - Direct

1 telephone? It's possible, but I don't think  
2 so. I cannot recall; that's a better response,  
3 I cannot recall.

4 Q. Remember the documents in here that  
5 showed a report by Davershaw Cooper on air  
6 sampling, taken in the building in California,  
7 sir?

8 A. Yes.

9 Q. That was in the Wells Fargo building,  
10 was it not?

11 A. Yes.

12 Q. That product was Kafco, is that  
13 correct?

14 A. I believe so.

15 Q. What's your opinion about the  
16 results of that air sampling?

17 I have the document tabbed, if you  
18 would like to look at it.

19 A. May I?

20 Q. Yes. There's certainly more than  
21 one document, and I will try to give you the two  
22 key ones.

23 For the record, the two documents  
24 I'm showing you, I believe, are the two main  
25 reports. There are other documents that are in

DR. LANGER - Direct

1 the transmittal letters, one dated September  
2 23rd.

3 A. This is 1970 and '71, isn't it?

4 MR. BROWNSON: Let him finish.

5 Q. There's a subsequent one dated  
6 November 5th, 1970, and there are other letters,  
7 but these are the two key ones.

8 A. Here on my notes which I consider  
9 important, and whether I get out of this, so to  
10 speak.

11 Q. Please read your notes. I  
12 appreciate it.

13 A. There's a letter of 23 September, 1970.  
14 This is Fowler of Davershaw Cooper of Mr.  
15 Levine, a preliminary report. This is  
16 Montgomery Ward.

17 Q. I think it was Wells Fargo.

18 A. Well, hold it a second. Let's go down to  
19 Wells Fargo, Fowler to Cooper to the Sprayed  
20 Mineral Fiber Manufacturer's Association.  
21 That's 5 November, '70.

22 Q. Those are the two I put in front of  
23 you now?

24 A. Yeah. The values are 00085, 0011, 0019,  
25 rounds it out to 001, 001, 002.

DR. LANGER - Direct

1 Now, they --

2 Q. Can we stop right there for a  
3 second?

4 A. Sure.

5 Q. Are those the values of the report  
6 or values that you have recalculated yourself  
7 from other data?

8 A. The values in the report are as follows:  
9 0.00085, 0.0011 and 0.0019, and I just rounded  
10 them out.

11 They're all pretty much -- but say  
12 that they are the same, for argument's sake.  
13 Now, this was couched in 1970, according to the  
14 TLV, to prevent asbestosis.

15 Again, the threshold limit values at  
16 that time, 1970, this predates OSHA two years.  
17 We are relying on the American Conference of  
18 Governmental Industrial Hygienists, ACGIH, in  
19 which the TLV, to prevent asbestosis, what they  
20 call 5,000 fibers per liter, five fibers per CC,  
21 no firm guidelines on levels, and they say that  
22 these fiber levels, 001 or 01, probably such  
23 amounts constitutes no risk.

24 So, given asbestosis, given the  
25 TLV's at the time, given the fiber levels they

DR. LANGER - Direct

1 found, it's not such an outrageous conclusion.

2 In fact, it's pretty good.

3 Q. Do you agree with the other  
4 conclusion reached in both of those reports  
5 regarding the same study, that air passing along  
6 the airplane line with Kafco has more asbestos  
7 in it after passing through an air plenum, before  
8 it passes through it, is in a statistical  
9 increase in asbestos?

10 A. That is their conclusion.

11 Q. Do you have any reason to doubt  
12 that?

13 A. No. Why should I?

14 Q. Do you have any further comments  
15 about that?

16 You're looking at your notes, sir.

17 A. No, I think that --

18 Q. The next, category 9, "Air sampling  
19 data obtained by Asbestospray consultants in  
20 other property damage litigation."

21 I have another quick question before  
22 you do that.

23 A. Shoot.

24 Q. Some of the other information  
25 concerns a Maryland project.

DR. LANGER - Direct

1                   What type of building or buildings was  
2                   that, do you know?

3           A.     My understanding is that this was from the  
4           State office building, Preston Street.

5           Q.     The next set of information I see  
6           concerns samples taken in the Trans World  
7           Airline terminal in Kennedy Airport in New York.

8                   Is that the same TWA terminal which  
9           had some samples taken in these documents that  
10          we saw in Exhibit A, early samples, if you know?

11          A.     I don't know.

12          Q.     Okay. The next samples come from  
13          Columbia, South Carolina, USC Business  
14          Administration Building.

15                   Is that a university, if you know?

16          A.     Yes.

17          Q.     The next samples come from a  
18          convention center in Wichita, Kansas, is that  
19          correct, sir?

20          A.     Yes.

21          Q.     Next samples come from a West  
22          Virginia University coliseum in Bordentown, West  
23          Virginia, is that correct?

24          A.     Correct.

25          Q.     The last samples refer to a drop

DR. LANGER - Direct

1 test in the coliseum in West Virginia  
2 University.

3 What was that test all about?

4 THE WITNESS: Do you have an  
5 objection that you want to get on the  
6 record?

7 MR. BROWNSON: No, I have no  
8 objection to that question.

9 A. The contention at that time that concerned  
10 plaintiff's data was that when and if this  
11 material failed, it would drop to the ground and  
12 generate dust, that there could be a catastrophic  
13 failure if this material was on the coliseum  
14 ceiling. So, they constructed an isolated  
15 chamber and they dropped some stuff at a certain  
16 height, whether it was three meters or four  
17 meters or 10 meters, whatever it was, and they  
18 dropped the stuff into this glove box, which is,  
19 for many human beings, it's 20 feet high and 10  
20 feet by 10 feet, whatever the dimensions were,  
21 and they dropped the stuff down and they  
22 measured the amount of fiber liberated in this  
23 drop test.

24 Q. Is the information that you have  
25 here as part of this category 9, the

DR. LANGER - Direct

1 plaintiffs's generated information on the drop  
2 test, or is this information that you or  
3 somebody in your office have prepared?

4 A. I think I took the information from the  
5 plaintiff's data and I may have recalculated a  
6 couple of things, but that's it.

7 Q. Was the plaintiff's data published,  
8 if you know?

9 A. I don't think so.

10 Q. This was part of the West Virginia?

11 A. Wait a minute. I think it may be  
12 published in part in the Collegium Ramazzini,  
13 but I'm not sure.

14 Q. Was this drop test originally part  
15 of the West Virginia litigation, asbestos  
16 property damage litigation?

17 A. You mean, was it carried out for that  
18 purpose?

19 Q. Yes, sir, if you know.

20 A. I think so.

21 Q. Now, I've gone through this category  
22 9, and to the best of your recollection, have I  
23 listed all the different types of buildings and  
24 locations of air sampling that you have under  
25 this category 9?

DR. LANGER - Direct

1 A. Well, actually, there's two other work  
2 sites which use the Asbestospray T formulation.  
3 One is the Wallbrook High School, and the other  
4 is the one that's in Maryland, and the other is  
5 the Erasmus Hall; I mean, it's arguably  
6 Asbestospray product, Erasmus Hall in Brooklyn,  
7 so there's two other data sets.

8 MR. MILLER: Mr. Brownson, I guess  
9 there's no objection to provide the other  
10 data sets?

11 MR. BROWNSON: I don't -- oh, we  
12 just didn't have the written reports?

13 THE WITNESS: I may have them in our  
14 computer.

15 MR. BROWNSON: To the extent that  
16 they can be found and generated, we will  
17 provide them.

18 THE WITNESS: Of course.

19 Q. Can you tell me, in summary, what  
20 the air sampling data shows for each of those?

21 A. I think Erasmus Hall was 0008. That was  
22 an average. The outside air was a little  
23 higher. The Wallbrook High School also was  
24 triple digits, some numeral.

25 MR. MILLER: Let's break.

DR. LANGER - Direct

1 (Whereupon a brief recess was taken  
2 at 2:00 p.m.)

3 (Whereupon the proceedings resumed  
4 at 2:15 p.m.)

5 BY MR. MILLER:

6 Q. Doctor, back to Exhibit 3, which is  
7 the listing of materials in which you will rely  
8 in this case, subsections 10 and 11 both refer  
9 to the symposium held at Harvard in 1988,  
10 published in 1989.

11 I have questioned you about this  
12 before. I would appreciate it if you can, very  
13 briefly, summarize for me, if I were Mr. Brownson,  
14 asking you to explain to the jury the lessons  
15 from that symposium, including, of course, your  
16 article which was part of it.

17 MR. BROWNSON: Well, the question is  
18 broad and I'll object to it, but go ahead.

19 A. Very broad. However, I shall attempt to  
20 answer it.

21 The papers presented at Harvard,  
22 actually in the Kennedy School of Government,  
23 reported on current epidemiological findings,  
24 current experimental findings, current fiber  
25 levels found in buildings. A synthesis of those

DR. LANGER - Direct

1 data sets was attempted, and the conclusion was  
2 that "the asbestos in the buildings problem,"  
3 put that in quotes, was overblown in the United  
4 States, to use a phrase, and that it was not as  
5 serious a problem as envisioned by various  
6 groups, including groups within the Federal  
7 government, agencies within the Federal  
8 government.

9 Q. With regard to the asbestos problem,  
10 reference specifically was to the asbestos  
11 problem for passive building occupants, is that  
12 correct, sir?

13 A. No. As a matter of fact, we touched on  
14 asbestos exposure in a range of settings, not  
15 merely building occupants but, of course, the  
16 nature of the symposium was the health effects  
17 to building occupants, which included passive  
18 occupants.

19 Q. If you can summarize briefly to the  
20 jury your paper that was presented there and  
21 published there.

22 A. That paper focused on fiber type and the  
23 asbestos diseases. It reviewed much  
24 epidemiological data, at least those studies  
25 which delineated among the fiber types. It

DR. LANGER - Direct

1 touched upon environmental mesothelioma in  
2 certain settings. It touched upon the papers  
3 upon which risk is calculated, and clearly  
4 showed that there is a significant difference in  
5 the mortality experience of workers exposed to  
6 chrysotile asbestos as compared to those workers  
7 exposed to one of the amphibole asbestos types.

8 The paper also included some data  
9 pertaining to fibers in the lungs of workers in  
10 the United States.

11 The paper also included some  
12 interesting data on fiber types found in certain  
13 kinds of products in the United States, and  
14 basically concluded that there is a very  
15 significant difference in fiber type potency to  
16 reduce asbestos diseases, and that because  
17 chrysotile was one of the prominent types that  
18 we deal with in buildings, the risks associated  
19 with such exposures were much less than  
20 previously perceived.

21 Q. Category 12 of Exhibit 3 refers to  
22 the "Health Effects Institute - Asbestos  
23 Research," a 1991 document. Again, I've asked  
24 you about this before.

25 Would you be kind enough to

DR. LANGER - Direct

1 summarize briefly, as if I were Mr. Brownson  
2 asking you to summarize for the jury, the main  
3 lessons for that document?

4 MR. BROWNSON: Again, I'll object to  
5 the form of the question, but go ahead.

6 A. Well, you have the document here.

7 Q. I do?

8 A. There's an executive summary and --

9 Q. Would you simply refer to the  
10 lessons of the executive summary?

11 A. You're not going to give me that nice  
12 volume that you have all marked up?

13 Oh, okay.

14 The executive summary includes a  
15 general background to this problem with asbestos  
16 in schools, some brief description of what  
17 asbestos is and how it was used in the United  
18 States, the methods by which the panel reviewed  
19 and either accepted or rejected data sets, the  
20 methodology of the review committee, the  
21 presence of asbestos in public and commercial  
22 buildings, the general categories of exposed  
23 groups within these buildings, how asbestos is  
24 measured in various environments, what the  
25 exposure to asbestos in buildings is based on

DR. LANGER - Direct

1 the available data, some measurement of what the  
2 asbestos levels are in the ambient air, a focus  
3 on the levels found inside of buildings with  
4 asbestos-containing products, exposure  
5 categories and distinctions made on the basis of  
6 different categories of occupants, from passive  
7 occupants to emergency workers who come in and  
8 fight fires, the control of the asbestos  
9 exposure in buildings through operations and  
10 maintenance, the potential health effects  
11 associated with exposure to fiber in buildings,  
12 and the various physical chemical properties  
13 which are thought to govern these risks, the  
14 risks to building occupants based on the fiber  
15 levels, and the various models used to calculate  
16 risks, the presence of man-made mineral fibers,  
17 the so-called vitreous fibers in buildings,  
18 whether or not these are of concern, and  
19 finally, research needs.

20 Q. Were the risks, as calculated in the  
21 Summary to the Harvard Symposium, one in  
22 100,000; that is, the risks of asbestos related  
23 to the death for somebody in a school?

24 A. I don't recall. Why don't you give me the  
25 paper and let me look at it.

DR. LANGER - Direct

1                   Okay. I think this is it, sir, and  
2                   this is the summary, also. Oh, that's what I  
3                   want, the summary of it.

4                   Q.     I think that may be it.

5                   A.     Yes, Spengler and colleague's summary.

6                                 MR. BROWNSON: I'm going to object  
7                   to the form of the question. I think the  
8                   risk calculated was in buildings, not  
9                   schools.

10                  A.     Buildings, yes.

11                                 Now, the question is: What is the  
12                  risk in?

13                  Q.     The Summary of the Harvard Symposium  
14                  to persons in buildings?

15                  A.     In conclusion, number seven in the  
16                  executive summary, the following statements are  
17                  present:

18                                 Recent data indicate the average  
19                  concentration of asbestos in schools and other  
20                  buildings is that asbestos-containing materials  
21                  is generally well below the 0.001 fibers per ML  
22                  used in risk calculations performed for school  
23                  children. Of course that's mixed fibers of  
24                  different types T.

25                                 Using these conservative risk models

DR. LANGER - Direct

1 of exposures higher than typically measured are  
2 the projected lifetime risk from exposure to  
3 mixed asbestos fibers is one death among the  
4 cohort of one in a thousand children.

5 Q. Now, to the HEI executive summary  
6 table, 1-1, Page 1-11, also has some lifetime  
7 cancer risks, is that correct?

8 A. Yes, it does.

9 Q. Do you consider those risks to be  
10 substantially the same as the Harvard University  
11 risks you just read for exposure in a building?

12 A. Are they the same, you said?

13 Q. Yes, sir.

14 A. Okay. Reading this table, we're talking  
15 about school-aged children, 5 to 18 years, 180  
16 days per year, five hours per day. Given two  
17 different averages which are different by an  
18 order of magnitude, one is five times higher  
19 than the value that we just read .001, and the  
20 other is one half that value.

21 So, therefore, we're dealing with an  
22 order of magnitude difference in dose, and then  
23 given these various conditions, the premature  
24 cancer deaths, the lifetime deaths per million.  
25 So six per million would be .6 per 100,000.

DR. LANGER - Direct

1       Let's say it's one per 100,000, at half the dose  
2       given in the Harvard school, and the 60 per  
3       million or six per 100,000 is the risk which is  
4       five times higher.

5                     So, are these values the same? Yes,  
6       they're pretty much the same.

7             Q.     Do you think that in making risk  
8       predictions that a difference of five times  
9       something you can say is basically the same?

10       A.     No, no, no, I didn't say that.

11             Q.     Okay. I misunderstood you, then.

12       A.     The Harvard, Spengler, et al., executive  
13       summary says, given the fiber level of .001, it's  
14       approximately one in a 100,000. This table says  
15       given a level .005, which is five times the  
16       value of 001, is approximately 60 per million,  
17       or six per 100,000. So, you have five times the  
18       level, linear five times one is five, so they  
19       have six instead of five. So, they're given the  
20       numbers five and six. They are statistically  
21       identical. So this is the same model and the  
22       same people crunching the numbers.

23             Q.     Thank you, Doctor.

24                     On Page 1-6 on the AGI executive  
25       summary, there is a figure 1-1.

DR. LANGER - Direct

1 Can you turn to that, please?

2 A. Sure, yes.

3 Q. Can you explain, if you have an  
4 answer, to why the mean value for average air  
5 board concentrations in non-litigation data by  
6 building type is at least twice as high in  
7 schools as in all buildings, residences and  
8 public and commercial buildings?

9 MR. BROWNSON: Can you just read  
10 that back for me, please? I'm not sure I  
11 caught the question.

12 (Whereupon the pending question was  
13 read back.)

14 MR. VALENZA: Objection.

15 MR. BROWNSON: I'll object to the  
16 form. Go ahead.

17 Q. Did you understand my question,  
18 Doctor?

19 A. I understand the question that I'm looking  
20 the data and that which you've stated is  
21 correct, the schools are twice as high as these  
22 other structures. So, if the schools are at  
23 0005 and these are about 00025, they're about  
24 half, that is correct.

25 Why is it higher in the school

DR. LANGER - Direct

1 buildings? There have been a lot of interesting  
2 hypotheses generated, it may be the activity in  
3 the building, it may be any number of reasons,  
4 but can I answer it definitively? No, no, I  
5 can't do it.

6 Q. Do you have an answer that you  
7 believe is more likely than others?

8 A. I'm sorry?

9 Q. Do you have an answer that you  
10 believe is more likely than others?

11 MR. VALENZA: Objection. Speculation.

12 A. No.

13 Q. Okay. Doctor, the last category of  
14 documents on which you will specifically rely in  
15 this case as listed in Exhibit 3 is the article  
16 you wrote with Drs. Wilson, Nolan, Gee and Ross,  
17 titled: "Asbestos in New York City Public School  
18 Buildings - Public Policy: Is There a Scientific  
19 Basis?"

20 I have just a couple of questions to  
21 ask you about that, and if you would like, I'd  
22 put a copy of the article in front of you and if  
23 you want to refer to it, you may now.

24 First of all, sir, did you receive  
25 any type of grant or sponsorship, financial

DR. LANGER - Direct

1 sponsorship from any asbestos litigation  
2 defendant for writing this paper?

3 A. No.

4 Q. Do you know if anyone did?

5 A. No, I'm quite sure no one did.

6 Q. Okay. There is a specific reference  
7 to an analysis of a sample in one of the New York City  
8 schools. It's on Page 165.

9 Was that sample analyzed as part of  
10 the litigation?

11 A. Yes. Pending litigation, correct.

12 Q. There are, of course -- I take it  
13 that some asbestos defendant paid for the  
14 analysis of that sample, is that correct?

15 A. Yes.

16 Q. Which defendant was it?

17 A. Asbestospray.

18 Q. Page 162 is the following statement,  
19 the first full paragraph: "NYC's Board of  
20 Education was not required by law to measure the  
21 asbestos fiber concentrations in air, or the  
22 type of asbestos present before any asbestos  
23 abatements was to take place."

24 Do you believe that it should be so  
25 required by law?

DR. LANGER - Direct

1 A. Should it be required by law?

2 Well, I think before any abatement  
3 activity, number one, you want to make sure you  
4 have asbestos in the product that you are  
5 abating, ripping out. You may think that this  
6 is trivial and kind of stupid, but let's carry  
7 on from there.

8 Do I believe that it should be  
9 required to measure fibers in the air? I think  
10 that if someone gives advice, they should base  
11 this on some perceived, or some not perceived so  
12 much, base this on some estimate of risk  
13 associated with each of these instances.

14 Q. Therefore, do you believe that, by  
15 law, they should be required to consider:  
16 Number one, concentrations in the air; and  
17 number two, the type of asbestos present before  
18 any asbestos abatement?

19 MR. BROWNSON: Well, I guess I'll  
20 object to the form of the question, and I'm  
21 not sure what the exact legal objection is  
22 other than the fact that you're asking for a  
23 hypothetical legal conclusion.

24 A. Yeah, it is a legal conclusion.

25 MR. BROWNSON: Go ahead.

DR. LANGER - Direct

1 A. I'm one of those people that believes you  
2 ought to do what's right without having it  
3 mandated.

4 Q. You believe certainly --

5 A. What do I believe? Let me just interrupt  
6 you. Let me finish this.

7 If, let's say, you are a school  
8 district, like Chicago, New York or Los Angeles,  
9 and you're going to expend \$125 million in an  
10 asbestos abatement activity, I think that you  
11 should know something about the risks that you  
12 are addressing. I think the way to do that is  
13 to measure that which is the hazardous elements  
14 of environment, which means measure fiber in the  
15 air and come to some understanding as to, at  
16 least prioritize various buildings and places  
17 and so on and so forth. Some might have a  
18 measurable risk, others not, but you ought to do  
19 something in terms of establishing a data base  
20 upon which you will base your decisions.

21 Q. Do you believe that another thing a  
22 school district should do in terms of  
23 prioritizing is to establish the type of asbestos  
24 present?

25 A. Yes, I do. I certainly believe that.

DR. LANGER - Direct

1 Q. Would you, in general, all other  
2 things being equal, recommend the removal of an  
3 amosite-containing, asbestos-containing material  
4 before the removal of a chrysotile  
5 asbestos-containing material?

6 A. You mean, all of the factors equal?

7 Q. Sure.

8 A. Probably.

9 Q. On Page 163 of your article is a  
10 list of EPA guidance documents.

11 Did you have any connection with the  
12 Yellow Book?

13 A. No.

14 Q. Did you have any connection with the  
15 first Green Book of 1983?

16 A. I don't think so. I may have reviewed it,  
17 but I'm not sure.

18 Q. Did you have any connection with the  
19 Silver Book of 1984?

20 A. No, I don't think so.

21 Q. Do you still agree with this  
22 sentence which is written on Page 166, "The  
23 acceptance of risk is a social and moral issue,  
24 and scientists are no better qualified than  
25 anyone else to decide whether a risk is

DR. LANGER - Direct

1 acceptable or not"?

2 A. Absolutely.

3 Q. You also still believe that  
4 scientists will provide the best available data  
5 for decision makers and that scientists should  
6 be consulted?

7 A. Sure.

8 Q. Okay. On Page 166, at the very  
9 bottom, just before the heading "Other  
10 approaches to address asbestos in schools," is  
11 the statement: "If such removals have taken  
12 place, the lifetime risk of school children and  
13 teachers increase," citing the US EPA 1990,  
14 which in the back, you indicate, I believe was  
15 the Green Book, is there a specific statement in  
16 the Green Book, this being the second Green Book  
17 that says, "If there's a poorly executed removal  
18 program, that will increase the lifetime risk of  
19 school children and teachers"?

20 A. I think that's listed directly from the  
21 Green Book, or is the citing of a study in Great  
22 Britain, and I'm thinking of Bridet and Rude  
23 (phonetic), their study which showed elevated  
24 levels in buildings after abatement, school  
25 buildings, that followed the six months after

DR. LANGER - Direct

1       abatement.

2                       So, we're talking about the actual  
3       fiber levels where they talk about that in that  
4       particular reference.  If you calculate the  
5       fiber levels found before, during and after, the  
6       lifetime risk of those individuals increased.

7               Q.     This was done in the Green Book, you  
8       believe?

9       A.     I think so.  As I sit here and recall it.

10              Q.     I'm now going to ask you a couple  
11       questions, Doctor, about your article titled  
12       "chrysotile, its occurrence and properties as  
13       variables controlling biological effects," and I  
14       have a copy of it in front of you, in case you  
15       would like to look at it.

16       A.     Sure.

17              Q.     Do you know, first of all, which  
18       industry sources gave funds to support this  
19       conference?

20       A.     No.

21              Q.     Do you know any of them?

22       A.     No.  This conference was to be supported  
23       by an international program for chemical safety,  
24       but I think NIOSH withdrew some support, so they  
25       generated funds from other places.

DR. LANGER - Direct

1 Q. Do you believe that the mechanical  
2 manipulation required for the industrial  
3 application of chrysotile can increase the  
4 carcinogenic effects of chrysotile?

5 A. Yes.

6 Q. Specifically, what is there about  
7 that mechanical manipulation which leads to an  
8 increased carcinogenic effect?

9 A. We're talking in the generic sense now?

10 Q. Yes, sir.

11 A. We're not talking about the degradation,  
12 the grinding of stuff -- "stuff", that's such a  
13 bad word -- the grinding of fiber which alters  
14 surface properties decreases crystallinity or  
15 thermal shock brought about by friction product  
16 usage, things like that, that decreases it.

17 It is the opening of the fiber  
18 bundle, for example, in the textile industry, in  
19 which you get a lot of long, thin fibers  
20 generated in the willowing and spinning  
21 processes in asbestos textiles, which increases  
22 the carcinogenic textile of this mineral fiber,  
23 yes.

24 Q. Do you believe that that manipulation  
25 is responsible for the results found in the

DR. LANGER - Direct

1 Charleston textile mill study?

2 A. It's one of the possible explanations,  
3 yes.

4 Q. Do you know of any other possible  
5 explanations?

6 A. You mean, for lung cancer in Charleston,  
7 South Carolina?

8 Q. Yes.

9 A. As you know, Charleston, South Carolina is  
10 the northernmost extent of the cancer belt in  
11 the United States, which begins around the Gulf  
12 Coast and goes up the coast of North America.  
13 It's a paper written in 1976 by Bill, Blott and  
14 Fraumin (phonetic). They talked about cancer  
15 belts in the United States, and Charleston  
16 happens to be one of the last of the high cancer  
17 areas for lung cancer in which the SMR's,  
18 standardized mortality ratios, for lung cancer  
19 are elevated above national background. No one  
20 knows quite why. That's one explanation, that  
21 the referent population used by Dement was the  
22 wrong one.

23 There's another one given by Corbit  
24 McDonald. He seems to favor the use of oils in  
25 the dust suppression as being another factor in

DR. LANGER - Direct

1       **this.**

2                       There is the third additional  
3       factor, Charleston's a big port; city people are  
4       exposed to amphiboles, that's another factor.

5                       Then there's a factor that the  
6       actual machinery, itself, broke apart the fiber  
7       bundles and produced an aerosol with  
8       characteristics unlike fibers found in other  
9       environments.

10                      Then there's another factor which is  
11       not stated by Dr. Dement, that the tissue burden  
12       study was done by Fred Pooley in Great Britain.  
13       Fred Pooley found crocidolite, and those  
14       tissues showed that those working in this plant  
15       also spun crocidolite for a short time, so  
16       there's many of these confounders and variables  
17       which haven't been embellished or brought out in  
18       the ideology of this peculiarly high incident of  
19       lung cancer by physical chemical properties.

20                      One of these -- and I'm one of the  
21       people who believes that we were dealing with a  
22       very interesting dust, meaning, it was -- I  
23       don't understand the resolution of the light  
24       microscope, it was very thin, but certainly  
25       sufficiently high in long, thin fibers to be

DR. LANGER - Direct

1 produced in the thesis.

2 Q. How do you know that Pooley found  
3 crocidolite fibers?

4 A. He told me, and from -- the records also  
5 report these, I think they're reported in the --  
6 I think they are reported in the General Motors  
7 biological effects of chrysotile, the meeting  
8 which was held by Chris Vogna, in Cardiff, in  
9 1986 or '85, something like that.

10 Q. Why hasn't that information, which is  
11 now almost a decade old, in terms of going to  
12 the public, become generally accepted as the  
13 explanation for the excess lung cancer at  
14 Charleston?

15 MR. VALENZA: Objection.

16 MR. BROWNSON: Object to the form of  
17 the question. I think he said it was one  
18 factor to be considered.

19 Q. Do you think that that could explain  
20 all of the excess lung cancers?

21 A. No.

22 Q. Okay. That's fine.

23 Let me ask you --

24 A. The next time you're speaking with John  
25 Dement, ask him a perfectly good question.

DR. LANGER - Direct

1 Q. Did you read his article on the  
2 subject in The Third Wave Book?

3 A. I've looked at it, I have not formed an  
4 opinion as yet.

5 Q. You referred to the harsh form of  
6 chrysotile as opposed to the -- what's the word  
7 you used?

8 A. Soft.

9 Q. Do you believe that the harsh form  
10 of chrysotile, which you say on Page 438, tends  
11 to behave after amphibole asbestos fibers were  
12 aerosolized?

13 A. Correct.

14 Q. Could be one of the reasons why  
15 chrysotile can have a carcinogenic effect?

16 A. In part, yes. I think that was what I was  
17 trying to do in that paper. I was trying to  
18 explain the differences seen among different  
19 cohorts around the world and explain the  
20 different experiences on the basis of the  
21 physical chemical properties in the materials,  
22 themselves. There are a number of factors which  
23 have not been properly addressed, and this is  
24 just another one of them, yes.

25 I'm just so tickled pink someone's

DR. LANGER - Direct

1 read that paper.

2 (Whereupon a discussion was held off  
3 the record.)

4 BY MR. MILLER:

5 Q. There's a statement on Page 448 that  
6 "Tremolite and amphibole material is important  
7 in this regard since tremolite asbestos in  
8 appropriate concentration is considered to be  
9 the agent responsible for pleural mesothelioma  
10 found amongst chrysotile exposed workers."

11 Do you believe that?

12 A. Sure.

13 Q. By "chrysotile exposed workers," are  
14 you talking about workers in the mines and mills  
15 in Canada?

16 A. It's possible.

17 Q. Your last paragraph states,  
18 "Mineral nature of chrysotile controls  
19 biological behavior. These factors must be  
20 considered in developing any health criteria  
21 document in resolving health effects following  
22 exposure to dust."

23 If you were able to legislate or not  
24 legislate, at least to give advice to someone,  
25 what types of factors would you ask them to take

DR. LANGER - Direct

1 into effect based upon your research in this  
2 paper?

3 MR. BROWNSON: Excuse me, I'll  
4 object to the form of the question. Go  
5 ahead.

6 Q. You really what, Doctor?

7 A. I'm not sure I would.

8 Why do I say this? I know that  
9 there are all of these interesting observations,  
10 experimental observations, epidemiological  
11 observations, and they point to many, many  
12 interesting aspects of this, but if I was a  
13 regulator and I was given the fact that I'm  
14 going to have an industrial hygienist, certified  
15 industrial hygienist, a certified industrial  
16 hygienist using a phase contrast microscope  
17 going out to the field and doing dust counts, I  
18 would not do that. I would have a bulk sample  
19 read that generates fiber type and regulates  
20 across the board.

21 If we're dealing with -- the best of  
22 all possible worlds would be other techniques  
23 and other instruments, but in dealing with the  
24 pragmatics of everyday life, and the challenges  
25 that face us all, I would probably not regulate

DR. LANGER - Direct

1       them differently, I'd probably just use one  
2       standard for chrysotile.

3                   MR. MILLER: This is 6.

4                   (P-6, report by Dr. Langer, received  
5                   and marked for Identification.)

6           Q.     Dr. Langer, this picture I was  
7       referring to when I said some of your pictures  
8       come out pretty well, do you like the picture?

9       A.     No, let's go on.

10          Q.     Do you like the title?

11       A.     Voice of reason, I think that that  
12       underestimates my true value and worth.

13          Q.     Tell me how you got involved with  
14       U.S. News and World Report, in this article?  
15       Somebody called you up, you called them or what?

16       A.     Do you want to hear the whole story, for  
17       the record?

18          Q.     I do.

19       A.     It's fascinating.

20          Q.     I'd like to.

21       A.     Well, normally when I tell the story, I  
22       have a single malt Scotch in one hand.

23          Q.     I wish I could.

24       A.     It all started out with New York City's  
25       asbestos episode in the fall of '93, and I wrote

DR. LANGER - Direct

1 a letter to the editor of The New York Times. I  
2 was joined with several colleagues, specifically  
3 those who are on the paper in the Journal of  
4 Regulatory, so on and so forth.

5 The New York Times did not publish  
6 this letter, and we basically said, "Wait a  
7 minute. Before you start to invest a lot of  
8 money and time and it's evident that these  
9 people really are at risk, why don't you do some  
10 air measurements of data from other schools,  
11 indicate that there's very small risks." We  
12 just completed a small study in one New York  
13 City school and we don't see very much, so on  
14 and so forth.

15 The New York Times chose not to  
16 publish that paper. To add insult to injury,  
17 they published a letter to the editor by an  
18 asbestos abatement contractor, the president of  
19 the company, who said something grotesquely  
20 stupid. It was ghastly.

21 The other was an Op-Ed piece by a  
22 well-known ideologist, whose name I seem to have  
23 forgotten, so I decided --

24 Q. Somebody who's at Mount Sinai?

25 A. Well, I've forgotten that, but I've

DR. LANGER - Direct

1 decided that if this is the case, then we ought  
2 to get a paper out somewhere, and I did the  
3 first draft of a major paper which was then  
4 circulated among our colleagues. We sent it  
5 down to the Journal of Regulatory Toxicology and  
6 Pharmacology. We sent it out. When they  
7 reviewed it, they said, "Hey, this is a hot  
8 topic. Why don't you guys publish this with a  
9 few minor changes," and so on. Minor changes,  
10 there was too much data description, but we  
11 did. We cited a lot of chapters and verses and  
12 all of the documents that are outlined, so we  
13 had to reduce that significantly. They said,  
14 "Yes, we're going to publish this."

15 Now, this paper was then picked up  
16 by someone in the Office of Technological  
17 Assessments in Congress. They were doing a  
18 study of problems in U.S. schools, and I was  
19 contacted by this person. Of course, the  
20 problems in U.S. schools focus on the physical  
21 problems of radon, lead asbestos. They also had  
22 several other interesting areas, like violence,  
23 and so on.

24 This was picked up by the OTA.  
25 Then, the preliminary report was circulated in

DR. LANGER - Direct

1 Washington and someone picked it up from U.S.  
2 News and World Report. They contacted me  
3 saying, "We've seen this particular paper.  
4 We're interested in the New York City experience  
5 and that particular episode. What did the EPA  
6 do, and what didn't they do?"

7 Of course, they interviewed me for  
8 two hours and took what they wanted to take and  
9 misquoted me there, but nonetheless, they  
10 contacted me and this was an evolutionary  
11 process because The New York Times didn't  
12 publish our letter to the editor.

13 Q. Is it fair to say that you gave the  
14 reporter for U.S. News much or most of the  
15 information published here about the history of  
16 the EPA?

17 A. I don't think so. I think the EPA's  
18 history is eloquent and speaks for itself.

19 Q. I'm trying to figure out how the  
20 reporter heard it.

21 A. The reporter spoke to many, many people,  
22 and my selection is mysterious, to me, anyway.

23 Q. Did you have any contact with John  
24 Welch during this process of giving an interview  
25 to U.S. World Report?

DR. LANGER - Direct

1 A. No. As a matter of fact, John Welch, I  
2 think, has left the Safe Building Alliance, as  
3 far as I believe.

4 Q. I believe he's quoted here as being  
5 with the Safe Building Alliance, at least  
6 president of a former manufacturer of asbestos  
7 products.

8 So at the time of this interview,  
9 he's thought to be there, but you had no contact  
10 during the course of this?

11 A. I don't think so.

12 Q. Is the U.S. News and World Report a  
13 journal on which you would customarily rely in  
14 the medical or scientific field, that you would  
15 call authoritative?

16 A. Would I call it authoritative? Is this a  
17 real question?

18 Q. Yes.

19 A. I don't consider lay press as  
20 authoritative, any more than I would consider a  
21 book by Paul Gradore (phonetic) to be  
22 authoritative in the sense of an unimpeachable  
23 source of scientific source.

24 Q. Let me ask you a few questions about  
25 the article. I believe you have a copy in front

DR. LANGER - Direct

1 of you. Here it is. Sorry, it never quite got  
2 over to you.

3 The first paragraph of the article  
4 talks about a number of precautions that are  
5 taken by a man named Bill Lee before he can  
6 replace an offending valve.

7 Do you believe those cautions are  
8 wise and appropriate from a health point of  
9 view?

10 A. I don't know.

11 MR. BROWNSON: Well, I'll object to  
12 the form of the question.

13 A. I don't know. Is the pipe wrapped with  
14 fiberglass or is it wrapped with crocidolite?

15 Q. Assume that it has some form of  
16 asbestos around it.

17 A. Well, then, what is the percentage of that  
18 asbestos; 90 percent or one percent?

19 Q. If it were 90 percent, you might  
20 agree that the cautions were wise. If it was  
21 one percent, you might say it's not wise, is  
22 that how I should interpret that response?

23 A. No. What we're dealing with is some kind  
24 of product on a pipe, and this product has been  
25 in service for a number of years, but this

DR. LANGER - Direct

1 product may have been in service for two months,  
2 this product may have been in service for 50  
3 years. One product may have an integral  
4 physical condition, another may be more, to use  
5 your word, EPA's word, "friable," some of these  
6 materials may contain a crocidolite, others may  
7 contain goat hair, so there are different  
8 materials, there are different conditions, there  
9 are different scenarios, so to speak.

10 Now, let's assume that this is a  
11 worst-case scenario. Let's say this is the  
12 stuff that's a very high temperature pipe and  
13 it's a combination of chrysotile and amosite.

14 Do I think these precautions are  
15 warranted, sure.

16 Q. In the middle column on the first  
17 page there's a sentence about six or seven lines  
18 down, starts "Across the nation."

19 Do you see the sentence, Doctor?

20 A. Yes.

21 Q. "Across the nation, school districts  
22 that can't buy new library books are spending  
23 hundreds of thousands of dollars to deal with  
24 asbestos because they mistakenly believe their  
25 children are in great danger."

DR. LANGER - Direct

1 Do you agree with that?

2 A. It's possible that there are some school  
3 districts that possibly cannot buy new library  
4 books that are possibly spending hundreds of  
5 thousands of dollars to deal with a problem in  
6 which there's asbestos in the basement or  
7 asbestos above suspended tile ceilings in which  
8 the levels in the buildings are 0001 and kids  
9 can't buy new math books.

10 I think that that would be a mistake  
11 of the administration. These are your risks,  
12 these are your quantitative risks. Here are your  
13 children, they're out there scoring 50 points  
14 less than the school there on their math SAT's.

15 What do I think?

16 I think you ought to reconsider  
17 removal, yeah, I think that it depends.

18 Q. In your third column under the  
19 middle sentence, right next to the blurb, U.S.  
20 News Investigative Report, it starts with,  
21 "there is now broad consensus among scientists  
22 and physicians that asbestos in public buildings  
23 is not much of a threat to health."

24 Do you agree with that?

25 A. Consensus, what does that mean to you,

DR. LANGER - Direct

1 Counsel?

2 Q. I'm asking you, Doctor. I don't  
3 know what it means.

4 A. Well, I don't know what it means, either,  
5 if there's a consensus.

6 MR. BROWNSON: I'm sorry, so we're  
7 clear, you're asking if he disagrees with  
8 the consensus, or if he agrees with the  
9 statement that there's that much of a  
10 risk?

11 Q. The first statement: Do you believe  
12 that asbestos in public buildings is not much of  
13 a threat in health?

14 A. From the data that I've seen, I think it's  
15 pretty close to the truth.

16 Q. Now, the next sentence: Do you  
17 believe there's no broad consensus among  
18 scientists and physicians that asbestos in  
19 public buildings is not much of a threat in  
20 health?

21 A. I haven't the foggiest.

22 Q. The last paragraph refers to a study  
23 soon to be released by the federal Office of  
24 Technology Assessment.

25 Is that the same study which you

DR. LANGER - Direct

1 were referring to?

2 A. What is its technology, yes.

3 Q. Have you seen any conclusions from  
4 that study?

5 A. Not yet, no, I haven't, but they're  
6 quoting Richard Wilson, isn't that right?

7 Q. Not for that purpose, no.

8 A. I see. Okay.

9 Q. Do you have any idea what that study  
10 will say regarding asbestos in schools?

11 A. No.

12 Q. On the next page, sir, there's a  
13 sentence beginning at the top, "Less  
14 understandable is the role of government  
15 agencies, especially the federal Environmental  
16 Protection Agency, which created a public panic  
17 on the basis of paper-thin scientific  
18 information."

19 Do you agree with that, sir?

20 A. What part of the statement?

21 Q. Any part. I'll divide it up as you  
22 wish.

23 A. Less understandable is the role of the  
24 government, yeah, that's probably true,  
25 especially the EPA, that's less understandable,

DR. LANGER - Direct

1 more or less understandable. You have to have  
2 been there and to know the players in the game  
3 as to who advised what, which created a public  
4 panic. Well, it's not so much a public panic.  
5 People didn't know what to do, so they did what  
6 they thought the EPA was telling them to do,  
7 which was to take out asbestos from buildings on  
8 the basis of paper-thin scientific information.

9 Paper-thin scientific information,  
10 well, what did we know?

11 We knew asbestos in the workplace  
12 was dangerous, but it was a function of  
13 dose based on the risk calculations and fiber  
14 levels to which people were exposed. They had  
15 less of a risk than we certainly knew, so it's  
16 kind of overwritten, yeah.

17 Q. They say -- they're quoting you in  
18 the sentence, "When everybody's shouting 'Fire!'  
19 in a theater, the man who quietly stands in the  
20 corner and says, 'There's no fire,' is rarely  
21 heeded."

22 Is that a correct quotation of what  
23 you told the interviewer?

24 A. Not bad. Yeah.

25 Q. In fact, is that what you believe

DR. LANGER - Direct

1 you told the EPA during the years when you were  
2 there consulting as a peer-reviewer on those three  
3 rainbow books we talked about?

4 A. Three rainbow books, 1979, I thought that  
5 friable asbestos was a problem in school  
6 buildings. I participated in that. As time  
7 went on and more data became available, I was  
8 less convinced that there was a problem, and  
9 probably by the Health Effects Update.

10 As a matter of fact, I wanted to put  
11 in a section on fiber type and risk associated  
12 with the fiber types because I believe that an  
13 inspection should focus on and prioritize  
14 problems in buildings. So, I was much in favor  
15 of a fiber-type kind of approach to this  
16 problem.

17 Of course, as time went on and the  
18 Health Effects Update was published in 1986 and  
19 those documents were made available and people  
20 were measuring fibers in buildings, that I no  
21 longer believed that there was much of a problem  
22 in buildings.

23 Q. You talked about your wanting a  
24 section on fiber type.

25 Where, in regard to what paper did

DR. LANGER - Direct

1 you want a section on fiber type?

2 A. This was in the, I think it's the Purple  
3 Book. When we talked about algorithms and such,  
4 I was interested in a fiber type section.

5 Q. What happened to your request for  
6 fiber type?

7 A. It was never put in, they dismissed me,  
8 like I was a shoe salesman. That's the phrase  
9 that's used, I was dismissed; in more ways than  
10 one.

11 Q. Were there other specific advices  
12 that you gave during your work at any of the  
13 three rainbow books that were not followed that  
14 you can recall at this time?

15 A. Well, yes, I think that at these very same  
16 meetings, when a hearing was being formulated,  
17 the Asbestos Hazard Emergency Response Act, I  
18 objected to the language and I objected to the  
19 use of emotive words, and thought that the data  
20 pointed the other way and that people should be  
21 calm and not pushed into any action without some  
22 data base; but that was never done, neither.

23 Q. Under the picture of you is the  
24 statement, "Professor Arthur Langer kept trying  
25 to warn policy makers they were overreacting."

DR. LANGER - Direct

1           Is one of the places where you tried  
2           to warn policy makers they were overreacting was  
3           in AHERA conversations you just described?

4           A.     I would say that every year I attended a  
5           number of meetings, both nationally and  
6           internationally, in which there were members of  
7           various federal agencies, and many discussions,  
8           public and private, followed.

9           As time went on, I continued to  
10          voice the opinion based on observations and  
11          analysis and analysis of data, that the risks  
12          posed by asbestos products in buildings were  
13          overblown, and the very first time that I  
14          participated in such an exercise with a  
15          colleague, we evaluated documents brought  
16          forward in the Service Employees International  
17          Union lawsuit against the Environmental  
18          Protection Agency, in which we evaluated the  
19          risk analysis which was being proposed at that  
20          time by a Bill Nicholson, and had lots of  
21          concerns. I mean, there were official concerns,  
22          there were unofficial concerns, but this was a  
23          continuing kind of dialogue for various members  
24          of government.

25          Q.     When was the first time that you

DR. LANGER - Direct

1 believe you tried to warn policy makers they  
2 were overreacting, what year?

3 A. Probably 1983, maybe earlier, but  
4 certainly by '83.

5 Q. The Blue Book came out in 1983.

6 During the course of those discussions  
7 and that review in the Blue Book, did you try to  
8 warn anybody at that time that you thought they  
9 were overreacting?

10 A. You keep using this word "warn." What's  
11 "warn"? Don't walk on 42nd Street against the  
12 light, that's a warning; open and broad and  
13 frank discussions as to the contents of certain  
14 documents, I think that's more appropriate.

15 Q. Okay.

16 A. Did I raise concern? Did I bring forward  
17 any objections? Did I critique the contents?  
18 Did I recommend alterations of text? Did I  
19 carry forward the normal kind of operations of  
20 an outside reviewer and contribute to a federal  
21 document? Yes; did I try to warn someone,  
22 that's kind of, you know...

23 Q. Take out the word "warn."

24 What I'm interested in is the idea  
25 that you believe the federal policy makers were

DR. LANGER - Direct

1       overreacting.

2                   Can you tell me when you first, in  
3       some way, indicated to federal --

4       A.     Well, the federal policy, did they  
5       overreact? They didn't do anything other than  
6       write these documents. Everyone else reacted,  
7       some more than others, and therefore, you might  
8       say they overreacted.

9                   What did the feds do? The feds put  
10      forward a position that generated position  
11      documents, and they said, "This is our position:  
12      We think you ought to have an inspector come  
13      in. We think if you follow this algorithm of  
14      conditions of materials and places in buildings  
15      where they exist in proximity to air supply," so  
16      on and so forth, "air supply units, and whether  
17      or not these materials are easily accessible and  
18      whether or not they are," and there's a whole  
19      strategy for coming to some conclusion.

20                  Each of these factors are then  
21      multiplied by some normalizing weighted factor,  
22      and there's a number that's generated. On the  
23      basis of that number, one proceeds in certain  
24      ways to ameliorate. This is the algorithm  
25      technique, without using microscopy to measure

DR. LANGER - Direct

1 fibers in the air. This is a whole evolutionary  
2 process that I did warn people, you discuss it;  
3 "this algorithm may work, it may not."

4 It turns turned out the algorithm  
5 didn't work. It turns -- out the material was, as  
6 to prognosis data, the fibers in the air neither  
7 is fiber content nor fiber percentage or this or  
8 that.

9 What is it that you have to do? You  
10 have to measure fibers in the air, that's what's  
11 necessary to calculate risk. This is the bottom  
12 line, and did I warn people? That's such an  
13 unfortunate word in this instance; you discuss.

14 Q. On the second page in the third  
15 column on the right-hand side there's a heading  
16 in bold, "On second thought," and then there's a  
17 sentence, "But by 1985, some notable  
18 environmental health scientists were backing  
19 off."

20 Were you one of those?

21 A. I wouldn't characterize myself as a  
22 notable, that's rather self-aggrandizing, don't  
23 you think?

24 Q. Were environmental scientists backing  
25 off in 1985?

DR. LANGER - Direct

1 A. You mean in asbestos school buildings?

2 Q. Just as discussed here, and you can  
3 feel free to look at the exact context.

4 A. Let me read that. Where is that?

5 Q. Second page, right-hand side  
6 underneath the picture. Under the picture it  
7 says, "On second thought," in bold heading.

8 Would you say you were one of those  
9 there they're describing?

10 A. By 1985, yeah, maybe I would consider by  
11 1985, '86 for sure, by the time the models were  
12 more available and characterized by.

13 Q. Turning to the next page, the last  
14 page, it's Page 63, at the top in the first  
15 column, bold headline, "Powerful convert:  
16 Perhaps most important, Selikoff himself had  
17 drifted from the position of being a neutral  
18 research scientist to that of an antiasbestos  
19 activist. He told a congressional panel in 1984  
20 that risk posed by asbestos in schools was  
21 intolerable."

22 Do you agree that by 1984, Dr. Selikoff  
23 had drifted from the position of being a neutral  
24 research scientist to that of an antiasbestos  
25 activist?

DR. LANGER - Direct

1 A. Do I think that's accurate?

2 Q. Yes, sir.

3 A. An anti-asbestos activist, no.

4 Q. How would you characterize?

5 A. Who, Irv?

6 Q. Irv's position, changes,  
7 modification, if there was any in the 1980's?

8 MR. BROWNSON: With respect to  
9 asbestos in buildings?

10 Q. Yes.

11 MR. BROWNSON: Okay.

12 A. I don't know.

13 Q. Do you believe he did change in any  
14 way?

15 A. No. I think Irving was always himself. I  
16 don't think he changed very much, no. He was  
17 right on one side and I think he was wrong on  
18 another issue.

19 Q. What side was he right on and what  
20 side was he wrong?

21 A. I think that his work on exposure to  
22 asbestos in, for example, the insulation work,  
23 was the best work ever done in that field,  
24 without question, that Selikoff, Hammond,  
25 Cherring, Canastein (phonetic), and others.

DR. LANGER - Direct

1 Q. You were part of that too, weren't  
2 you?

3 A. I was involved in some of it.

4 Irving was brilliant and articulate  
5 and charismatic and carried the day in that  
6 area.

7 Q. Where was he wrong?

8 A. He was wrong in not considering dose  
9 response. If his insulation worker were exposed,  
10 on average, to somewhere between 10 and 20 fibers  
11 per cc of air, it begged that question: What  
12 will exposure to .001 fiber -- and based on the  
13 models generated by one of his own people,  
14 Nicholson, the risk was very much less, and the  
15 question begged was: Can we provide an  
16 environment which is absolutely safe? I think  
17 that it is a question which is decided by  
18 society. That's not an answer that anybody else  
19 can reach a resolution on, those issues;  
20 nevertheless, I think his contributions are many  
21 in a brilliant and occupational sphere, but  
22 diminished in the environmental setting. I  
23 think that his position was extreme, and it's  
24 unfortunate.

25 Q. While you were still at Mount Sinai,

DR. LANGER - Direct

1 did you ever bring up with either Dr. Selikoff  
2 or Dr. Nicholson or anyone else the points  
3 you just made: What about .001 in the Nicholson  
4 risk model?

5 A. As you know, Dr. Nicholson served on the AGI  
6 committee and we had many, many, many open  
7 discussions at a table just like this one, where  
8 we discussed all of this. Everyone brought  
9 forward their data, and Nicholson was on one  
10 side, Peter was down there, and I was here, and  
11 we argued this loudly. Nicholson also would not  
12 be moved nor persuaded by our arguments, and I  
13 was entitled to have a different discussion with  
14 Irving Selikoff. No.

15 Q. My question wasn't clear. I  
16 wondered if before you left Mount Sinai --

17 A. Did I have a discussion with Irving  
18 Selikoff concerning this subject?

19 Q. Or anyone else there at that time  
20 before 19 --

21 A. No. Nicholson, I'm sure we banged heads  
22 on this once or twice.

23 Q. Before you left?

24 A. Before 1988?

25 Q. Yes, sir, that was my question.

DR. LANGER - Direct

1 A. Before 1988, yes, I think we discussed  
2 this.

3 Q. Okay.

4 MR. MILLER: Off the record.

5 (Whereupon a brief recess was taken  
6 at 3:15 p.m.)

7 (Whereupon the proceedings resumed  
8 at 3:20 p.m.)

9 BY MR. MILLER:

10 Q. Doctor, do you agree that chrysotile can  
11 cause pleural mesothelioma?

12 MR. SENFTLEBEN: Objection to the  
13 form.

14 A. If present in high enough concentration,  
15 possibly, yes.

16 Q. Do you believe that chrysotile can  
17 be an initiator of lung cancer?

18 A. It's possible.

19 Q. Do you believe that amphiboles can  
20 be initiators of lung cancer?

21 A. It's possible.

22 Q. Do you believe that asbestosis  
23 progresses after exposure to asbestos --

24 A. What grade asbestosis?

25 Q. That would make a difference to your

DR. LANGER - Direct

1 results, sir?

2 A. Yes.

3 Q. Explain the different grades of  
4 asbestosis and how your answer would differ.

5 A. I believe it is like a silicosis, the more  
6 the pulmonary burden, the greater the chance of  
7 it progressing after cessation of exposure, but  
8 if the dose is low enough, I believe the process  
9 stops.

10 Q. On what evidence do you base that  
11 conclusion?

12 A. On the basis of some animal studies which  
13 showed very minimum scarring or no scarring  
14 present after very low exposures to animals, but  
15 with higher exposures, the lungs are progressively  
16 scarred. As a matter of fact, I'm sitting here  
17 thinking, maybe some of Chris Vogner's early  
18 work showed that, but its outcome was malignancy  
19 among scarring, but it's just reported.

20 Q. Can you state to a reasonable degree  
21 of scientific certainty that no one will ever  
22 contract an asbestos-related disease in any of  
23 the schools in the plaintiff's case in which  
24 Asbestospray T is allegedly present?

25 MR. BROWNSON: I'll object to the

DR. LANGER - Direct

1 form of the question. Go ahead, to a  
2 reasonable degree of scientific  
3 certainty.

4 A. Well, to a reasonably degree of scientific  
5 certainty, if you use the risk models, eventually,  
6 maybe not this century or millennium, but in the  
7 next, there may be someone who might develop  
8 mesothelioma on the basis of exposure.

9 Q. Can you state to a reasonable degree  
10 of scientific certainty that no one ever has, in  
11 the past, contracted an asbestos-related disease  
12 in those same schools?

13 MR. VALENZA: Objection.

14 MR. BROWNSON: I'll object to the  
15 form of the question.

16 A. No.

17 MR. BROWNSON: Calling for  
18 speculation.

19 A. Which of the individuals are you talking  
20 about; occupants; maintenance workers?

21 Q. Any persons.

22 A. Any person?

23 Q. Any persons.

24 A. No, I would think that someone engaged in  
25 maintenance activities which are carried out

DR. LANGER - Direct

1 without the proper precaution may have developed  
2 some asbestos disease, it's possible.

3 Q. Would you ever refer to the presence  
4 of asbestos in a surface in a school where it's  
5 not an ingredient in surface material, for  
6 example, asbestos in surface dust, would you  
7 refer to that asbestos as a contamination?

8 MR. VALENZA: Objection. Calls for  
9 legal conclusion.

10 Q. Using your scientific work?

11 MR. VALENZA: I object to the term  
12 because it is susceptible of many  
13 different reasons, one, which has a legal  
14 scenario, and I object to the use of the  
15 word, but the doctor may answer.

16 A. You mean, if I find fiber in a settled  
17 dust, and settled dust in an interior  
18 environment normally does not contain that  
19 particular kind of material, would I call it a  
20 contaminant?

21 Q. Yes.

22 A. Yes, I probably would, or adventitious  
23 particle.

24 Q. Is there any particular numerical  
25 connotation of asbestos in the dust that would

DR. LANGER - Direct

1 be required before you would call it a  
2 contaminate?

3 MR. VALENZA: Objection. Same  
4 objection.

5 A. I wouldn't, but there may be some  
6 nomenclature which I'm not familiar with.

7 Q. Have any of your published articles  
8 ever been supported by a grant from a defendant  
9 in asbestos litigation?

10 A. Sure.

11 Q. Every time that's happened, has  
12 there been an acknowledgment made in the  
13 publication that it was supported, at least in  
14 part, by a grant from a defendant?

15 A. Well, most certainly, of course.

16 Q. In those cases where an asbestos  
17 defendant has the support by some form of grant,  
18 an article you eventually published -- strike  
19 that.

20 Would you believe that it would be  
21 proper for you to give a draft or advance copy  
22 of that article to the defendant or its counsel  
23 for their review prior to submission of the  
24 document for publication?

25 A. I think it's improper.

DR. LANGER - Direct

1 Q. I take it you've never done that, is  
2 that correct?

3 A. No.

4 Q. No, you have done it? It's a double  
5 negative, that's why I want to be very clear.

6 A. No, I have not.

7 Q. In the OSHA regulations that were  
8 published Wednesday, August 10th, 1994, there  
9 are a couple of statements I want to ask you  
10 about. I have the regulations here, if you  
11 want to see them.

12 A. Just read them to me.

13 Q. Do you believe that a significant  
14 level of risk exists at 0.1 fibers per?

15 MR. VALENZA: Objection.

16 MR. SENFTLEBEN: Jon, this is a  
17 hell of time to bring it up, but  
18 I assume you're operating that an  
19 objection by one is an objection  
20 by all?

21 MR. MILLER: Yes.

22 A. 0.1, is that the level?

23 Q. Yes, sir.

24 A. The term used is significant, which is  
25 OSHA's term.

DR. LANGER - Direct

1 Q. Yes, sir.

2 A. 0.1, that would be 1/100 of insulation  
3 work. All factors being equal, the risk of  
4 mesothelioma would be one in a thousand, and, of  
5 course, per thousand, let's just calculate this,  
6 let's say there's a 17 percent -- 16 percent  
7 excess lung cancer, it would be 160 and a hundredth  
8 of that would be 1.6, so it would be roughly  
9 three excess cancer deaths per thousand workers.

10 Now, you say there's still a  
11 significant risk. It's okay. Three in a  
12 thousand, yeah, I would say that's still a  
13 significant risk.

14 Q. At approximately Page 40979, they  
15 give their reasons for not separating the fiber  
16 types.

17 A. Oh, this is good.

18 Q. Do you agree with their decision not to  
19 separate fiber types?

20 A. What are their reasons?

21 Q. Well, there are lots of pages.  
22 We'll start with at least three reasons.

23 A. Start, please.

24 Q. I have to show it to you, and you  
25 can tell me if you agree with the reasons. I'm

DR. LANGER - Direct

1 pointing to where they start with the three  
2 reasons they made mention of.

3 A. "As OSHA explained in the Preamble to 1986  
4 standards ... to summarize."

5 MR. BROWNSON: Just for the record,  
6 you're reading aloud here.

7 (Whereupon a discussion was held off  
8 the record.)

9 MR. BROWNSON: Let's start over and  
10 pose a question here.

11 A. You better ask me a question.

12 Q. Dr. Langer, as we have noted, OSHA  
13 says that there are at least three reasons why  
14 they have decided not to separate fiber types.

15 Would you please read into the  
16 record each one of the reasons, and whether or  
17 not you agree with them and the reasons for your  
18 agreement or disagreement.

19 A. "To summarize the data on risk differential  
20 by asbestos fiber type, human epidemiological  
21 studies have suggested that occupational  
22 exposure to amphiboles is associated with  
23 greater risk of mesothelioma than is exposure to  
24 asbestos."

25 I agree with that, so they're saying

DR. LANGER - Direct

1 basically you're exposed to amphibole asbestos  
2 fiber. It's worse for mesothelioma induction.  
3 That certainly is true.

4 However, they go on to say, "No  
5 clear risk differential for lung cancer or other  
6 asbestos-related disease has been demonstrated  
7 by epidemiological studies." Not true.

8 The increased risk of gastrointestinal  
9 cancer is found among amphibole exposed cohorts.  
10 No clear risk differential for lung cancer is  
11 true, and that is why I have written papers on  
12 the properties of chrysotile, as related to the  
13 disease risk.

14 So, for lung cancer, that's probably  
15 true. So what OSHA had said is: Yes, there are  
16 more mesotheliomas with amphiboles. They have a  
17 mistaken notion that GI cancer is the same as  
18 amphibole cohorts and chrysotile cohorts. Nay,  
19 not so.

20 That there is no clear differential  
21 for lung cancer, that is true.

22 Animal experiments. All of a sudden  
23 they're drawing on animals. "However, have  
24 indicated that chrysotile is a more potent  
25 carcinogen than amphiboles when administered by

DR. LANGER - Direct

1 inhalation or intrapleural injection."

2 This is generally true. This is  
3 generally true, that when one uses route of  
4 administration, such as intracavitaries, as they  
5 call it, you do induce more tumors with  
6 chrysotile, this is so; by inhalation, is it  
7 true?

8 That's the Vogner experiment, and  
9 also John Davis. It's probably true. So the  
10 animal studies support this, as well, but why they  
11 have it with epidemiology, I don't understand.

12 It says OSHA agreed with the  
13 testimony of Dr. Davis, who stated that, "the  
14 evidence cannot answer with certainty if one  
15 fiber of amphibole is more dangerous than one  
16 fiber of chrysotile."

17 That begs the question: Are the  
18 amphiboles more dangerous? I think so, yeah.

19 Do I think that chrysotile exposure  
20 in the textile industry is very dangerous? Yeah,  
21 I certainly believe that.

22 Do I think the stuff in products in  
23 buildings is more dangerous? No. I think the  
24 properties differ significantly.

25 So, this first part of this OSHA,

DR. LANGER - Direct

1 that first part of it is an embellishment of all  
2 of these kinds of facts.

3 "Second, as stated in the 1986  
4 asbestos standard, even if OSHA were to accept  
5 the premise, which it does not, that chrysotile  
6 may present a lower cancer risk than other type  
7 of fiber types, occupational exposure to  
8 chrysotile asbestos still presents a significant  
9 risk of disease at the revised PEL." Yeah, it's  
10 probably so. I think so, significant risk.

11 The revised permissible exposure  
12 level is -- let's say that they are interested  
13 in 0.1, it's 100th of insulation worker. I  
14 mean, all the factors equal, insulation workers  
15 are exposed to amphiboles. Most of their --  
16 much of their risk is enmeshed in mesothelioma,  
17 which is an amphibole component exposure.

18 It's fascinating, this exercise is.

19 "In particular, asbestos, the  
20 disabling and often fatal fibrosis" -- I don't  
21 believe that. It's not often fatal. Many  
22 asbestosis cases live out their lives.

23 -- "of the deep portions of the lung  
24 is caused by exposure to all types of asbestos."

25 Yes, the evidence on this is strong,

DR. LANGER - Direct

1       okay. All right. Let's say it's true.

2                       Okay. "Lung cancer risks associated  
3       with chrysotile exposures are also high - 6.7  
4       lung cancer deaths per thousand workers exposed  
5       to 0.2 fibers." Let's see whether that's true.

6                       6.7 per thousand at 0.2, that would  
7       be at, let's say 25 is for the insulation  
8       workers would be a tenth. That would be eight  
9       percent -- no, there's something wrong with this  
10      figure, by the way. I think this lung cancer  
11      risk is wrong.

12                      Now, it may be that this is a  
13      Xeroxed copy, and that fiber, 6.7 lung cancer  
14      deaths, is not correct.

15                      Well, hold it a second.

16                      Let's say you have 1,000 people and  
17      you have a 16 percent among insulation  
18      workers -- they're looking at all these other  
19      data. Let's use insulation workers. There's a  
20      16 percent excess, of course, 10 times greater  
21      in current cigarette smokers than people who  
22      never smoke. Nevertheless, let's say at 16  
23      percent, would be 16 per hundred or 160 per  
24      thousand. That's 20 fibers. You go down to two  
25      fibers, it would be 16. If you go down to .2,

DR. LANGER - Direct

1 it would be 1.6.

2 I think that their figure for lung  
3 cancer risk includes the expected as well as the  
4 observed. Meaning, the observed as expected,  
5 plus observed. Observe over expected is your  
6 standardized mortality ratio. I think it's a  
7 little high.

8 Q. You're going through all three  
9 reasons now?

10 A. No.

11 Q. Then let's do it, please.

12 A. Lung cancer risks associated, Dr. Crump  
13 acknowledged -- that's Kenny Crump, isn't it?

14 Q. Yes.

15 MR. BROWNSON: Let me take that.

16 (Whereupon a brief recess was  
17 taken.)

18 MR. BROWNSON: I think we'll  
19 continue.

20 A. I think that the risk of lung cancer is a  
21 little bit high. Okay. Here we go.

22 I stated about OSHA estimated  
23 asbestosis risks at 0.25 per cc's exposure, as  
24 an unacceptably high five cases per thousand.  
25 This is asbestosis on five cases per thousand.

DR. LANGER - Direct

1 That would be 50 at .2 or 500 per thousand.

2 Now, isn't that goofy? The highest  
3 levels reported in Selikoff's cohort is 10  
4 percent mesothelioma mortality, and they have 50  
5 percent mesothelioma. I don't know where they  
6 got that from, I really don't.

7 Okay. Let's say that they're  
8 concerned, okay, "lung cancer risk associated" --  
9 we've gone through that.

10 "Third, the record shows that  
11 employees are likely to be exposed to mixed  
12 fiber types at most construction and shipyard  
13 industry work sites most of the time.

14 Assuming a higher PEL to chrysotile  
15 with presenting agencies and analytical  
16 difficulties, they should all be the same.

17 Okay. All right. What do I think?

18 Well, that's a real interesting  
19 agglomeration of comments, but let's say that  
20 you people aren't exposed to all of this stuff.  
21 Let's say people are exposed to a defined fiber  
22 type in a defined setting. Then you can use the  
23 data specifically for that particular fiber  
24 type. Why not?

25 If I were doing OSHA, I would also

DR. LANGER - Direct

1 probably do it this way, and say let's not  
2 distinguish the fiber types. In fact, I  
3 recommended that in the HEI report. I was the  
4 one that recommended it.

5 Q. You mean, OSHA, would you also agree  
6 with 1. fibers per cc as a level that shows --

7 A. That's as good as any level. Okay. .1 is  
8 all right.

9 Q. Look at the standard hypothesis.  
10 There's a short chrysotile fiber  
11 which had been mechanically manipulated because  
12 it went through the industrial process, and it  
13 was harsh. By short, I mean less than five  
14 microns.

15 A. How short? Three microns.

16 Q. Okay. Three microns.

17 Do you believe that that fiber has  
18 some carcinogenic potential?

19 A. It might, but you need a lot of it.

20 Q. If the fiber were not harsh, would  
21 you require more of them?

22 A. Probably not. Doesn't matter if it's soft  
23 to harsh in that case. I was thinking of long  
24 fibers, actually, rather than the curlicue in  
25 which the effective diameter is the diameter of

DR. LANGER - Direct

1 the spiral. The harsh fiber tends to be more  
2 splintery and is more effective in getting to  
3 the distal tissues.

4 Q. Doctor, is there a length or a ratio  
5 of length to diameter or to width of a fiber,  
6 either chrysotile or amphibole, let's say with  
7 chrysotile, below which you believe that it has  
8 no carcinogenic potential?

9 A. I generally do not count fibers less than  
10 one micron in length when I do a tissue burden  
11 assay.

12 Q. Does that mean that you effectively  
13 did not believe that fibers less than one micron  
14 in length can have any potential for causing  
15 cancer?

16 A. No, it means that I have examined the  
17 cases in the general population, and those  
18 fibers, chrysotile, tend to be extremely short.  
19 In fact, most of them lie below one micron in  
20 length.

21 Q. Do you then have a limit below which  
22 you believe a chrysotile fiber has no cancer-  
23 producing potentiality?

24 A. I'm shaking my head. You mean, none,  
25 zero, it has no potential?

DR. LANGER - Direct

1 Q. Right.

2 A. No, I think that it may be significantly  
3 reduced, but is there some residual risk?

4 Well, it's probable. Probably so.

5 Q. Is there a point at which you make a  
6 distinction in the cancer-causing potentiality  
7 in a fiber based upon its life? For example --

8 A. Sure.

9 Q. -- what is that point or what is the  
10 distinction?

11 A. Well, I am concerned mostly with fibers  
12 greater than five microns in length, in that  
13 this is the standard index against which we  
14 measure risk or hazard, and everything else is  
15 just embellishment.

16 What does it mean?

17 Q. Doctor, do you have an opinion about  
18 the scientific value of the work done by the  
19 Canadian Tumor Registry Panel?

20 A. The value of the work?

21 Well, it's like every registry, it  
22 has value, of course.

23 Q. How can you describe that value?

24 MR. BROWNSON: Well, I'll object to  
25 the form of that question.

DR. LANGER - Direct

1 A. It gives us a better idea of what people  
2 are dying with or from.

3 MR. MILLER: Thank you.

4 I have no more questions today.

5 However, I do want to leave open the  
6 possibility of the return visit in this  
7 case after receiving further documentation  
8 from Mr. Brownson, which I understand will  
9 be the full air sampling results and  
10 back-up documents.

11 Given that, though, aside from that,  
12 we're done in this case.

13 Thank you, Doctor.

14 (Whereupon the witness was excused  
15 at 3:50 p.m.)

16 \* \* \*

17

18

19

20

21

22

23

24

25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

C E R T I F I C A T E

I, BERNADETTE H. MASTRANGELO, a Certified  
Shorthand Reporter, License No. XIO1860, and  
Notary Public of the State of New York do hereby  
certify that prior to the commencement of the  
examination

DR. ARTHUR M. LANGER

was sworn by me to testify to the truth, the  
whole truth, and nothing but the truth.

I DO FURTHER CERTIFY that the foregoing is  
a true and accurate computer-aided transcript of  
the testimony as taken stenographically by and  
before me at the time, place, and on the date  
hereinbefore set forth.

I DO FURTHER CERTIFY that I am neither a  
relative of nor employee nor counsel nor  
attorney for any party in this action, and that  
I am not interested in the event nor outcome of  
this litigation.

Bernadette Mastrangelo

Notary Public of the State of New York

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

C E R T I F I C A T I O N O F W I T N E S S

I have read the foregoing transcript of my  
deposition and find it to be true and accurate  
to the best of my knowledge and belief.


-----

DR. ARTHUR M. LANGER

Sworn and subscribed to before me on  
this \_\_\_\_\_ day  
of \_\_\_\_\_, 1995

Notary \_\_\_\_\_  
My Commission Expires \_\_\_\_\_





CURRICULUM VITAE

Arthur M. Langer, Ph.D.

**CURRENT POSITIONS:** Director, Environmental Sciences Laboratory of the Institute of Applied Sciences, Brooklyn College of the City University of New York, Brooklyn, NY 11210.

Deputy Director of the Center for Applied Studies of the Environment, Applied Science Coordinating Institute, City University of New York.

Professor of Geology, Department of Geology, Brooklyn College.

Professor of Geology, Ph.D., Graduate Faculty, Program: Earth and Environmental Sciences, City University, New York, NY, 1982-present.

Research Associate, Department of Mineral Sciences, American Museum of Natural History, New York, NY, 1979-present.

**ADDRESS:**

**Office:** Environmental Sciences Laboratory  
Ingersoll Hall - Room 5144-6  
Brooklyn College of the City University of New York  
Brooklyn, NY 11210  
Telephone: (718) 951-4793; 951-4242  
Facsimile: (718) 951-4199

**Home:** 6 Rochambeau Drive  
Hartsdale, NY 10530  
(914) 428-3667

**DATE OF BIRTH:** February 18, 1936

**PLACE OF BIRTH:** New York, NY

---

**ACADEMIC DEGREES:**

B.A., Geology, Hunter College-CUNY, New York, NY, 1956.  
M.A., Petrology (Geology), Columbia University, New York, NY, 1962.  
Ph.D., Mineralogy (Geology), Columbia University, New York, NY, 1965.

**PREVIOUS POSITIONS:**

Associate Professor, Center for Polypeptide and Membrane Research, Mount Sinai School of Medicine, New York, NY 1986-1988.  
Associate Professor, Mineralogy, Department of Community Medicine, Mount Sinai School of Medicine, New York, NY, 1968-1986, 1987-1988.  
Science Administrator, Environmental Sciences Laboratory, Mount Sinai School of Medicine, New York, NY, 1983-1984.  
Associate Director, Environmental Sciences Laboratory, Mount Sinai School of Medicine, New York, NY, 1969-1986.  
Director of Laboratories, Environmental Sciences Laboratory, Mount Sinai School of Medicine, 1976-1986.  
Head, Physical Sciences Section, Environmental Sciences Laboratory, Mount Sinai School of Medicine, New York, NY, 1969-1986.  
Adjunct Associate Professor, Mineralogy, Graduate Division, City University of New York, NY, 1968-1969.  
Assistant Professor, Mineralogy, Department of Community Medicine, Mount Sinai School of Medicine, New York, NY, 1967-1968.  
Research Associate, Environmental Medicine, Department of Medicine, Mount Sinai Hospital, New York, NY, 1965-1967.  
Lecturer, Geology, City College of City University of New York, NY, 1964-1965.  
Research Assistant, Mineralogy, Department of Geology, Columbia University, New York, NY, 1961-1964.  
Teaching Assistant, Economic Geology, Department of Geology, Columbia University, New York, NY, 1959-1960.  
Teaching Assistant, Department of Geology, Columbia College, New York, NY, 1958-1959.  
Field Assistant, Geology, Beartooth Mountains, MT, Columbia University, 6/57-8/57; 6/58-8/58.  
Exploration Geologist, Rosario Exploration Chibougamau Mining and Smelting, 6/56-8/56.  
Consulting Mineralogist, Columbia University, New York, NY:  
-Texas Gulf Sulphur Company, 1965 (with Professor Kerr).  
-Tidewater Oil Company, 1962 (with Professor Kerr).  
-Consulting Mineralogist, Creole Oil Company, 1962 (with Professor Kerr).  
-Consulting Mineralogist, American Metals Climax, 1961 (with Professor Kerr).  
-TAMS Dam site, East Pakistan, WHO, 1960 (with Professor Fairbridge).

**FELLOWSHIPS:**

Research Mineralogist, Department of Geology, Columbia University, New York, NY. Sponsored by the U.S. Air Force Cambridge Research Laboratories under the direction of Prof. P.F. Kerr, 3/61-9/63.

**MEMBERSHIPS AND OTHER PROFESSIONAL ACTIVITIES:**

Fellow, Geological Society of America.  
Fellow, Mineralogical Society of America.  
Fellow, New York Academy of Sciences.  
Fellow, Collegium Ramazzini.  
Geochemical Society.  
American Association for the Advancement of Science.  
Electron Microprobe Society of America.  
Sigma Xi, Kappa Chapter (Honorary Scientific).  
International Association of Bioinorganic Scientists.

**HONORS AND AWARDS:**

Honors, Department of Geology, Hunter College, New York, NY, 6/56.  
Sigma Xi, Kappa Chapter, Columbia University, New York, NY, 9/64.  
Dust Research, Polachek Foundation Award, 9/65-6/67.  
Career Scientist Award, National Institute of Environmental Health Sciences, 6/69-5/74.  
Phi Beta Kappa, Nu Chapter, Hunter College, New York, NY, 6/77.  
Hunter College Hall of Fame HC-CUNY, 6/78.  
Biography in: American Men of Science; Who's Who in the East; Who's Who in America (September, 1992).  
Elected Fellow, Collegium Ramazzini, 1983.

**EXPERT CONSULTANT:**

Atlantic Legal Foundation. Amici Curiae in support of respondents to the Supreme Court of the United States. October Term, 1992. Daubert et.al. Petitioners v. Merrell Dow Pharmaceuticals, Inc., Respondent.  
Environmental Protection Agency, Superfund Cases, 3/85-Present.  
National Institute for Occupational Safety and Health, 6/75-Present.  
National Institute for Environmental Health Sciences, 4/75-Present.  
Environmental Protection Agency, 6/75-Present.  
National Heart, Lung and Blood Institute, 6/75-Present.  
National Institutes of Health, Section of Grants, 6/74-Present.  
World Health Organization, Geneva, Biomedical Expert, 6/75-Present.

**GRADUATE THESES:**

Geology of the Manhattan Formation. Submitted in partial fulfillment for the degree of Master of Arts, in the faculty of Pure Science, Columbia University, NY, p. 132, 1962.

Mineralogy and Physical Properties of Mojave Desert Playa Crusts. Submitted in partial fulfillment for the degree of Doctor of Philosophy, in the faculty of Pure Science, Columbia University, NY, p. 155, 1965.

**EDITORIAL BOARD SERVICE:**

Assistant Editor, Environmental Research, 1978-1985.

Advisory Editor, Environmental Research, 1985-1987.

Assistant Editor, American Journal of Industrial Medicine, 1980-1985.

Associate Editor, American Journal of Industrial Medicine, 1985-1986.

Editorial Review Board, Journal of Environmental Pathology and Toxicology, 1978-1982.

Editorial Advisory Board, Advances in Modern Environmental Toxicology, 1981-1982.

Editorial Review Board, Journal of Environmental Pathology Toxicology and Oncology, 1983-Present.

**REVIEW MANUSCRIPTS (Journals other than those cited above):**

Journal of Histochemistry and Cytochemistry.

Pharmacology Reviews.

American Chemical Society Reviews.

Advances in Chemistry

Annals New York Academy Sciences.

Science (AAAS).

SEM-IITRI Symposia.

Lung.

American Review of Respiratory Diseases.

American Mineralogist.

Clay Minerals Society (Clays and Clay Minerals).

Canadian J. Fisher Aquatic Sciences.

Journal National Cancer Institute.

American Journal Pathology.

Annual Meeting SEMA.

Chest.

Laboratory Investigations.

Journal of the American Medical Association.

New England Journal of Medicine.

Toxicology In Vitro.

Journal of the American Industrial Hygiene Association.

**REVIEW MANUSCRIPTS (Journals other than those cited above) (contd):**

Annals of Occupational Hygiene.  
Pathology Annual.  
Environmental Health Perspectives.  
Health Effects Institute.  
American College of Chest Physicians.  
Heterogeneous Chemistry Reviews.  
Bulletin of the Geological Society of America.  
Applied Occupational and Environmental Hygiene.

**REVIEW AND AUTHOR FEDERAL, INDUSTRY DOCUMENTS (1978-PRESENT):**

NIOSH Fibrous Glass Criteria Document, 1978. Reviewer. CDC-NIOSH.  
NIOSH Talc Criteria Document, 1979. Reviewer, contributor. CDC-NIOSH. OSHA  
Fiber Manuscript (Definitions, Nomenclature, Properties), 1980. Reviewer. US  
Department of Labor.  
ALOSH Mineralogy Manuscripts (Occupational Lung Disease), 1979-1980. Reviewer,  
contributor. CDC-NIOSH.  
Asbestos, Smoking and Disease. The Scientific Evidence. Burns, DM, Ed.,  
Commercial Union Insurance, 1982. Contributor.  
Environmental Protection Agency, Office of Pesticides and Toxic Substances-  
Asbestos in Buildings Guidance Documents; Guidance Documents; Operations  
and Maintenance Programs. "Orange", "Purple", "Blue" Books. Reviewer,  
contributor. US Environmental Protection Agency.  
Surgeon General's Report: Cancer and Chronic Lung Disease in the Workplace:  
The Health Consequences of Smoking, 1985. Reviewer, contributor. Federal.

**INTERNATIONAL COMMITTEES AND CONSULTATIONS:**

US-Japan Cooperative Science Program Working Group on Air Pollution and Health.  
NIEHS-Institute of Health, Japan, February, 1969.  
International Agency for Research on Cancer, WHO Development of V.14 Chemical  
Carcinogenesis Monograph Series, Evaluation of Carcinogenic Risk of Chemicals  
to Man: Asbestos. Member of working group, Lyon, France, 1976.  
International Association of Geochemistry and Cosmochemistry, Working Group on  
the Geochemistry of Health and Disease, 1976-1979.  
Consultant, South African Ministry of Mines, Asbestos Symposium, Johannesburg,  
South Africa, 1977.  
Consultant, Institute of Public Health, Norway, Microscopy Facility, Oslo, Norway,  
1977. Seminars on vitreous fibers as asbestos substitutes.  
Consultant, International Metalworkers Federation, Problems Focusing on Asbestos  
Contamination of Nickel Ores, Geneva, Switzerland, 1980.

**INTERNATIONAL COMMITTEES AND CONSULTATIONS (cont):**

- Research Consultant, Societe Nationale de l'Amiante, Quebec, Canada, Work on Modified Fiber, 1984.
- WHO-International Program on Chemical Safety (IPCS), Environmental Health Criteria Document on Asbestos and Other Natural Mineral Fibers, Section Chairman, Hannover, Federal Republic of Germany, 1985.
- Organizing Committee, Third International Conference, In Vitro Effects of Mineral Dusts, Schluchsee, Federal Republic of Germany, 1984.
- Societe Nationale de l'Amiante. Consultant. Modified Fiber and the Environmental Protection Agency Asbestos Ban, Montreal, Canada, 1986.
- International Agency for Research on Cancer, WHO Development of V.42, Chemical Carcinogenesis Monograph Series, Evaluation of Carcinogenic Risk to Chemicals in Man: Silica and Some Silicates, Member of Working Group, Lyon, France, 1986.
- Consultant, Asbestos Institute, Canada, Organization of Symposium on Biological Effects of Asbestos Substitutes, 1987.
- Vllth International Pneumoconiosis Conference. International Organizing Committee; Organizer of Session: Hazard Recognition of Mineral Dust. Pittsburgh, PA, August, 1988. Chaired Two Sessions at Meeting: Mineral Recognition by Membranes and Mineral Toxicity; Mineral Fiber and Diseases of the Pleura.
- International Federation of Building and Wood Workers, Conference on Interior Works, Geneva, Switzerland. Presented paper: Hazards in the Painting Trades. Panel on Hazards in the Interior Workplace, May 9-12, 1989.
- Hoffman-LaRoche Pharmaceuticals. Development of Microscopy Method for the Analysis of Mineral Fiber in Parenteral Drugs. Edinburgh, April, 1993; Basel, March, 1994; Frankfurt, May, 1994.
- Eurometaux - European Association of Metals. Protocol Format and Development of Proposed Meeting on Carcinogenicity of Metals and the Compounds. Brussels, November, 1994.

**NATIONAL COMMITTEES, CONSULTATIONS:**

- Food and Drug Administration, Asbestos, Talc, Asbestos Bodies, and Consumer Talcums, Seminar, Washington, DC, June, 1968.
- National Air Pollution Control Administration, Asbestos in Ambient Air. Arlington, VA, June, 1969.
- National Institute for Occupational Safety and Health, USPHS, Asbestos Research in the United States, Cincinnati, OH, January, 1970.
- Food and Drug Administration, Asbestos in Consumer Talcums, Seminar, Washington, DC, August, 1971.
- Environmental Protection Agency, National Air Pollution Control Techniques Advisory Committee, Asbestos Emissions Document, Atlanta, GA, 1971.
- NIOSH Task Force on Occupational Respiratory Diseases, 1975.

## NATIONAL COMMITTEES, CONSULTATIONS (cont):

- Environmental Protection Agency, HERL, Ad Hoc Committee for the Fibrous Amphibole Study Protocol, Triangle Park, NC, 1976.
- NIEHS-NIOSH-EPA-ERDA. Interagency Retreat and Colloquium. Man-made Vitreous fibers, Asbestos Substitutes and the Energy Crisis. Potential Risks to Health. Pinehurst, NC. 7-9 January, 1976.
- NIOSH Criteria Document Recommended Standard For Occupational Exposure to Fibrous Glass, Reviewer. November, 1976.
- Environmental Protection Agency, HERL, Biological Effects on Fibrous Inorganic Particles, 1977.
- DHHS, Interagency Committee to Coordinate Environmental and Related Problems, Biological Effects of Fibrous Particulates: Serpentine-Containing Host Rocks, Amphibole-Containing Host Rocks, 1980.
- Mount St. Helen's Volcanic Ash: Mineral Nature and Biological Activity, Interagency Task Force, Bethesda, MD, 1980.
- NHLBI, Evaluation of Existing Inorganic Microparticulate Laboratories: Vermont Lung Group, Tulane Occupational Lung Hazards Group, 1978.
- National Institute of Environmental Health Sciences, Workshop, Pathobiology of Mesothelioma, RTP, NC, January, 1983.
- Occupational Safety and Health Administration, Expert to write and review Asbestos Standard-Talc Standard, US Department of Labor, 1983.
- National Academy of Sciences, Division of Life Sciences Committee to Evaluate Risk to Low-Level Exposure to Asbestiform Fibers in the Environment, 1982-1984.
- Environmental Protection Agency. Prepared for meeting Substitute Fibers. Pre-market Testing of Fibers. USEPA, Washington, DC. 26 June 1984.
- Environmental Protection Agency, Committee Member, Review and Rewrite EPA "Guidance Document for Controlling Friable Asbestos-Containing Minerals in Buildings," 1985.
- American Society Testing Materials, Committee, D22-Indoor Air Pollution Asbestos: D22.05-Methodology and Measurement of Fibers in Air. Electron Microscopy, 1985.
- American Society Testing Materials, Organizing Committee, Silica and Silica-Induced Diseases, International Conference, 1985.
- NIOSH, Mine Health Research Advisory Committee Meeting, Tucson, AZ: The Impact of Mineral-Asbestos Definitions on the Mining Industry, 1986.
- Environmental Protection Agency. Develop guidance document for identifying asbestos hazards and implementing abatement programs in public buildings, Washington, DC, April, 1986.
- NIOSH Review Panel for Project "Evaluation of Mesothelioma Production by Asbestos Substitutes." Cincinnati, OH, June, 1986.
- Environmental Protection Agency, Guidance Document for Assessing and Managing Exposure to Asbestos in Building, Arlington, VA, September, 1986.
- Environmental Protection Agency, Operations and Maintenance Programs for Asbestos-Containing Materials in Buildings: A Guide for Building Owners and Managers, Washington, DC, January, 1987.

**NATIONAL COMMITTEES, CONSULTATIONS (cont):**

NIEHS-NIOSH - National Toxicology Program. To formulate study protocol comparing biological activities of asbestiform and non-asbestiform amphibole minerals. NIEHS - Res. Triangle Park, NC, October 11, 1989.  
Health Effects Institute. Asbestos Literature Review Panel. April, 1990 - August, 1991.  
Health Effects Institute. Reviewer of Research Proposals - RPI-1-91.

**TESTIMONY BEFORE FEDERAL AGENCIES:**

Expert Testimony, Toxic Substances Control Act, 1973. Provided evidence to Sen. Tunney's committee hearing, Washington, D.C.  
Expert Witness, Contamination of Lake Superior. On behalf of the Department of Justice of the United States, 1974. Minneapolis, MN.  
Expert Testimony, Occupational Safety and Health Administration, US Department of Labor, Asbestos Standard, 1984. Washington, D.C.  
Expert Testimony, Consumer Products Safety Commission. Asbestos in Play Sand. Washington, DC, December 7, 1988.  
Expert Testimony Occupational Safety and Health Administration, U.S. Department of Labor. Asbestos Standard Revisions. April, 1990. Washington, D.C.

**REGIONAL CONSULTATIONS:**

Health Research Council of New York City, Subcommittee on Asbestos Hazards - Air Pollution Working Corp. Seminar on Asbestos in Construction Products, Rockefeller University, June 9, 1969.  
New York City Board of Education: Asbestos in Schools, 1981-1983.  
New York City Department of Sanitation; Fire Department: Insulation Products, 1979-1983.  
New York State Consumer Affairs and Protection: Construction and Insulation Products, 1980-1983.  
City University of New York-Brooklyn College: Asbestos Problems, 1981-1982.  
New York City Asbestos Taskforce. Inspector General's Office. Asbestos in schools. Analysis and evaluation of samples removed from school buildings. Fall, 1993.

**ACADEMIC COMMITTEES:**

Academic Council, Department Representative, MSSM, 1977-1979.  
Medical Center Safety Committee, MSSM, 1979-1988.  
Chemical Hazards Committee, MSSM, 1979-1988.  
Alternate Medical Safety Officer (in absence of Dr. S. Kochwa), MSSM, 1980-1983.  
Space Committee (Department and Institution), MSSM, 1982-1985.

**ACADEMIC COMMITTEES (cont):**

New York Academy of Sciences, Conference Organizing Committee, 1976-1980.  
Visiting Professor Program. Mt. Sinai School of Medicine. 1971-1973.  
Educational Policy Committee. Mt. Sinai School of Medicine. 1972-1974.  
Ad Hoc Reviewer, National Institutes of Health, Minneapolis Medical Center, 1977.  
Ad Hoc Reviewer, National Institutes of Health, Harvard Medical Center, 1978.  
Workshop Organizer and Chairman, Significance of Aspect Ratio in Asbestos Diseases, New York Academy of Sciences, 1977.  
Workshop Organizer, Third International Workshop on In Vitro Testing of Mineral Dusts, 1984.  
Executive Committee, Ph.D. Program, Earth and Environmental Sciences, City University of New York, 1985-1993.  
Curriculum and Examination Committee, Ph.D. Program, Earth and Environmental Sciences, City University of New York, 1987-1990.  
Faculty Membership Committee - Chairman - Ph.D. Program, Earth and Environmental Sciences, City University of New York, 1989-1992.

**CONSULTANT:**

Cyprus Minerals-Nature of US Talc Deposits, 1979.  
General Accident Insurance Company: Asbestos Compensation, 1981.  
Gulf Minerals: Modified Chrysotile Fiber, 1982.  
Oil, Chemical and Atomic Workers International Union, Safe Handling of Asbestos, Training Film, 1976.  
Lung Center and NHLB-SCOR, in the Departments of Physiology, Medicine, Pathology, and Engineering in the University of Vermont, Burlington, VT, 1984.  
Societe Nationale de l'Amiante: Phosphorylated Fiber; Asbestos Substitutes, 1984.  
W.R. Grace & Company: Asbestos and Indoor Air Pollution, 1984.  
Asbestos Institute of Canada, Asbestos and Asbestos Substitutes, 1985-1986.  
Litigations. Represented numerous plaintiffs, defendants, insurance carriers, US Department of Justice, Brooklyn and New York counties' District Attorneys.  
R.T. Vanderbilt Company, Nature of Tremolite in the Gouverneur Talc Deposit, 1987.  
Safe Building Alliance, Problems of Asbestos in Buildings, 1987.  
Review applications for funding requests: FCAC, Quebec, Canada, 1985.  
Battelle Columbus Laboratories: Analysis of Microparticles by Analytical Electron Microscopy, 1987-1989.

**INDUSTRY PROJECT REPORTS:**

Chrysotile and chrysophosphate. A comparative study of their physicochemical properties and membrane activities. A report to SNA-Chrysophosphate, Canada. Langer AM, Nolan RP, p. 87, June 1, 1987.

## INDUSTRY PROJECT REPORTS (cont):

Wollastonite in the pulmonary tissues on animals. A report to Northrop Services Industries, National Toxicology Program. Langer AM, Nolan RP, p. 101, June 15, 1989.

Preparation, examination and characterization of mineral standards by analytical electron microscopy. A report to Battelle Columbus Laboratories, Langer AM, Nolan RP, Pooley FD, Gieseke JA, Fisher G, 61 p., December 12, 1989.

Comparison and evaluation of the analytical capabilities of three U.S. laboratories for submicroscopic particulate analysis.

A report to Battelle Columbus Laboratories, Langer AM, Nolan RP, Gieseke JA, Fisher G. February, 1991.

Report on the measurement of fiber release from simulated steam-stressed Durabla gaskets (120°, 160°, 190° for 5 hours) for health hazard evaluation. A report to Durabla, Inc., Langer AM, Nolan RP, 21 p., January 31, 1992.

Measurement of fiber release from simulated steam-stressed Durabla gaskets for health hazard evaluation. A report to Durabla, Inc., Langer AM, Nolan RP, (revision 1/31/92 report) 29 p., July 16, 1992.

Report on the measurement of fiber release from simulated steam-stressed Durabla gaskets (120°C, 160°C, 190°C for 5 days) for health hazard evaluation. A report to Durabla, Inc., Langer AM, Nolan RP, 23 p., November 6, 1992.

Report on the measurement of fiber release from simulated steam-stressed Durabla gaskets (250°C, 30 days) for health hazard evaluation. A report to Durabla, Inc., Langer AM, Nolan RP, 25 p., December 9, 1992.

The Identification and Quantitation of Small Asbestos Fibres in Injectable Medicines. Technical Expert Report Prepared for Hoffman-LaRoche, Basel. 16 p. Addison J, Burdett GJ, Langer AM, Muhle H. 1993.

Analysis of rockwool fibers by scanning electron microscopy. A report to Lapinus Fibres, B.V., Netherlands. Nolan RP, Langer AM, 13 p., November 29, 1993.

Analysis of rockwool fibers by scanning electron microscopy. A report to Lapinus Fibres, B.V., Netherlands. Nolan RP, Langer AM, 25 p., November 29, 1993.

Release of Rockwool Fibers From Compressed Gasket Material. A report to Lapinus Fibres, B.V., Netherlands. Nolan RP, Langer AM, 38 p., Appendix, January 31, 1994.

Analysis of Quarry Sample #01, #08 and #18 for asbestos content. The Readymix Group, Australia, Nolan RP, Langer AM, 39 p., March 9, 1994.

Health Hazard Evaluation of the CD #1 Pit Empire Mine, Palmer, Michigan. A report to Cleveland-Cliffs Corp., Nolan RP, Langer AM, Wilson R, 90 p., January, 1995.

## GOVERNMENT PROJECT REPORTS:

Asbestiform Fibers - Non-Occupational Health Risks. National Academy of Sciences. National Research Council. National Academy Press, 334 p., 1984.

## GOVERNMENT PROJECT REPORTS (cont):

Report to the U.S. Consumer Product Safety Commission: Mineralogical Analysis of Two "Play Sands" For Their Asbestos Contents. Langer AM, Nolan RP. 26 November, 1986. 9p., 4 Tables, 18 plates.

Report to the U.S. Consumer Product Safety Commission: Mineral Analysis of a Carbonate Play Sand. Langer AM, Nolan RP. July, 1987. 19 p., 3 Tables, 8 plates.

Asbestos in Public and Commercial Buildings: A Literature Review and Synthesis of Current Knowledge. Health Effects Institute, Cambridge, MA and U.S. Environmental Protection Agency. 300 p., 1991.

## INTERNATIONAL DOCUMENTS:

Evaluation of Carcinogenic Risk of Asbestos. Volume 14. Asbestos. Series. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Intl Agency for Res. on Cancer - WHO, Lyon. 106 p. 1977. Co-author, Panel Member.

International Programme on Chemical Safety (IPCS). WHO. Environmental Health Criteria 53: Asbestos and Other Natural Mineral Fibres. Hannover, Germany. 194 p., 1986. Co-author, Panel Member.

Silica and Some Silicates. Volume 42. Series IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Intl Agency for Res. on Cancer - WHO, Lyon. 289 p., 1987. Co-author, Panel member.

International Programme on Chemical Safety (IPCS), WHO. Workshop on Health Risks Associated With Chrysotile Asbestos. Isle of Jersey. Ann. Occup. Hyg., 38, 397-646. Presenter. Author.

## PUBLICATIONS IN PEER-REVIEWED JOURNALS:

1. Kerr PF, Thomas AM, Langer AM: The nature and synthesis of ferrimolybdate. Am Mineral 48:14-32, 1963.
2. Kerr PF, Langer AM: Mineralogical features of Mojave playa crusts. In: Mineralogy and Hydrology of US Playas. Neal J (ed), US Air Force Cambridge Research Laboratories Environmental Research Paper No. 96, pp. 31-72, 1965.
3. Langer AM, Kerr PF: Experimental variables influencing DTA curves of kaolinite. Dupont Thermogram 3:1-4, 1966.

## PUBLICATIONS IN PEER-REVIEWED JOURNALS (cont):

4. Langer AM: Older paleozoic metamorphism and pegmatization in Bronx, New York. *Ann NY Acad Sci* 136:1-32, 1966.
5. Langer AM, Kerr PF: Mojave Desert playa crusts: physical properties and mineral content. *J Sed Patrol* 36:377-396, 1966.
6. Langer AM, Kerr PF: Evaluation of kaolinite and quartz differential thermal curves with a new high-temperature cell. *Am Mineral* 52:509-523, 1967.
7. Berkley C, Langer AM, Baden V: Instrumental analysis of inspired pulmonary particulates. *Trans NY Acad Sci* 30:331-350, 1967.
8. Neal JT, Langer AM, Kerr PF: Giant desiccation polygons of Great Basin playas. *Bull Geol Soc Am* 79:59-90, 1968.
9. Langer AM, Bowes DR: Polyphase deformation in the Manhattan formation of Manhattan Island, New York City. *Memoir 115 Geol Soc Am* 358-373, 1969.
10. Langer AM, Selikoff IJ, Sastre A: Chrysotile asbestos in the lungs of persons in New York City. *Arch Environ Health* 22:348-361, 1971.
11. Langer AM, Mackler AD, Rubin IB, Hammond EC, Selikoff IJ: Inorganic particles in cigars and cigar smoke. *Science* 174(4009):585-587, 1971.
12. Selikoff IJ, Nicholson WJ, Langer AM: Asbestos air pollution in urban areas. *Arch Environ Health* 25:1-13, 1972.
13. Liebling R, Langer AM: Optical properties of fibrous brucite from asbestos, Quebec. *Am Mineral* 57:857-864, 1972.
14. Langer AM, Rubin IB, Selikoff, IJ: Chemical characterization of asbestos body cores by electron microprobe analysis. *J Histochem Cytochem* 20 (9):723-734, 1972.
15. Langer AM, Rubin IB, Selikoff IJ, Pooley, FD: Chemical characterization of uncoated asbestos fibers from lungs of asbestos workers by electron microprobe analysis. *J Histochem Cytochem* 20(9):735-740, 1972.
16. Bowes DR, Langer AM: Petrochemistry of the Manhattan formation, New York City. *Krystalinikum* 10:39-51, 1974.
17. Langer AM, Ashley R, Baden V, Berkley C, Hammond EC, Mackler AD, Maggiore CJ, Nicholson WJ, Rohl AN, Rubin IB, Sastre A, Selikoff IJ: Identification of asbestos in human tissues. *J Occup Med* 15:287-295, 1973.

## PUBLICATIONS IN PEER-REVIEWED JOURNALS (cont):

18. Ehrenreich T, Mackler AD, Langer AM, Selikoff IJ: Les fibers d'amiante dans les poumons humains: leur signification medicolegale dans les maladies de l'environnement. *Arch des Maladies Professionnelles* 34(4-5):189-204, 1973.
  19. Bowes DR, Langer AM: Hornblende schists in the Manhattan formation in the Bronx, New York:Discussion. *Bull Geol Soc Am* 84:1483-1490, 1973.
  20. Ehrenreich T, Mackler AD, Langer AM, Selikoff IJ: Identification and characterization of pulmonary dust burden in pneumoconiosis. *Ann Clin Lab Sci* 3(2):118-131, 1973.
  21. Kleinfeld M, Messite J, Langer AM: A study of workers exposed to asbestiform minerals in commercial talc manufacture. *Environ Res* 6(2):132-143, 1973.
  22. Nicholson WJ, Langer AM, Selikoff IJ: Discussion: asbestos fibers in the air of towns. *Atmosph Environ* 7:666-668, 1973.
  23. Langer AM: Inorganic particles in human tissues and their association with neoplastic disease. *Environ Health Perspect* 9:229-233, 1974.
  24. Langer AM: Approaches and constraints to identification and quantitation of asbestos fibers. *Environ Health Perspect* 9:133-136, 1974.
  25. Langer AM: Research perspectives concerning asbestos minerals and their effects on biological systems. *Environ Health Perspect* 9:335-338, 1974.
  26. Langer AM: The subject of continuous vigilance. *Environ Health Perspect* 9:53-56, 1974.
  27. Rohl AN, Langer AM: Identification of asbestos in talc. *Environ Health Perspect* 9:95-109, 1974.
  28. Langer AM, Mackler AD, Pooley FD: Electron microscopical investigation of asbestos fibers. *Environ Health Perspect* 9:63-80, 1974.
  29. Miller A, Langer AM, Teirstein, AS, Selikoff IJ: "Non-specific" interstitial fibrosis: association with fibers detected by electron microscopy. *N Engl J Med* 292:91-93, 1975.
  30. Rohl AN, Langer AM, Selikoff IJ, Nicholson WJ: Exposure to asbestos in use of consumer spackling, patching, and taping compounds. *Science* 189(4204):551-553, 1975.
-

## PUBLICATIONS IN PEER-REVIEWED JOURNALS (cont):

31. Rohl AN, Langer AM, Klimentidis R, Wolff MS: Asbestos exposure during brake lining maintenance and repair. *Environ Res* 12:110-128, 1976.
32. Rohl AN, Langer AM, Selikoff IJ, Tordini A, Klimentidis R, Bowes DR, Skinner D: Mineral and chemical characterization of selected consumer talcum products. *J Toxicol Environ Sci* 2:255-284, 1976.
33. Bowes DR, Langer AM, Rohl AN: Nature and range of mineral dusts in the environment. *Phil Trans Roy Soc London* 286:593-610, 1977.
34. Rohl AN, Langer AM, Klimentidis R, Wolff MS, Selikoff IJ: Asbestos content of dust encountered during brake maintenance and repair. *Proc Roy Soc Med* 70:32-39, 1977.
35. Rohl AN, Langer AM, Selikoff IJ: Environmental asbestos pollution related to use of quarried serpentine rock. *Science* 196:1319-1322, 1977.
36. Langer AM, Wolff MS, Rohl AN, Selikoff IJ: Variation of properties of chrysotile asbestos, subjected to prolonged milling. *J Toxicol Environ Sci* 4:173-188, 1978.
37. Fischbein A, Langer AM, Suzuki Y, Selikoff IJ: Carcinoma of the lung in a drywall taping worker: report of a case. *Toxicol Letters* 2:231-236, 1978.
38. Langer AM: Crystal faces and cleavage planes in quartz as templates in biological processes. *Quart Rev Biophys* 11:543-575, 1978.
39. Rohl AN, Langer AM, Selikoff IJ: Airborne asbestos in the vicinity of a freeway: discussion. *Atmosph Environ* 12:2030-2031, 1978.
40. Langer AM, Rohl AN, Selikoff IJ: Asbestos on Maryland's roads. *The Lancet* i:1263-1264, 1978.
41. Fischbein A, Rohl AN, Langer AM, Selikoff IJ: Drywall construction and asbestos exposure. *Am Industr Hyg Assoc* 40:402-407, 1979.
42. Langer AM, Rohl AN, Selikoff IJ, Harlow G, Prinz M: Asbestos as a co-factor among nickel processing workers. *Science* 209:420-422, 1980.
43. Nolan RP, Langer AM, Harington JS, Oster G, Selikoff IJ: Quartz hemolysis as related to its surface functionalities. *Environ Res* 26:503-520, 1981.
44. Rohl AN, Langer AM, Moncure G, Fischbein AS, Selikoff IJ: Endemic pleural disease associated with mixed fibrous dust exposure in Turkey. *Science* 216(4545):518-520, 1982.

## PUBLICATIONS IN PEER-REVIEWED JOURNALS (cont):

45. Langer AM, McCaughey WET: Mesothelioma in a brake repair worker. *The Lancet* ii:1101-1103, 1982.
46. Ehrenreich T, Espinoza T, Langer AM, Rohl AN, Daum SM: Algorithm for forensic pathological diagnosis of asbestos-related diseases. *Am J Foren Med Pathol* 3(4):315-321, 1982.
47. Langer AM, Rohl AN, Fischbein AS, Selikoff IJ: Cancer in nickel processing workers in New Caledonia: discussion. *Science* 215:425-426, 1982.
48. Yeager H, Russo D, Yanez M, Gerardi D, Nolan RP, Kagan E, Langer AM: Preliminary observations on acute cytotoxicity of short fiber chrysotile asbestos for human alveolar macrophages. *Environ Res* 30:224-232, 1983.
49. Brody J, Miller A, Langer AM: Pneumoconiosis associated with exposure to glass and abrasive fragments. *Am J Industr Med* 6:339-346, 1984.
50. Constantopoulos S, Goudevenos J, Saratzis N, Charalampopoulos C, Laparidou S, Langer AM, Selikoff IJ, Moutsopoulos H: Endemic asbestos-like pleural calcifications in the absence of occupational asbestos exposure. *Arch Hellenic Med* 1(10):165-171, 1984.
51. Sawyer R, Rohl AN, Langer AM: Fiber contamination in buildings resulting from removal of asbestos-containing materials. *Environ Res* 36(1):46-55, 1985.
52. Constantopoulos SH, Goudevenos JA, Saratzis N, Langer AM, Selikoff IJ, Moutsopoulos HM: Metsovo lung: pleural calcification and restrictive lung function in northwestern Greece. Environmental exposure to mineral fiber as etiology. *Environ Res* 38:319-331, 1985.
53. Langer AM, Nolan RP: Asbestos in potable water supplies and attributable risk of gastrointestinal cancer. *Northeast Environ Sci* 5(1/2):41-53, 1986.
54. Langer AM, Nolan RP, Constantopoulos SH, Moutsopoulos HM: Association of Metsovo lung and pleural mesothelioma with exposure to tremolite-containing whitewash. *The Lancet* i:965-967, 1987.
55. Nolan RP, Langer AM, Weisman I, Herson R: Surface character and membralytic properties of the titania polymorphs. *Br J Ind Med* 44(10):687-698, 1987.
56. Nolan RP, Langer AM, Eskenazi RA, Herson GB, Foster KW: Membranolytic activities of quartz standards. *Toxicol In Vitro* 1(4):239-245, 1987.

## PUBLICATIONS IN PEER-REVIEWED JOURNALS (cont):

57. Langer AM, Nolan RP: Fiber type and mesothelioma risk. Symposium of Health Aspects of Exposure to Asbestos in Buildings. Energy and Environmental Policy Center, Kennedy School of Government. Harvard University. December, 1989, 91-141.
58. Freed JA, Miller A, Gordon R, Fischbein A, Kleinerman J, Langer AM: Desquamative interstitial pneumonia associated with chrysotile asbestos fibers. Br J Ind Med, 48: 332-337, 1991.
59. Nolan RP, Langer AM, Herson GB: Characterization of palygorskite specimens from different geological locales for health hazard evaluation. Br J Ind Med, 48: 463-475, 1991.
60. Langer AM, Nolan RP: Chrysotile biopersistence in the lungs of persons in the general population and exposed workers. Env. Health Perspect. Supplts., 102, Suppl. 5, 235-239, 1994.
61. Nolan RP, Langer AM, Addison J: Lung content analysis of cases occupationally exposed to chrysotile asbestos. Env. Health Perspect. Supplts., 102, Suppl. 5, 249-250, 1994.
62. Langer AM, Nolan RP: Chrysotile: Its Occurrence and Properties as variables controlling Biological Effects. Ann. Occup. Hyg., 38, No. 4, 427-451. 1994.
63. Wilson R, Langer AM, Nolan RP, Gee JBL, Ross M: Asbestos in New York City public school buildings. Public Policy: Is there a scientific basis? Jour. Regulatory Toxicology and Pharmacology, 20, 161-169, 1994.

## PUBLICATIONS IN SYMPOSIA PROCEEDINGS:

1. Berkley C, Langer AM, Sastre A, Arneson A: Electron microprobe analysis of asbestos bodies. In: Int'l Konferenz über die Biologischen Wirkungen des Asbestos, Dresden, 22-24 April, 1968. Holstein, Anspach M (eds), Deutsches Zentralinstitut für Arbeitsmedizin, Berlin, DDR, pp. 12-22.
2. Schwartz J, Langer AM: Technique of removal and analysis of single fibrous particles from human lung tissue. In: Int'l Konferenz über die Biologischen Wirkungen des Asbestos, Dresden, 22-24 April, 1968. Holstein, Anspach M (eds), Deutsches Zentralinstitut für Arbeitsmedizin, Berlin, DDR, pp.8-12.
3. Bowes DR, Langer AM: Polyphase deformation in the schist of the Bronx, New York City. In: Geology, Queens College, CUNY, Alexandroff E (ed) 1(3):17-32, 1969.

## PUBLICATIONS IN SYMPOSIA PROCEEDINGS (cont):

4. Langer AM: Electron microprobe analysis (study of asbestos fibers and bodies from lung tissue). In: Laboratory Diagnosis of Diseases Caused by Toxic Agents. Sunderman FW, Sunderman Jr FW (eds), W.H. Green; St. Louis, MO, Chapt. 14, pp. 126-136, 1970.
5. Langer AM, Rubin IB, Selikoff IJ: Electron microprobe analysis of asbestos bodies. In: Pneumonconiosis, Proc Int'l Conf, Johannesburg. Shaprio HA (ed), Oxford University Press; Capetown, pp. 57-69, 1970.
6. Langer AM, Baden V, Hammond EC, Selikoff IJ: Inorganic fibers, including chrysotile in the lungs at autopsy: preliminary report. In: Inhaled Particles III, Proc Conf Brit Occup Hyg Soc, London. Walton WH (ed), Unwin Bros; Surrey, England, 2:683-694, 1971.
7. Langer AM, Selikoff IJ: Chrysotile asbestos of lungs in residents of New York City. In: 2nd Int'l Clean Air Congress, Washington, DC. Englund HM, Beery, WT (eds), Academic Press; New York, pp. 161-165, 1971.
8. Langer AM, Pooley FD: Identification of single asbestos fibers in human tissues. In: Proc Int'l Agency for Research on Cancer, Biol. Effects of Asbestos, Lyon, 1972, Bogovski P, Gilson JC, Timbrell V, Wagner JC (eds), pp. 119-125, 1973.
9. Langer AM: Aspects of mineralogy of talc. In: Proc Symp on Talc, Washington, DC, May 9, 1973. Goodwin A (ed), USBM IC 8639, US Department of Interior, pp. 82-88, 1974.
10. Pooley FD, Rohl AN, Langer AM, Bowes DE, Skinner DL: Mineralogy and chemistry of British talc and consumer talcum products. In: 4th Int'l Symp Inhaled Particles and Vapors. Walton WH (ed), Pr. 8.6, pp. 1-18, 1975.
11. Langer AM, Rohl AN, Wolff MS, Klimentidis R, Shirey SB: Review of current techniques for the analysis of fibers in talc. In: Electron Microscopy of Microfibers. Asher IM, McGrath PP (eds), US Government Printing Office, pp. 28-33, 1977.
12. Langer AM, Wolff MS: Asbestos carcinogenesis. In: Inorganic and Nutritional Aspects of Cancer. Adv Exper Med Biol Series, Schrauzer GN (ed), Plenum Press; New York, pp. 29-55, 1977.
13. Nicholson WJ, Langer AM, Selikoff IJ: Epidemiological evidence on asbestos, Part I: Human health effects; Part II: Extrapolation to other inorganic fibers. In: Proc of Workshop on Asbestos, NBS SP 506. Gravatt CC, LaFleur PD, Heinrich KFJ (eds), with discussion. US Government Printing Office, Washington, DC, pp. 71-93, 1978.

## PUBLICATIONS IN SYMPOSIA PROCEEDINGS:

14. Rohl AN, Langer AM: Fibrous mineral content of consumer talc-containing products. In: Dusts and Diseases. Lemen R, Dement JM (eds), Pathotoxical Publishers, Inc; Forest Park, IL, pp. 393-403, 1979.
15. Langer AM, Rohl AN, Wolff MS, Selikoff IJ: Asbestos, fibrous minerals, and acicular cleavage fragments: nomenclature and biological properties. In: Dusts and Diseases. Lemen R, Dement JM (eds), Pathotoxical Publishers, Inc; Forest Park, IL, pp. 1-22, 1979.
16. Langer AM, Maggiore CJ, Nicholson WJ, Rohl AN, Rubin IB, Selikoff IJ: The contamination of Lake Superior with fibrous amphiboles. In: Proc NY Acad Sci Asbestos Conf, New York, NY, June 1978, Ann NY Acad Sci 330:549-572, 1979.
17. Langer AM: Significance of aspect ratio in regulation of asbestos fiber exposure. Ann NY Acad Sci 330:601-604, 1979.
18. Langer AM, Selikoff IJ, Rosenberg C: Defining new asbestos high risk groups. In: Int'l Conf Critical Current Issues in Environmental Health Hazards, Tel Aviv, Israel, March 4-7, p. 11, 1979.
19. Langer AM, Sebastien P: Physical-chemical properties of fibers: discussion. In: Biological Effects of Asbestos, IARC, Vol. 1, Wagner JC (ed), WHO, Lyon, France, pp. 143-145, 1980.
20. Suzuki Y, Rohl AN, Langer AM, Selikoff IJ: Mesothelioma following intraperitoneal administration of zeolite. Fed Proc 39(3):640, 1980.
21. Langer AM: Natural non-fibrous asbestos substitutes: talc. In: Proc Nat'l Workshop on Substitutes for Asbestos, Guimond RJ, Rowe J (eds), US Environmental Protection Agency, Office of Pesticides and Toxic Substances, Washington, DC, pp. 563-569, 1980.
22. Rohl AN, Ehrenreich T, Langer AM: Characterization and identification of asbestos materials in human tissues. In: Adv Pathol (Anat and Clin), Vol. 2, Anatomic Pathology, Cytopathology, Forensic Pathology and Toxicology, Levy E (ed), Pergamon Press, New York, pp. 523-525, 1982.
23. Langer AM, Weisman I, Adams A: Characterization of crystalline particles in human tissues by analytical electron microscopy. J Rheumatol 8(6):1018-1019, 1982.

## PUBLICATIONS IN SYMPOSIA PROCEEDINGS (cont):

24. Nolan RP, Langer AM: Quartz and hemolysis: physico-chemical factors controlling membrane activity. In: 4th Ann RMCOEH Conf Health Issues Related to Mining and Minerals, Wagner W, Merchant J, Rom W (eds), Chapt. 4, Ann Arbor Press, Michigan, pp. 63-81, 1983.
25. Langer AM: Surface characteristics and biological properties of minerals. In: World Symp on Asbestos, May 25-27, 1982, Canadian Asbestos Information Center, Montreal, Quebec, pp. 393-400, 1983.
26. Langer AM, Nolan RP: Minerals, rocks and ore bodies: sources of agents of human disease. In: Proc 2nd Int'l Congr on Applied Mineralogy in the Minerals Industry. Park WC, Hausen DM, Hagni RP (eds), pp. 1159-1179, 1985.
27. Harlow GE, Kimball MR, Dowty E, Langer AM: Observations on amosite-grunerite dusts. In: Proc 2nd Int'l Congr on Applied Mineralogy in the Minerals Industry. Park WC, Hausen DM, Hagni RP pp. 1147-1157, 1985.
28. Nolan RP, Langer AM, Foster KW: Particle size and chemically induced variability in the membralytic activity of quartz: preliminary observations. In: In Vitro Effects of Mineral Dusts, 3rd Int'l Workshop. Beck EG, Bignon J (eds), Springer-Verlag, Berlin, pp. 39-50, 1985.
29. Langer AM, Nolan RP: Physico-chemical properties of minerals relevant to biological activities. State of the Art. In: In Vitro Effects of Mineral Dusts, 3rd Int'l Workshop. Beck EG, Bignon J (eds), Springer-Verlag, Berlin, pp. 9-24, 1985.
30. Langer AM, Nolan RP: Physico-chemical properties of quartz and biological activity. In: Silica, Silicosis, and Cancer. Controversy in Occupational Medicine. Ca Res Monogr 2, Goldsmith DF, Winn DM, Shy CM (eds), Praeger, NY, pp. 125-136, 1986.
31. Langer AM, Nolan RP: The properties of chrysotile asbestos as determinants of biological activity. Variations in cohort experience and disease spectra as related to mineral properties. In: General Motors Workshop, Biol Effects Chrysotile Asbestos, Cardiff, 7-9 May, 1986, Wagner JC (ed), Accomplishments in Oncology, Lippincott Press, 1(2):30-51, 1986.
32. Langer AM: Fibers in friction products. Discussion and Summary of Symposium. In: Proc Fibres in Friction Materials Symposium. The Asbestos Institute, Montreal, Canada, pp. 67-74, October, 1987.
33. Nolan RP, Langer AM: Quantitative aspects of fiber morphology. In: Proc Fibres in Friction Materials Symposium. The Asbestos Institute, Montreal, Canada, pp. 75-97, October, 1987.

## PUBLICATIONS IN SYMPOSIA PROCEEDINGS (cont):

34. Langer AM, Nolan RP: Fiber type and burden found in parenchymal tissues of workers occupationally exposed to asbestos in the United States. In: Mineral Fibers in the Non-Occupational Environment, Spec. Publ. 90. IARC-WHO, Lyon, France, pp. 310-315, 1989.
35. Langer AM, Nolan RP, Bowes DR, Shirey: Inorganic particles found in cigarette tobacco, cigarette ash, and cigarette smoke. In: Biological Interaction of Inhaled Mineral Fibers and Cigarette Smoke. Wehner AP, Felton DL, Eds., Battelle Press, Columbus, OH, pp. 421-439, 1989.
36. Nolan RP, Langer AM, Herson GB: Physico-chemical properties and membranolytic activities of the titanium dioxide polymorphs compared to quartz. In: Biological Interaction of Inhaled Mineral Fibers and Cigarette Smoke. Wehner AP, Felton DL, Eds., Battelle Press, Columbus, OH, pp. 391-419, 1989.
37. Langer AM, Nolan RP: Mineral fibers in lung tissues of persons exposed to asbestos in the United States. In: VIIth Int'l Pneumoconiosis Conf., August 23-26, 1988.
38. Nolan RP, Langer AM: Physicochemical characteristics of quartz dust which controls its biological activity. In: VIIth Int'l Pneumoconiosis Conf., August 23-26, 1988.
39. Langer AM, Nolan RP: Distinguishing asbestiform tremolite from non-asbestiform tremolite. In: VIIth Int'l Pneumoconiosis Conf., August 23-26, 1988.
40. Nolan RP, Langer AM, Herson GB: Membranolytic activity of palygorskite and sepiolite. In: IVth Int'l Workshop: Effects of Mineral Dusts on Cells. Mossman BT, Begin RO, Eds., Springer-Verlag, Oxford, Quebec, Canada, September, pp. 37-48, 1989.
41. Langer AM, Nolan RP, Pooley FD,: Phyllosilicates: associated fibrous minerals. In: Health Related Effects of Phyllosilicates. J. Bignon, Ed., 59-74, Springer-Verlag, N.Y., 1990.
42. Langer AM, Nolan RP, Addison J: Physico-chemical properties of asbestos as determinants of biological potential. In: Mineral Fibers and Health. Liddell FDS, Miller K, Eds., CRC Press, Ann Arbor, Michigan, pp. 207-224, 1991.
43. Langer AM, Nolan RP, Addison J: Distinguishing between amphibole asbestos fibers and elongate cleavage fragments of their non-asbestos analogues. In: NATO Advanced Research Workshop on Mechanisms in Fibre Carcinogenesis. RC. Brown, J. Hoskins, N. Johnson, Eds., Albuquerque, New Mexico, October 22-25, 1990. p. 253-267. 1991.

## PUBLICATIONS IN SYMPOSIA PROCEEDINGS (cont):

44. Nolan RP, Langer AM, Oechsle GW, Addison J, Colflesh DE: Association of tremolite habit with biological potential. In: NATO Advanced Research Workshop on Mechanisms in Fibre Carcinogenesis. RC. Brown, J. Hoskins, N. Johnson, Eds., Albuquerque, New Mexico, October 22-25, 1990. p.231-251. 1991.
45. Langer AM, Nolan RP: Zeolite catalysts. Is there a health risk? The erionite experience and its application to other zeolites. In: Chemicals and the Environment. Symposium on Chemical Specialties USA, Philadelphia. Spring Innovations, Ltd. 91-95, 1992.
46. Nolan RP, Langer AM: Limitations of the Stanton Hypothesis. Chapt. 9. Health Effects of Mineral Dusts, Reviews in Mineralogy, 28, Guthrie GD., Jr. and Mossman BT, Eds, Mineral. Soc. America, Wash., D.C., 309-326, 1993
47. Ross M, Nolan RP, Langer AM, Cooper WC: Health effects of mineral dusts other than asbestos. Chap. 12. Health Effects of Mineral Dusts, Reviews in Mineralogy, 28, Guthrie GD., Jr. and Mossman BT, Eds, Wash., D.C., 361-407, 1993.
48. Langer AM, Nolan RP: Factors controlling the biological potential of inorganic dusts. Surface chemistry and character. In: Toxic and Carcinogenic Effects of Solid Particles in the Respiratory Tract, Mohr U, Dungworth DL, Mauderly JL, Oberdorster G, Eds., ILSI Monographs, ILSI Press, Wash. D.C., 147-157, 1994.

## OTHER PUBLICATIONS:

1. Langer AM, Mackler AD: Mineral particles and human disease. In: Encyclopedia of Geochemistry and Environmental Sciences. Fairbridge RW (ed), Van Nostrand; Reinhold, NY, Vol. IVA, pp. 730-739, 1972.
2. Miller A, Teirstein AS, Langer AM, Selikoff IJ: Submicroscopical asbestos fibers and disease. Letter to the Editor. Reply to discussion. N Engl J Med 292:1195-1196, 1975.
3. Wolff MS, Langer AM, Shirey SB: Gas chromatographs: health effects. Letter to the Editor. Science 191:13, 1976.
4. Langer AM, Pooley FD: Mineralogy of asbestos minerals and methods of their characterization in human tissues. In: Asbestos: Volume 14 in the Chemical Carcinogenesis Series, Int'l Agency for Research on Cancer, p. 107, 1977.
5. Rom WN, Langer AM: Carcinogenicity of fibrous glass. Letter to the Editor. West J Med 126:413, 1977.

## OTHER PUBLICATIONS (cont):

6. Rohl AN, Langer AM, Selikoff IJ: Asbestos pollution. Letter to the Editor. Reply. Science 197:716-718, 1977.
7. Rohl AN, Langer AM, Selikoff IJ: Chrysotile asbestos, effects of human exposure. Letter to the Editor. Reply. Science 198:1202, 1977.
8. Langer AM, Holaday D, Nicholson WJ, Rohl AN: Chapter 2. Asbestos Minerals: Nature, Occurrence and Properties, pp. 34-50. Chapter 4. Identification and Quantitation of Asbestos Fibers, pp. 71-100. Chapter 5. Environmental Distribution, pp. 102-134. In: Asbestos and Disease. Selikoff IJ, Lee WHK (eds), Academic Press; NY, 1978.
9. Langer AM: Relationship between chemical and physical properties of mineral fiber and health effects. NBS SP506, Workshop on Asbestos: Definitions and Measurement Methods. Gravatt CC, LaFleur PD, Heinrich KFJ (eds), pp. 104-195:198, 1978.
10. Langer AM: Mineralogical factors in asbestos health effects. NSB, SP506, Workshop on Asbestos: Definitions and Measurement Methods. Gravatt CC, LaFleur PD, Heinrich KFJ (eds), pp. 91-92:198, 1978.
11. Rohl AN, Langer AM, Wylie AG: Mineral characterization of asbestos-containing spray finishes. In: Asbestos-Containing Materials in School Buildings. US Environmental Protection Agency, Document EPA 450-2-78-014, US Government Printing Office; Washington, DC, pp. 59-64, 1979.
12. Fischbein AS, Rohl AN, Langer AM, Selikoff IJ: Pleura-und-peritoneal mesothelioma. Letter to the Editor. Med Klin 74(19):742, 1979.
13. Langer AM: Electron microscopy and x-ray applications to environmental and occupational health analysis. Book Review. J Toxicol Environ Health, 1979.
14. Langer AM: Mineralogy and physical properties of fibers. Talcs contaminated with other minerals. Discussions. In: Dusts and Disease. Lemen R, Dement J (eds), Pathotoxicol Pub Inc, Park Forest, IL, 120:122-123, 341-344, 1979.
15. Langer AM: Round-table discussion on talc as an asbestos substitute. Chairman's remarks. In: Proc Nat'l Workshop on Substitutes for Asbestos, Arlington, VA, Guimond RJ, Rowe JN, Levin A, Pillsbury H (eds), USEPA Office Toxic Substances, Washington DC, pp. 612-619, July 14-16, 1980.
16. Fischbein AS, Langer AM, Rohl AN, Selikoff IJ: Asbestos disease in drywall construction workers. Letter to the Editor. Am Industr Hyg Assoc 40(9):829-830, 1980.

## OTHER PUBLICATIONS (cont):

17. Langer AM: Mineralogy of dust diseases. In: Maxcy-Rosenau Public Health and Preventive Medicine. Last J (ed), Appleton-Century-Crofts Publishers; NY, 11th Edition, pp. 637-641, 1981.
  18. Fischbein AS, Rohl AN, Langer AM, Selikoff IJ: Past asbestos exposure among cable splicers. Letter to the Editor. *Am J Pub Health* 71:1277-1278, 1981.
  19. Langer AM: Host rocks and gangue materials in relation to pneumoconiosis and cancer. Editorial. *Am J Industr Med* 2:89-90, 1981.
  20. Langer AM, Sebastien P: Physical-chemical properties of fibers. Rappateur Report. In: Biological Effects of Mineral Fibers, Int'l Agency for Research on Cancer, Wagner JC (ed), IARC-WHO, Lyon, France, 1:143-145, 1981.
  21. Langer AM, Selikoff IJ: Scientific data on chrysotile. Letter to the Editor. *Chem Engineer News* 2:59, 1984.
  22. Zoltai T, Langer AM: Chapter 2. Asbestiform fibers: historical background, terminology, and physicochemical properties. In: Asbestiform Fibers - Non-Occupational Health Risks. NAS-NRC, Nat'l Acad Sci, pp. 25-47, 1984.
  23. Lynch J, Langer AM: Chapter 4. Measurement of exposure to asbestiform fibers. In: Asbestiform Fibers - Non-Occupational Health Risks. NAS-NRC, Nat'l Acad Sci, pp. 82-96, 1984.
  24. Langer AM: Mineral dust and pulmonary lesions: etiological link or epiphenomenon? Editorial. *Am J Industr Med* 6:169-171, 1984.
  25. Fischbein AS, Langer AM, Rohl AN: Asbestos-associated diseases: lessons from the past for the future. Letter. *JAMA* 254:1309-1310, 1985.
  26. Langer AM, et al.: Asbestos and other natural mineral fibers. In: Int'l Program on Chemical Safety. *Environ Health Criteria* 53, Chapters II, III, IV, V, WHO, Geneva, 1986.
  27. Langer AM, Nolan RP: Asbestos in play sand. Letter, *N Engl J Med* 316:882, 1987.
  28. Constantopoulos SH, Langer AM, Saratzis N, Nolan RP: Regional findings in Metsovo lung. Correspondence, *The Lancet* ii:452-453, 1987.
-

## OTHER PUBLICATIONS (cont):

29. Langer AM: Mineralogy. Chapter II. Presidential Report on Occupational Chest Diseases, Vol. 1, Characterization and Measurement of the Environment. Merchant J, Dement J (eds), ALOSH-NIOSH-CDC; Washington, DC, pp. 3-40, 1987.
30. Langer AM: Asbestos. In: Collier's Encyclopedia, 3:4-5, 1987.
31. Langer AM, Nolan RP, Constantopoulos S: Endemic pleural calcification and mesothelioma. JAMA 260(3):339-340, 1988.
32. Langer AM: Chairman's Summary and Discussion. In: Biological Interaction of Inhaled Mineral Fibers and Cigarette Smoke. Wehner AP, Felton DL, Eds., Battelle Press, Columbus, OH, pp. 590-593, 1989.
33. Langer AM, Nolan RP, Ross M: Asbestos policy. Science, 249:1485, 1990.
34. Langer AM: Asbestos. In: Merit Students Encyclopedia, Macmillan Ed Pub, NY, pp. 270-271, 1990.
35. Langer AM, Nolan RP: Pleural mesothelioma resulting from exposure to amosite asbestos in a building. Letter. Respiratory Medicine 84:509-510, 1990.
36. Langer AM, Nolan RP, Addison J: Letter to the Editor concerning Editorial "On talc, tremolite and tergiversation," Reger R, Morgan WKC. British Journal Industrial Medicine 48:359-360, 1991.
37. Langer AM: Chrysotile: The mineral and its properties. Summary of Presentation In: Health Risks Associated with Chrysotile Asbestos. Ann. Occup. Hyg., 38, 407. 1994.
38. Langer AM: Asbestos chapter: American Medical Association Primer on Chemical and Radiation Exposures. Davis, A., Ed. in press.
39. Nolan RP, Langer AM: Mineralogy. Chapter 12. In: Occupational and Environmental Respiratory Disease, Harber P., Schenker M., Balmes J., Eds. in press.

## PUBLISHED ABSTRACTS:

1. Berkley C, Langer AM, Berkley LE, Anderson CA: Chemical changes in inspired asbestos fibers. Microscopy Symp, McCrone Laboratory, Chicago, IL, August, 1966.

## PUBLISHED ABSTRACTS (cont):

2. Berkley C, Langer AM, Selikoff IJ: Microbeam analysis and identification of the degradation products of inspired pulmonary particulates. *Trans NY Acad Sci*, May, 1967.
  3. Langer AM, Kerr PF: The nature of soft and harsh chrysotile. *In: Conference on the Physics and Chemistry of Asbestos Minerals*, Oxford, Pr. 2-2, July, 1967.
  4. Berkley C, Langer AM, Arneson A: Electron microprobe and electron diffraction analysis of asbestos bodies. *In: 2nd Intl. Conf. Biol. Effects Asbestos*, p. 7, Dresden, 22-25 April, 1968.
  5. Berkley C, Langer AM, Rubin IB: Electron Microprobe analysis of particles in tissues. *In: Proc 5th Nat'l Conf Elect Probe Soc Am*, New York, Pr. 29A, July, 1970.
  6. Selikoff IJ, Nicholson WJ, Langer AM: Asbestos air pollution in urban areas. *In: Proc AMA Air Pollution Med Res Conf*, New Orleans, October, 1970.
  7. Ehrenreich T, Langer AM, Selikoff IJ: Asbestos fibers in human lungs: forensic significance in environmental disease. *In: 6th Int'l Mtg Forensic Sci*, Edinburgh, *Int'l Assn Forensic Sci*, p. 86, September, 1972.
  8. Teirstein AS, Miller A, Langer AM, Selikoff IJ: Sublight microscopic mineral particles in the etiology of pulmonary fibrosis. *In: Proc Am Thorac Soc*, New York, pp. 33-34, May 21-21, 1973.
  9. Everett GA, Langer AM: Environmental contamination of Lake Superior asbestos from amphiboles in taconite wastes. *In: Proc Ann Mtg Geol Soc Am*, Miami, p. 728, November 18-20, 1974.
  10. Rohl AN, Anderson H, Langer AM: Asbestos exposure during brake lining maintenance and repair. *In: Proc Am Ind Hyg Assn*, Miami, May 12-16, 1974.
  11. Langer AM, Pooley FD, Bowes DR: Environment, disease and minerals. Read before the Geological Society, London, November 20, *J Geol Soc*, with discussion, 1974.
  12. Langer AM, Wolff MS, Rubin IB: Environmental assay: particles in human tissues. *In: Proc Int'l Conf Environ Sensing and assessment*, Environmental Protection Agency, Pr. 29-34, September 14-19, 1975.
  13. Bowes DR, Langer AM, Rohl AN: Nature and range of mineral dusts in the environment. *Roy Soc London (Geological)*, p. 18, April 7, 1976.
-

## PUBLISHED ABSTRACTS (cont):

14. Langer AM, Suzuki Y, Rohl AN: Identification of Microparticles. In: 3rd Intl. Symp. on Detection and Prevention of Cancer. ACS. New York, p. 91, April 26-May 1, 1976.
15. Fischbein A, Langer AM, Suzuki Y, Selikoff IJ: Carcinoma of the lung in a drywall taping worker: report of a case. In: Prog Abstr 3rd Int'l Symp Detect Prevent Cancer, No. 280, September 7, 1976.
16. Rom WN, Frank A, Suzuki Y, Langer AM, Selikoff IJ: Rapidly progressive interstitial pulmonary fibrosis from short term mixed dust exposure. 42nd An Sci Assem Am Coll Chest Phys, Atlanta, GA, October 21-28, 1976.
17. Fischbein A, Langer AM: Shale oil: A future energy alternative. A review of the mineralogic and carcinogenic properties of shale oil. Tenth Ann Conf Trace Substances in Environ Health, Columbia, MO, June 8-10, 1976.
18. Langer AM: Identification of microparticles in tissues. Workshop 13, 3rd Int'l Sump on Detection and Prevention of Cancer, September 1976.
19. Langer AM, Wolff MS: Asbestos carcinogenesis. In: Inorganic and Nutritional Aspects of Cancer, La Jolla, CA, January 2-5, 1977.
20. Selikoff IJ, Nicholson WJ, Langer AM: Epidemiological evidence on asbestos. Workshop on Asbestos, Definition and Measurement Methods, NBS Workshop, Gaithersburg, MD, July, 1977.
21. Langer AM: Contamination by submicroscopic particles in the biosphere. Int'l Symp Anal Electron Microscopy in Biol and Environ Routine and Research Work, Nat'l Inst Pub Health, Oslo, May 10, 1977.
22. Langer AM: Asbestos minerals and their carcinogenic effect. Int'l Symp Anal Electron in Biol and Environ Routine and Research Work, Nat'l Inst Pub Health, Oslo, May 10, 1977.
23. Langer AM, Oster G: Crystal faces and cleavage planes in quartz as templates in biological processes. Biophys Soc Am Phys Soc Mtg, Washington, DC, March, 1978.
24. Liis R, Langer AM: Chronic interstitial pulmonary disease with severe respiratory disfunction due to unsuspected occupational beryllium exposure. In: XIXth Int'l Congr Occup Health, Dubrovnik, Yugoslavia, pp. 89-90, September 25-30, 1978.

## PUBLISHED ABSTRACTS (cont):

25. Rohl AN, Langer AM: Asbestos and asbestiform minerals in non-asbestos mines in the United States. In: XIXth Int'l Congr Occup Health, Dubrovnik, Yugoslavia, pp. 121-122, September 25-30, 1978.
26. Russo DA, Kagan E, Langer AM, Yeager H: Human alveolar macrophages: cytotoxicity of naturally-occurring short fiber. Federation Proceedings, Section Physiology, Federation American Societies of Experimental Biology, 1980.
27. Langer AM: Physical-chemical characteristics of chrysotile and their relationship to biological activity. In: 29th Ann Clay Minerals Conf, Baylor, Waco, TX, p. 58, October 5-9, 1980.
28. Bowes DR, Langer AM: Mineralogy and geochemistry of particulates in cigarette smoke. In: Ann Mtg Geol Soc, London, Environmental Mineralogy, January 11, 1980.
29. Langer AM: Particulate inhalants. In: Occupational Toxicology, College of Medicine and Dentistry, NJ, September 26, 1980.
30. Langer AM: Minerals as toxic agents: parameters and mechanisms. In: Proc 50th Geol Alumni Assn, Brooklyn College, CUNY, May 7-9, 1981.
31. Langer AM, Weisman, I, Adams A, Pooley FD: Characterization of crystalline particles in tissue by analytical electron microscopy. In: Symp on Crystalline Deposits in Tissues, Toronto, August 13-14, 1981.
32. Russo DA, Kagan E, Langer AM, Nolan R, Yeager H: Cytotoxicity of naturally-occurring short fiber asbestos. In: 20th Int'l Congr Occup Health, Cairo, September 25-October 1, 1981.
33. Ehrenreich T, Langer AM, Selikoff IJ: Algorithm of pathologic diagnosis of asbestos-related diseases for forensic purposes. Significance of quantitative and morphological correlates. In: 20th Int'l Congr Occup Health, Cairo, September 25-October 1, 1981.
34. Rohl AN, Langer AM, Suzuki Y, Lilis R, Moncure G, Selikoff IJ: Endemic pleural disease associated with mixed fibrous dust exposure in Turkey. In: 20th Int'l Congr Occup Health, Cairo, September 25-October 1, 1981.
35. Nolan RP, Langer AM: Surface functionalities of quartz and hemolytic activity. In: Proc 2nd Int'l Workshop of the In Vitro Effects of Mineral Dusts, Arkadelphia, AR, April 5-6, 1982.

## PUBLISHED ABSTRACTS (cont):

36. Langer AM, Nolan RP: Membrolytic properties of quartz. In: Proc 2nd Ann Geol Alumni Assn, Brooklyn College, CUNY, p. 4, April 28-30, 1983 (abstracts).
37. Nolan RP, Langer AM, Foster KW: Recognition of quartz by erythrocyte membranes. In: 6th Int'l Pneumoconiosis Conf, Bochum, FDR, September 20-23, 1983 (Abstract 198).
38. Nolan RP, Langer AM, Foster KW: Physico-chemical factors effecting membrolytic properties of quartz. In: 6th Int'l Pneumoconiosis Conf, Bochum, FDR, September 20-23, 1983 (Abstract 199).
39. Langer AM, Nolan RP: Surface properties of quartz and membrane activity. In: Int'l Symp Silica, Silicosis and Cancer, Chapel Hill, NC, April 3-5, 1984.
40. Langer AM: Asbestos, fibrous minerals, acicular cleavage fragments and the mineral industries. In: Int'l Congr Applied Mineralogy, Los Angeles, February, 1984.
41. Langer AM: Minerals and disease: the association between exposure to minerals and rock dust and the occurrence of human disease. In: Int'l Congr Applied Mineralogy, Los Angeles, February, 1984.
42. Langer AM: Mineral fiber in water? In Medical Geology Conference on Health Threatening Toxins in Water, Brooklyn College, NY, May, 1984.
43. Constantopoulos SH, Langer AM, Saratzis N, Goudevenos JA, Selikoff IJ: Metsovo lung: pleural calcifications and malignant pleural mesothelioma in northwestern Greece. Tremolite asbestos used for whitewashing as etiology. In: 3rd Int'l Conf Environmental Lung Disease, Am Coll Chest Phys, Montreal, Canada, October 15-18, 1986. Chest 91(2):300, 1987.
44. Langer AM, Nolan RP: Fiber type and parenchymal burden found in workers occupationally exposed to asbestos fiber in the United States. Implications for risk assessment in the general population. Mineral Fiber in the Non-Occupational Environment, Lyon, France, October 8-10, 1987.
45. Langer AM, Nolan RP: Mineralogical and biological comparison of asbestiform and non-asbestiform tremolite. AIME Annual Meeting, Phoenix, AZ, January 25-28, 1988.
46. Langer AM, Nolan RP, Bowes DR, Shirey S: Inorganic particles in cigarettes and cigarette smoke. In: Biological Interaction of Inhaled Mineral Fibers and Cigarette Smoke. International Symposium/Workshop, Seattle, WA, April 10-14, 1988.

## PUBLISHED ABSTRACTS (cont):

47. Nolan RP, Langer AM, Herson GB: Physico-chemical properties of the titanium dioxide polymorphs and biological activity. *In*: Biological Interaction of Inhaled Mineral Fibers and Cigarette Smoke. International Symposium/Workshop, Seattle, WA, April 10-14, 1988.
  48. Nolan RP, Langer AM, Herson GB: Membranolytic activity of palygorskite and sepiolite. *In*: IVth International Conference on the Effects of Mineral Dusts on Cells, p. 15, Oxford, Quebec, Canada, 1988.
  49. Langer AM, Nolan RP, Herson GB: Membranolytic activity and physicochemical characterization of phosphorylated Canadian chrysotile. *In*: IVth International Conference on the Effects of Mineral Dusts on Cells, p. 14, Oxford, Quebec, Canada, 1988.
  50. Nolan RP, Langer AM, Herson GB: Physicochemical characteristics of quartz dust which controls its biological activity. *In*: VIth International Pneumoconiosis Conference, DHHS (NIOSH) Publication No. 90-108, Part I, 754, 1990.
  51. Langer AM, Nolan RP: Fiber type and risk of mesothelioma to building occupants. *In*: Health Aspects of Exposure to Asbestos in Buildings. Energy and Environmental Policy Center, John F. Kennedy School of Government, Harvard University, Cambridge, MA, December 14-16, 1988.
  52. Langer AM, Pooley FD, Nolan RP: Phyllosilicates: Associated fibrous minerals. *In*: First International Conference on Health Related Effects of Phyllosilicates. NATO Advanced Research Workshop, Paris, France, March 16-18, 1989.
  53. Nolan RP, Langer AM, Herson GB: Characterization of palygorskite specimens from different geological locales for health hazard evaluation. *In*: First International Conference on Health Related Effects of Phyllosilicates. NATO Advanced Research Workshop, Paris, France, March 16-18, 1989.
  54. Langer AM, Nolan RP: The importance of mineral subpopulations in biological assays. *In*: NATO Advanced Research Workshops on Mechanisms in Fibre Carcinogenesis. Albuquerque, New Mexico, October 22-25, 1990. 49-50.
  55. Nolan RP, Langer AM, Oechsle GW, Addison J, Colflesh DE: Association of tremolite habit with biological potential. *In*: NATO Advanced Research Workshops on Mechanisms in Fibre Carcinogenesis. Albuquerque, New Mexico, October 22-25, 1990. 57.
  56. Langer AM: Fiber types, fiber sizes, and asbestos diseases. Andrews Communications Seminars. 2nd Asbestos Litigation. The Eye of the Storm. 25-26 February, 1991. Bal Harbour, Florida.
-

## PUBLISHED ABSTRACTS (cont):

57. Nolan RP, Langer AM, Oechsle GW, Johnson NF: Physicochemical characterization of selected zeolite minerals for health hazard evaluation. Fourth Intl. Conf. Env. Lung Disease. Montreal, Canada, September 25-28, 1991.
58. Nolan RP and Langer AM: Characterization of fibers for Health Hazard evaluation. Critical Research Needs. Workshop on Chemical and Biological Interactions of Glass. Bethesda, MD, 5-6 Mar, 1992.
59. Langer AM and Nolan RP (1992). Comparison of lung tissue mineral fibre retention of exposed workers and the general population. In: Biopersistence of respirable synthetic fibres and minerals. 7-9 Sept, 1992. Lyon. p. 26.
60. Nolan RP, Langer AM, and Addison J (1992). Health hazard evaluation of the lung tremolite fiber content among Canadian chrysotile workers. In: Biopersistence of respirable synthetic fibres and minerals. 7-9 Sept, 1992. Lyon. p. 52.
61. Langer AM, Nolan RP (1993). Factors controlling the biological potential of inorganic dusts: surface character and chemistry. 4th International Inhalation Symposium, Hannover. Toxic and Carcinogenic Effects of Solid Particles in the Respiratory Tract, 1-5 March, 1993, Hannover. Abst. A-10, p. 48.
62. Langer AM, Nolan RP (1993) Physico-chemical characteristics of quartz dust which controls its biological activity. Clay Minerals Society Meeting. San Diego, 25-30 Sept, 1993.

## MANUSCRIPTS IN PREPARATION:

Langer AM, Kimball MR, Harlow GE: A comparison of fibrillar structure in amosite and crocidolite.

Langer AM, Kimball MR, Harlow GE, Dowty E: Electron microscopy studies of amosite and grunerite dust particles.

Langer AM: Distribution of amosite and chrysotile fibers in the lung of an exposed worker: role of fiber size and type.

Nolan RP, Langer AM: Mineral surfaces and the anion transport system of the human red blood cell. Mechanism of hemolytic action.

Langer AM, et al: Amosite fiber size-distribution at a fabrication plant: mesothelioma and fiber dimension.

**MANUSCRIPTS IN PREPARATION (cont):**

Langer AM, et al: Asbestos bodies in two periods of time: review, secular trends, New York City, 1915-1970.

Langer AM, et al: Asbestos bodies and age, sex, occupation of urban dwellers: asbestos bodies as indices of disease risk

**PARTICIPATION IN POSTGRADUATE EDUCATION COURSES (1976-PRESENT):**

6/70 - Page and Black Postgraduate, Mount Sinai School of Medicine: Asbestosis.

4/71 - NY Academy of Sciences, Seminars for Trade Union Representatives: Occupational Health Hazards.

4/71 - American College of Chest Physicians, Mount Sinai School of Medicine, NY: Interstitial Pneumonias--Acute and Chronic.

5/75 - United States-USSR Environmental Protection Agreement: Workshop on Basic Practical Approaches to Environmental Carcinogenesis, Mount Sinai.

6/76 - Page and Black Postgraduate, Mount Sinai School of Medicine: Environmental Lung Disease.

2/77 - Office of Continuing Education, Baylor Medical College, Houston, TX: Pulmonary Diseases and Carcinoma of the Lungs, Baylor Medical School, Houston, TX.

11/77 - New York Lung Club, Cornell University Medical College: Silicosis revisited. New York City Tunnel and Caisson Workers: 1928-1977.

1/78 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Asbestos Carcinogenesis.

3/78 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Occupational and Environmental Pulmonary Diseases.

6/78 - Page and Black Postgraduate, Mount Sinai School of Medicine, NY: Health Effects of Asbestos Exposure. Course Director.

11/78 - Page and Black Postgraduate, Mount Sinai School of Medicine, NY: Asbestos Associate Diseases: With Particular Reference to United States Shipyards.

**PARTICIPATION IN POSTGRADUATE EDUCATION COURSES (1976-PRESENT) (cont):**

- 1/79 - Page and Black Postgraduate, Mount Sinai School of Medicine, NY: Scientific Basis for Evaluation of Occupational and Environmental Asbestos Disease.
- 10/79 - Office of Continuing Education, Baylor Medical College, Houston, TX: Asbestos-Associated Diseases, Houston, TX.
- 1/80 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Asbestos in Shipyards.
- 3/80 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Management and Control of Asbestos in Public Buildings.
- 6/80 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Health Effects of Asbestos in Public Buildings.
- 9/80 - College of Medicine and Dentistry of New Jersey: Rutgers Medical School, Recent Advances in Occupational Toxicology, Graduate Center, NY.
- 11/81 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Recent Advances in Occupational Medicine.
- 12/82 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Scientific Basis for Evaluation of Asbestos-Associated Diseases.
- 3/85 - Page and Black Postgraduate, Mount Sinai School of Medicine, New York, NY: Asbestos in Schools and Public Buildings, Hasbrook Heights, NJ.
- 9/91 - Environmental Lung Disease. American College of Chest Physicians. Mineralogy Techniques. Montreal, Canada.

**INVITED SEMINARS AND LECTURES:**

- Union College, Schenectady, NY, Department of Geology and Civil Engineering. "Asbestos and Lung Disease." April, 1967.
- Barnard College, NY, Department of Geology. "Asbestos Fiber in the Ambient Air and Disease Potential." December, 1968.
- The Rockefeller University, Air Pollution Working Group, Health Research Council. "Analysis of Air Samples for Inorganic Constituents." June 9, 1969.

**INVITED SEMINARS AND LECTURES (cont):**

New York University Medical Center, New York Lung Club. "Sublight Microscopic Mineral Particles in Talc Pneumoconiosis. Physiology and Mineralogical Studies." November, 1970.

Lehigh College, Department of Material Sciences and Metallurgy. "Electron Probe Characterization of Particles in Tissues." April, 1971.

Oberlin College, OH, Department of Geology. "Asbestos Dust in the Workplace and Human Disease." May, 1971.

State University of New York at Buffalo, Department of Biophysical Sciences. "The Asbestos Problem. An Interdisciplinary Approach." April, 1972.

Queens College of the City University of New York, Department of Earth and Environmental Sciences. "Asbestos and Disease. How Wide is the Spectrum?" November, 1972.

Columbia University, NY, Department of Geology and Biological Sciences. "Contamination of the Environment with Mineral Particles." December, 1972.

College of South Hampton, Long Island University, Division of Chemical Sciences and Oceanography. "The Contamination of Lake Superior with Fibrous Silicates." January, 1973.

National Institutes of Health. Review of Asbestos Problem. "Mechanism of Fiber Action." National Institutes of Health, Bethesda, MD, February, 1973.

City College of the City University of New York, Department of Earth and Planetary Sciences. "Mineral Particles and Human Disease." May, 1973.

Queens College of the City University of New York, Department of Health Sciences. "Occupational Hazards as Harbingers of Environmental Hazards." September, 1973.

Rutgers University, Colonial Conference Tri-State Environmentalists. "Recognition of Environmental Hazards: Use of Academic Facilities for Monitoring and Control of Hazards." November, 1973.

Johns Hopkins University, School of Public Health. "Asbestos Minerals and Disease." Seminar. April, 1974.

Rutgers University, Department of Environmental Sciences. "Mineral Particles in the Air." June, 1974.

**INVITED SEMINARS AND LECTURES (cont):**

Temple University, Department of Geology. "Amphibole Contamination of Lake Superior Water from Taconite Processing." September, 1974.

American Museum of Natural History, Department of Mineral Sciences. "Minerals and Disease." September, 1978.

Rutgers University, Department of Chemistry. "Minerals and Their Biological Activity." October, 1978.

University of North Carolina, Department of Medicine. 1) "Analytical Methods of Tissue Analysis, Asbestos Bodies and Asbestos Fibers"; 2) "Inorganic Particles in Cigarettes and Cigarette Smoke." November, 1978.

University of Maine, Farmington, Department of Geology. 1) "The Asbestos Problem"; 2) "Evolution of an Environmental Scientist, A Personal View." March, 1979.

School of Public Health, Columbia University. "Epidemiology of Asbestos Diseases." April, 1979.

New York Medical Examiner's Conference. "Analysis of Tissues for Asbestos Fiber and Asbestos Bodies." June, 1979.

Seton Hall University, Department of Chemistry. "Minerals and Disease: Interaction Mechanisms." October 2, 1979.

American Institute of Mining Engineers, Tucson. "The Biological Effects of Inorganic Fibers: The Case Against Asbestos" (invited speaker). October, 1979.

American Chemical Society, Staten Island Section. "Minerals and Diseases: Physical and Chemical Factors." February 19, 1980.

Society of Sigma Xi Lecture. "Man in Conflict with His Physical Environment." Invited Speaker for initiation ceremony, City University, New York, May 13, 1980.

National Institutes of Health, Bethesda, Department of Health and Human Services CCERP-26. "Serpentine-Containing Host Rocks: Amphibole-Containing Host Rocks." November, 1980.

NIEHS-EPA-NIOSH Joint Committee at Bethesda. "Mount St. Helen's Volcanic Ash: Mineral Nature and Biological Activity." July 23, 1981.

The Rockefeller University. "Minerals and Toxic Agents, Parameters and Mechanisms." Invited speaker in series on Comparative Toxicology, February 12, 1981.

**INVITED SEMINARS AND LECTURES (cont):**

Kettering Laboratory, University of Cincinnati Medical Center. "Silica and Silicosis: Mechanisms." April 8, 1981.

University of California, Irvine, Occupational and Environmental Health Center. "Physicochemical Properties of Inorganic Dusts and Biological Consequences of Exposure." Occupational Medicine Series, December 2, 1981.

Barlow Hospital, Los Angeles, University of Southern California Medical School. "Tissue Analysis for Asbestos, Comparative Techniques." Chest Service, Department of Medicine, December 3, 1981.

Appalachian Laboratory for Occupational Safety and Health NIOSH-CDC, Morgantown, West Virginia. "Surface Properties of Silica and Its Biological Activity." February 24, 1982.

National Institute for Occupational Safety and Health. "Silica and Silicosis." Cincinnati, March 24, 1982.

Society of Sigma Xi Lecture, Queens College of the City University of New York. "The Case Against Chrysotile Asbestos." December 2, 1982.

National Institute of Environmental Health Sciences, Pathobiology of Mesothelioma, Research Triangle Park, NC. "Physicochemical Character of Dust and its Role in Inducing Human Mesothelioma." January, 1983.

Geology Seminar, Long Island University, College at South Hampton. "The Biological Effects of Asbestos." March 18, 1983.

Graduate Seminar, Rutgers University, Department of Geology. "Physical-Chemical Properties of Minerals and Their Biological Activities." April 13, 1983.

Symposium on Fibrous Minerals, American Lung Association Annual Meeting, Kansas City, MO. "Mineralogy of Mineral Fibers." May 8, 1983.

Faculty Research Collegium, Ph.D. Program Earth and Environmental Studies, CUNY, Graduate Center, NY. "Physicochemical Properties of Minerals Controlling Biological Activity." March 6, 1984.

Graduate Seminar, Department of Geology, Princeton University. "Minerals and Disease." Princeton, NJ, March 8, 1984.

Graduate Seminar, Department of Biology, New York University, New York, NY. "Asbestos: Biological Considerations." April 16, 1984.

---

**INVITED SEMINARS AND LECTURES (cont):**

Medical Geology Conference on Health Threatening Toxins in Water. "Asbestos Fiber in Water." May 3, 1984.


Asbestos Information Association of North America, Annual Meeting, Alexandria, VA. "Asbestos Substitutes. How Safe are They?" September 18, 1985.

American Society for Testing Materials, Annual Meeting, Bal Harbour, FL. "Method for Testing Indoor Air for Asbestos. Analytical Electron Microscopy." November 4, 1985.

University of Southern California Medical School. "Membranolytic Properties of Quartz and Phosphorylated Chrysotile Fiber." January 29, 1985. Main Campus. "Asbestos Fiber in Lung Tissue - Analysis by Analytical Electron Microscopy." January 30, 1986.

Milton Kannerstein Lecture. "Mineral Dust and Pulmonary Lesions." Annual Meeting of the Klempner-Otani Society. Mount Sinai, June 5, 1986.

Northeast Regional Environmental Public Health Center, University of Massachusetts. Symposium: Asbestos in Play Sand. "Tremolite Analysis, Morphology, and Health Significance." February 11, 1987.

The Defense Research and Trial Lawyers Association, Reno, NV. "Analytical Protocol for the Study of Sublight Microscopic Particles in Human Tissues"; "Types and Amounts of Asbestos Fibers in the Pulmonary Tissues of Asbestos-Exposed Workers in the United States." October 30, 1987. 

The Manville Settlement Trust Asbestos Disease Seminar, Washington, DC. "Asbestos Fibers: The Physico-Chemical Properties and Health Effects." March 16, 1988.

Asbestos Fiber Type and Risk of Disease, Conference: New York - New Jersey Environmental Expo: The Source for Environmental Solutions. Seminar 7E, The Management of Asbestos in the 1990's. Thursday, October 18, 1990.

American Industrial Hygiene Association, Georgia Section, Atlanta Georgia. Conference: The Asbestos Controversy. Has the Public Been Properly Informed? "Understanding the Asbestos Risk." November 30, 1990.

Armstrong Defense Group. Memphis, Tennessee. The Asbestos Saga and the Star Wars Trilogy: The Empire Strikes Back! Thursday, April 25, 1991.

## INVITED SEMINARS AND LECTURES (cont):

Department of Medicine - Pulmonary, New York University Medical Center. Pulmonary Grand Rounds. Particle Characteristics Responsible for Pneumoconiosis and Cancer. Tuesday, September 3, 1991.

Nelson Institute of Environmental Medicine, New York University School of Medicine. Surface Properties of Minerals as Determinants of Biological Activity. Tuxedo, New York. Wednesday, October 23, 1991.

Defense Research Institute. Current Issues in Asbestos in Buildings Seminar. Report From the Health Effects Institute. Orlando, Florida. Friday, January 24, 1992.

Characteristics of Mineral Fibers - Critical Research Needs. Invited to Workshop on Chemical and Biological Interactions of Glass. Bethesda, Maryland, March 5-6, 1992.

Mealey's National Lead Litigation Conference. Presented: Bioavailability of Lead. April 22-23, 1993. Philadelphia, Pennsylvania.

McGrath Fund Lectures. Current Topics in Environmental Science. Division of Natural Sciences, South Hampton Campus of Long Island University. Update on Asbestos. An Asbestos Risk Assessment. May 3, 1994.

United States Environmental Protection Agency. Environmental Asbestos Workshop: Chrysotile Asbestos. Comparative carcinogenicity with the amphibole asbestos varieties. Monterey, California. October 7, 1994.

Defense Research Institute Symposium. Asbestos Medicine Seminar. Health risks associated with low-level asbestos exposures. (with Dr. B. Gee). New York. October 26-28, 1994.

## INVITED INTERNATIONAL MEETINGS AND CONFERENCES:

Physics and Chemistry of Asbestos Minerals. Oxford, July, 1967. Presented: The Nature of Soft and Harsh Chrysotile (with Kerr PF.).

Second International Conference on the Biological Effects of Asbestos. Dresden, DDR, April, 1968 (two papers with Berkley C, Sastre A, Arneson A and Schwartz J).

International Conference on Pneumoconiosis. Johannesburg, April 23-May 2, 1969. Presented: Electron Microprobe Analysis of Asbestos Bodies (with Rubin IB and Selikoff IJ).

## INVITED INTERNATIONAL MEETINGS AND CONFERENCES (cont):

Working Group: Asbestos and the Asbestos Diseases. Cardiff, April 6-9, 1970. Presented: Identification of Asbestos Fiber in Tissue.

British Occupational Hygiene Society: Inhaled Particles and Vapors. Imperial College, London, June, 1970. Presented: Inorganic Fibers, Including Chrysotile, in Lungs at Autopsy (with Baden V, Selikoff IJ, and Hammond EC).

Fifth National Conference on Electron Microprobe Analysis. New York, July 21-24, 1970. Invited paper: Electron Microprobe Analysis of Particles in Tissues (with Berkley C and Rubin IB).

Second International Clean Air Congress. Washington, DC, May 1971. Paper with Selikoff IJ.

International Agency for Research on Cancer. WHO, Lyon, September, 1972. Presented: Identification of Single Asbestos Fibers in Human Tissues with (Pooley FD).

6th International Meeting of Forensic Sciences. Edinburgh, September, 1972. Presented paper Asbestos Fiber in Human Lungs: Forensic Significance in Environmental Disease (with Ehrenreich T).

Dialogues in Microscopy, 1973, NY. Microscopical Society. Chaired Session: Identification of Asbestos, May, 1973.

International Conference on the Biological Effects of Ingested Asbestos. NIEHS sponsored. Pinehurst, NC, November, 1973.

International Conference on Environmental Sensing and Assessment. Las Vegas, NV, September, 1975 (paper with Rubin IB and Wolff M). Chaired 2 Sessions: Fine Particles-7; Fine Particles-2. United States Environmental Protection Agency.

Conference on Health Problems of Energy Technologies. Held by NIEHS, January, 1976.

Mineralogical Society of London. London, April, 1976. Presented paper Nature and Range of Mineral Dust in the Environment.

International Agency for Research on Cancer. The World Health Organization, Lyon. Invited member of working group, December, 1976. Chemical Carcinogenesis Monograph Series. Evaluation of Carcinogenic Risk of Asbestos, Vol. 14.

## INVITED INTERNATIONAL MEETINGS AND CONFERENCES (cont):

Royal Society of Medicine. Meeting Focusing on Occupational Diseases. London, April, 1977. Presented paper Asbestos Content of Dust Encountered During Brake Maintenance and Repair (with Rohl AN, Weisman I, and Klimentidis R).

Invited Consultant to Institute of Public Health. Oslo, Norway, May, 1977. Presented three papers: Contamination of the Biosphere by Submicroscopic Particles; Asbestos Minerals and Their Carcinogenic Effects; Are There Safe Substitutes for Asbestos Materials?

Invited Consultant to the Ministry of Mines. Biological Effects of Asbestos. Johannesburg, October, 1977. Monograph, Ministry of Mines.

Health Hazards of Asbestos Exposure. New York, June 24-27, 1978. Presented paper on Contamination of Lake Superior with Amphibole Gangue Minerals and organized and chaired workshop on Significance of Aspect Ratio in Regulation of Asbestos Fiber Exposure.

International Conference on Critical Current Issues in Environmental Health Hazards. Tel Aviv, March 4-7, 1979. Presented paper Defining New Asbestos High Risk Groups. Chairman Workshop: Laboratory Approaches in Environmental Medicine.

International Agency for Research on Cancer. WHO, Lyon, October, 1979. International Conference on the Biological Effects of Inorganic Fibers. Invited Rappateur. Physics and Chemistry of Asbestos Minerals.

Expert Consultant, International Metal Workers Federation. Geneva, September, 1980. Focus on problem: Asbestos Fiber Contamination of Metal Ore Deposits.

International Conference on Crystalline Deposits in Human Tissues. August 13-14, 1981. Mount Sinai Hospital, Toronto. Presented paper The Role of Analytical Electron Microscopy in Diagnosis of the Pneumoconiosis (with Weisman I, Adams A, and Pooley F).

Annual Symposium Scanning Electron Microscopy. Anaheim, CA, April, 1982. Presented paper Identification Characterization and Quantitation of Asbestos Fibers in Human Lung Tissue by Analytical Electron Microscopy.

Fourth Annual Rocky Mountain Center for Occupational and Environmental Health Center. Salt Lake City, April, 1982. Invited to present two papers: Fibrous Minerals: Properties and Biological Activity; Relationship Between Surface Properties and Biological Activity in Health Issues Related to Metal and Non-Metallic Mining.

World Symposium on Asbestos. Montreal, May 24-27, 1982. Presented paper Mineral Fibers: Properties Imparting Biological Activity.

## INVITED INTERNATIONAL MEETINGS AND CONFERENCES (cont):

6th International Pneumoconiosis Conference. Bochum, Federal Republic of Germany, September, 1983. Presented two papers: Recognition of Quartz by the Erythrocyte Membrane; Physicochemical Factors Effecting Membrolytic Properties of Quartz (with Nolan RP, Foster KW, and Simenski R). Chaired Session: Etiopathogenesis of Silicosis.

Program of Research on Asbestos. University of Sherbrooke, December 5-6, 1983. Presented lecture Physicochemical Properties of Minerals as Related to Biological Activities.

2nd International Congress on Applied Mineralogy. February 22-25, 1984. Presented two papers: Asbestos, Fibrous Minerals, Acicular Cleavage Fragments and the Minerals Industries; Minerals and Disease: The Association Between Exposure to Minerals and Rock Dusts and the Occurrence of Human Disease.

Workshop on the Assessment of Mineral Fibers from Human Lungs. Oxford, England, September 17-19, 1984. Keynote speaker Problems of Tissue Analysis with the Analytical Electron Microscope.

3rd International Workshop on the In Vitro Effects of Mineral Dusts. Schluchsee, Hochschwarzwald, FRG, October, 1984. Physicochemical Properties of Minerals Relevant to Biological Activities. State of the Art, (paper with Nolan RP); Alteration of surface of quartz and altered biological activity.

Workshop on Biological Effects of Chrysotile. General Motors Cancer Research Foundation. Cardiff, Wales, May 7-9, 1986. The Mineralogy of Chrysotile Asbestos: Physicochemical Properties as Determinants of Disease Potential (with Nolan RP).

International Programme on Chemical Safety (IPCS). WHO Environmental Health Criteria 53. Asbestos and other Natural Mineral Fibres. Hannover, Germany. Session chairman, co-author. 194 p., 1986.

International Agency for Research on Cancer. The World Health Organization. Invited member of working group. Lyon, France, July, 1986. Chemical Carcinogenesis Monograph Series. Evaluation of Carcinogenic Risk of Fibrous Talc, Wollastonite, Palygorskite, Sepiolite, Erionite and Crystalline Silica. Vols. 34-42.

Symposium: Mineral Fibers in the Non-Occupational Environment. IARC-WHO. Lyon, France, September 8-10, 1987. Summary of five presented papers; Round-table discussant on Environmental Risk. Presented paper: Fiber Type and Parenchymal Burden Found in Workers Occupationally Exposed to Asbestos Fiber in the United States (with Nolan RP).

## INVITED INTERNATIONAL MEETINGS AND CONFERENCES (cont):

Symposium: Fibers in Friction Materials. Society Automotive Engineers and the Asbestos Institute. Symposium organizer and Co-Chairman. Fibers and Health Issues. Atlantic City, NJ, October, 1987. Presented summary paper; co-authored Physicochemical Properties of Fibers and Biological Potential (with Nolan RP).

Symposium: Safe Use of Asbestos Cement. Peruvian Ministry of Health and the Environment. The Asbestos Information Association of South America. Lima, Peru, March, 1988.

International Symposium/Workshop: Biological Interaction of Inhaled Mineral Fibers and Cigarette Smoke. Session Chairman. Presented paper: Inorganic Particles Found in Cigarette Tobacco, Cigarette Ash, and Cigarette Smoke; co-authored Physico-Chemical Properties and Membranolytic Activities of the Titanium Dioxide Polymorphs Compared to Quartz. April 10-14, 1988.

Electron Microscopy Society of America; the Microscopical Society of Canada: Presented paper: Electron Diffraction of Mineral Fibers Vs. Acicular Cleavage Fragments. Milwaukee, WI, August 7-12, 1988.

National Organizing Committee, Workshop Chairman: Hazard Recognition of Mineral Dusts. Presented: Mineral Fibers in the Lung Tissues of Persons Exposed to Asbestos in the United States; Distinguishing Between Tremolite Asbestos and Tremolite Cleavage Fragments. VIth International Pneumoconiosis Conference, Scientific Organization Committee. Pittsburgh, PA, August, 1988.

Session Chairman: Asbestos, Pleural Pathology, and Lung Fiber Burden. VIth International Pneumoconiosis Conference, Pittsburgh, PA, August, 1988.

Workshop on Asbestos Research. Health Effects Institute, American Academy of Arts and Sciences, Cambridge, MA, October 31-November 1, 1988.

Symposium on the Health Aspects of Exposures to Asbestos in Public Buildings. Presented: Fiber Type and Risk of Mesothelioma to Building Occupants. John F. Kennedy School of Government, Harvard University, Cambridge, MA, December 14-16, 1988.

First International Conference on Health Related Effects of Phyllosilicates. International Scientific Organizing Committee. Session Chairman: Health Related Effects After Non-Occupational Exposure. Presented: Fibrous Minerals as Natural Contaminants of Phyllosilicates (with Pooley F). Paris, France, March 16-18, 1989.

International Federation of Building and Woodworkers. Health Hazards in Painting and Allied Trades. Presented: Hazards in the Painting Trade. Panelist. Geneva, Switzerland, May 8-12, 1989.

## INVITED INTERNATIONAL MEETINGS AND CONFERENCES (cont):

NATO Advanced Research Workshop on Mechanisms in Fibre Carcinogenesis. Presented: The Importance of Mineral Subpopulations in Biological Assays. Albuquerque, NM, October 22-25, 1990. Co-authored paper: Association of tremolite habit with biological potential, co-authored with Nolan RP, Oechsle G, Addison J, Colflesh D.

American Lung Association - American Thoracic Society. 1991 International Conference. Presented: Mechanisms of Asbestos-Induced Pulmonary Disease: Importance of Surface Properties of Asbestos and Non-asbestos minerals in cell interaction. Anaheim, California, May 12-15, 1991.

American College of Chest Physicians. Fourth International Conference - Environmental Lung Disease. Presented: Diagnostic Methods in Occupational Lung Disease: Mineralogic Techniques. Co-Chair session: Diagnostic Methods in Occupational Lung Disease. Montreal, Canada. September 25-28, 1991.

Chemical Industry Institute of Toxicology. Workshop on Approaches to Evaluating the Toxicity and Carcinogenicity of Man-made Fibers. Durham, North Carolina. November 11-13, 1991.

Institute for Glass Science and Engineering. Workshop on Chemical and Biological Interactions of Glass. Discussant on Biologically Important Properties. Bethesda, Maryland. March 5-6, 1992.

International Geological Congress. Environmental Mineralogy in relation to human health and activities. Session I-3-49. Co-chair with N. Kohyama, J. Addison, Kyoto, Japan. 24 August-3 September, 1992. Introduction. Importance of environmental mineralogy. Summing up. 1 September, 1992.

Biopersistence of Respirable Synthetic Fibres and Minerals. Presented: Comparison of lung tissue mineral fibre retention of exposed workers and the general population. With RP Nolan, co-authored: Health hazard evaluation of the lung tremolite fibre content among Canadian chrysotile workers. With RP Nolan and J Addison. Round-Table discussant on: Role of Biopersistence in Pathogenicity. IARC, Lyon. September 7-9, 1992.

Symposium on Chemicals and the Environment. Chemical Specialities, '92. Invited presentation: Zeolite catalysts. Is there a health risk? Philadelphia, 3-4 November, 1992.

International Life Sciences Institute. 4th International Inhalation Symposium, Hannover. Invited Faculty Presentation: Factors Controlling the Biological Potential of Inorganic Dusts. Surface Chemistry and Character. With R.P. Nolan. Hannover, 1-5 March, 1993.

## INVITED INTERNATIONAL MEETINGS AND CONFERENCES (cont):

Hoffmann-LaRoche Pharmaceuticals. Analysis of Medicines for Asbestos. Microscopy Protocol. Edinburgh, U.K. Institute of Occupational Medicine. April 25-26, 1993.

Cellular and Molecular Effects of Mineral and Synthetic Dusts and Fibres. NATO Advanced Workshop. Invited paper: Phosphorylated Canadian chrysotile. With RP Nolan and G Herson. Chaired session: Physico-chemical properties of minerals in relation to their biologic effects. Paris, 11-13 October, 1993.

Workshop on the Health Risks Associated with Chrysotile Asbestos. Intl. Commission on Occupational Health - Intl. Program on Chemical Safety (WHO) Presented paper: Chrysotile: The Mineral and Its Properties. Jersey, Channel Islands. 14-17, November, 1993.

Hoffmann-LaRoche Pharmaceuticals. Protocol for Analysis of Injectable Medicines for Asbestos. Workshop. Basel, Switzerland. March 2-4, 1994.

Verband der Chemischen Industries. Protocol for the Analysis of Chemicals for Asbestos. Workshop. Frankfurt, Germany. May 30-31, 1994.

Eurometaux (European Association of Metals) and the European Commission, Directorate General V. Scientific Organizing Committee InH. Seminar on Assessment of Respiratory Carcinogenic Risk from Occupational Exposure to Inorganic Substances. Meeting of the Scientific Committee. Brussels, 17-18 October, 1994.

FUNDING SOURCES

PROJECT	ROLE IN PROJECT	PROJECT PERIOD	SOURCE OF FUNDS	TOTAL DIRECT SUPPORT
Asbestos disease in New York City workers	Co-Principal Investigator/Mineralogist	07/01/66-06/30/67	Health Research Council, NYC	\$ 39,703
Silica and Silicosis	Principal Investigator Mineralogist	09/01/66-08/31/68	Polacheck Foundation	10,000
Microprobe analysis of asbestos-pseudo asbestos bodies	Co-Principal Investigator	06/01/67-05/31/69	NIH	133,245
Asbestos exposure risk in defined human populations	Co-Principal Investigator/Mineralogist	05/01/68-04/30/73	NIH	1,306,281
Biological effects of modified inorganic fibrous particles	Co-Principal Investigator/Mineralogist	07/01/68-06/30/69	Johns-Mansville Corporation	61,930
Insulation industry hygiene reports	Co-Principal Investigator	09/15/68-09/14/73	Johns-Mansville Corporation	500,000
Asbestos air pollution in New York City	Co-Principal Investigator	12/01/68-11/30/70	HRC-NY DAR-NY	110,455
Inorganic particles biological systems interactions	Principal Investigator Career Development Award	06/01/69-05/31/74	NIH-NIEHS	125,000
Asbestos exposure and cancer in the general population	Co-Principal Investigator	12/01/69-11/30/71	NIH	105,539

FUNDING SOURCES

PROJECT	ROLE IN PROJECT	PROJECT PERIOD	SOURCE OF FUNDS	TOTAL DIRECT SUPPORT
Inorganic particles in cigarettes and cigarettes smoke	Principal Investigator	07/01/71-06/30/73	NIH	65,730
Environmental cancer in US industries	Co-Principal Investigator	09/01/71-08/31/74	ACS	289,321
Asbestos exposure and cancer in the general population	Co-Principal Investigator/Mineralogist	12/01/71-11/30/73	NIH	254,569
Asbestos air pollution; extent persistence, effects	Co-Principal Investigator/Mineralogist	01/01/72-12/31/74	NIH	348,858
Asbestos in therapeutic drugs for human use	Co-Principal Investigator/Mineralogist	04/01/72-03/31/73	NIH	49,230
Effects of asbestos in water (Duluth)	Co-Principal Investigator/Mineralogist	06/01/73-10/30/73	EPA	47,970
Environmental agents, relation to human health effects	Co-Principal Investigator	06/01/73-08/31/78	NIH	2,823,220
Asbestos in brake drum dusts	Principal Investigator	07/01/73-06/30/75	Ford Motor Company	10,000
Population at high risk of lung cancer: establishment of cohort and development of serial surveillance	Co-Principal Investigator	08/01/73-07/31/75	NIH	78,572

FUNDING SOURCES

PROJECT	ROLE IN PROJECT	PROJECT PERIOD	SOURCE OF FUNDS	TOTAL DIRECT SUPPORT
Asbestos exposure of workers and public from brake linings	Co-Principal Investigator	07/01/75-06/30/76	HRC-NY	12,980
Asbestos exposure with brake lining service and repair	Co-Principal Investigator	07/01/75-06/30/77	HRC-NY	51,142
Residency training in occupational medicine	Co-Principal Investigator	07/01/76-06/30/78	NIOSH	105,491
Asbestos in brake workers' lungs	Principal Investigator	09/01/77-08/31/79	NIOSH	95,223
Environmental Health Sciences Center Grant	Co-Principal Investigator	09/01/78-08/31/83	NIEHS	4,841,529
Environmental dusts and macrophage activation	Co-Principal Investigator/Mineralogist	03/01/79-02/29/81	NCI via Sloan-Kettering Institute	168,589
Surface properties of chrysotile asbestos and its role in biological potential	Principal Investigator	07/01/79-continued yearly	Mobil Foundation	8,000 12,000
Environmental cancer research project	Co-Principal Investigator	09/01/80-08/31/81	ACS	284,540
Particle analysis St. Regis Health Study	Co-Principal Investigator	07/01/81-06/30/82	Canadian	1,016,581
Activity of amosite asbestos and grunerite fiber	Co-Principal Investigator/Mineralogist	09/01/82-08/31/84	NIOSH	143,396

FUNDING SOURCES

PROJECT	ROLE IN PROJECT	PROJECT PERIOD	SOURCE OF FUNDS	TOTAL DIRECT SUPPORT
Environmental Health Services Center Grant	Co-Principal Investigator/Mineralogy Group Leader	07/01/84-06/30/86	NIEHS	300,000
Biological activity of modified chrysoile asbestos fiber	Principal Investigator	09/01/84-12/31/86	SNA, Canada	300,000
Biological activity of asbestos substitutes	Principal Investigator	01/01/87-03/31/87	SNA, Canada	15,000
Analysis of play sand for asbestos content	Principal Investigator	11/01/87-02/01/88	Consumer Products Safety Commission	4,000
Analysis of talcs for mineral character	Principal Investigator	04/01/88-12/01/88	Vanderbilt Talc Company	32,000
Surface properties of asbestos and substitutes	Principal Investigator	04/01/87-03/31/88	Asbestos Institute	10,000
Evaluation Microscopy Laboratories	Co-Principal Investigator	03/01/88-06/30/90	Battelle, Columbus	130,500
Wollastonite in animal lungs	Principal Investigator	12/01/88-06/01/89 08/01/88-12/01/88	NSI - National Toxicology Program	38,000
Modified asbestos; asbestos substitutes; surface properties	Principal Investigator	04/01/88-09/01/90	SNA, Canada	50,000
Fibers in vermiculite	Principal Investigator	08/01/88-09/01/88	State of Montana	900

FUNDING SOURCES

PROJECT	ROLE IN PROJECT	PROJECT PERIOD	SOURCE OF FUNDS	TOTAL DIRECT SUPPORT
Characterization and biological potential of asbestiform and non-asbestiform amphiboles	Principal Investigator	06/01/89-current	Vanderbilt Talc Company	162,000
Talc and its associated mineral impurities	Principal Investigator	08/01/89-02/29/91	Georgia Pacific Company	32,000
Study of asbestos contamination of building air	Principal Investigator	06/30/88-present	CNA Insurance Company	50,000
Asbestos-emissions during gasket replacement	Co-Investigator	01/30/91-present	Durabla Company	40,000
Release of Rockwool fibres from gaskets	Principal Investigator	01/01/93-present	Lapinus Fibres, B.V.	7,000
Asbestos-release from plumbing supply products	Co-Investigator	10/01/92-present	Sexauer Manufacturing Company	10,000
Asbestos in the lungs of exposed workers	Principal Investigator	03/01/93-present	W.R. Grace & Company	90,000
Applied Technology - Equipment Assistance Grant	Co-Investigator	09/93-09/96	New York State Higher Education Assisting Technology	710,000
Mineral Analysis of Quarry Samples	Co-Investigator	12/10/93-present	Readymix Group & the A	10,000

FUNDING SOURCES

PROJECT	ROLE IN PROJECT	PROJECT PERIOD	SOURCE OF FUNDS	TOTAL DIRECT SUPPORT
Ecaterinburg Workshop Project - Chrysotile	Co-Investigator	6/94-7/94	The Asbestos Institute & the W.R. Grace Co.	30,000
Risk Identification and Management of Fibers in Iron Ore	Co-Investigator	4/1/94-present	Cleveland Cliffs, Inc., Cleveland, Ohio.	40,000



IN THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS  
COUNTY DEPARTMENT, LAW DIVISION

#9021

BOARD OF EDUCATION OF  
THE CITY OF CHICAGO,

Plaintiff,

v.


A, C AND S, INC., et al.,

Defendants.

)  
) Nos. 92 L 9934  
) 92 L 9933  
) 92 L 9932  
) 92 L 9927

) Honorable Michael Gallagher  
)  
)  
)

DEFENDANT ASBESTOSPRAY CORPORATION'S  
EXPERT WITNESS DISCLOSURES



Defendant Asbestospray Corporation ("Asbestospray") hereby gives notice that, pursuant to Rule 220 of the Illinois Supreme Court Rules and this Court's Scheduling Order dated November 1, 1994, Asbestospray has served upon Daniel P. Albers, Esq., Liaison Counsel for plaintiffs, and all defense counsel of record, Asbestospray's Expert Witness Disclosures for the expert witnesses it intends to call to testify at trial. All of the witnesses disclosed will serve as primary expert witnesses, although Dr. Cooper will also serve as a backup medical, state-of-the-art witness in the event Dr. Murray is unavailable to testify at trial. The curriculum vitae for each witness is attached hereto.

In addition to the witnesses listed below, Asbestospray hereby incorporates by reference the Expert Witness Disclosures served by or on behalf of each and every other defendant in these consolidated cases and reserves the right to call any witness listed by the plaintiffs or any other defendant (including, but not

Arthur M. Langer, Ph.D.

Environmental Sciences Laboratory  
Ingersoll Hall  
Brooklyn College of the City  
University of New York  
Brooklyn, NY 11210

**A. QUALIFICATIONS**

Dr. Arthur M. Langer is director of the Environmental Sciences Laboratory of the Institute of Applied Sciences, Brooklyn College of the City University of New York, Brooklyn College, City University of New York, Brooklyn, New York. He received a Bachelor of Arts degree in geology from Hunter College, City University of New York in 1956, M.A. in petrology from Columbia University in 1962, and a Ph.D. in mineralogy from Columbia University in 1965. From 1965 to 1988, Dr. Langer held various positions at the Mount Sinai School of Medicine in the Department of Medicine, Department of Community Medicine, Environmental Sciences Laboratory, and Center for Polypeptide and Membrane Research.

Dr. Langer has published extensively in the area of asbestos, asbestos fiber type, asbestos mineralogy, asbestos-related disease, and asbestos disease mechanism. He has peer reviewed numerous manuscripts, served on numerous editorial boards, and authored and reviewed numerous documents for NIOSH, ALOSH, MSHA, and EPA. He has served on numerous international committees and has spoken at numerous meetings.

**B. TESTIMONY**

Dr. Langer will testify that asbestos is a term for a number of minerals from around the world, some of which had been used commercially and some of which have not. He will testify that there has been a great deal of confusion in the medical and scientific literature concerning the term asbestos and that it is often improperly defined. He will testify concerning historical and current scientific knowledge concerning how asbestos fiber enters the human body, the disease mechanism within the human body, and disease processes. He will testify that different asbestos fiber types are not equally biologically active. He will testify concerning medical, scientific, and

epidemiological literature with respect to persons occupationally exposed to asbestos. He will testify concerning low-level exposure to asbestos. He will testify concerning asbestos fiber, how it is used in asbestos products, the concept of "friability", the aerodynamics of asbestos fibers, the dispersion of asbestos fibers in the air both inside and outside of buildings, and the nature of "fiber release" from asbestos fireproofing.

Dr. Langer will testify that air testing and monitoring is an appropriate method of determining whether an asbestos hazard exists within a building. He will testify concerning his own inspection of asbestos-containing materials in buildings, air monitoring in buildings, and asbestos levels both inside and outside of buildings.

Dr. Langer will testify concerning microscopic techniques, proper analysis of air and bulk asbestos samples, and the appropriate measurements of asbestos fiber levels.

Dr. Langer will testify concerning threshold limit values, both currently and historically, the EPA position on asbestos in buildings and threshold limit values, and the relation of low level asbestos exposure to various diseases including asbestosis, lung cancer, peritoneal mesothelioma, and pleural mesothelioma.

Dr. Langer will testify concerning proper responses to asbestos in buildings including, but not limited to, the necessity of removal, the advisability of removal, and operations and maintenance of asbestos in buildings.

Dr. Langer will testify concerning the risks to building occupants from asbestos, the lack of epidemiological studies with respect to such risks, and the nature and extent of such risks based upon fiber levels.


Dr. Langer will testify concerning the state of the art with respect to low-level exposure to asbestos and risks of different asbestos fiber types.

---



Dr. Langer will rely on the following materials in this case:


1. The reports of William Longo, Jim Millette, and Richard Hatfield;
2. Deposition transcripts of William Longo, Jim Millette, and Richard Hatfield;
3. Plaintiffs' product identification reports for South Shore High School, Leif Ericson Elementary, District 2 Offices, Glenbrook South High School, and Hawthorne Elementary;
4. Plaintiffs' air sampling results for South Shore High School, Leif Ericson Elementary, District 2 Offices, Glenbrook South High School, and Hawthorne Elementary;
5. Plaintiffs' dust sampling results for South Shore High School, Leif Ericson Elementary, District 2 Offices, Glenbrook South High School, and Hawthorne Elementary;
6. Photographs in building survey and inspection reports taken by Asbestospray's consultants in South Shore High School, Leif Ericson Elementary, and District 2 Offices;
7. Air sampling data obtained by Asbestospray's consultants with respect to South Shore High School, Leif Ericson Elementary, and District 2 Offices;
8. Documents pertaining to Asbestospray and/or the Sprayed Mineral Fibers Manufacturing Association (SMFMA);
9. Air sampling data obtained by Asbestospray's consultants in other property damage litigation;
10. "Proceedings of the Symposium on Health Aspects of Exposure to Asbestos in Buildings" (Harvard University, December 14-16, 1988);
11. Spengler, Özkaynak, McCarthy, and Lee, "Summary of Symposium on Health Aspects of Asbestos in Buildings" (Harvard University, August 1989);
12. Health Effects Institute - Asbestos Research, "Asbestos in Public and Commercial Buildings: A Literature Review and Synthesis of Current Knowledge" (1991); and
13. Wilson, Langer, Nolan, Gee, and Ross, "Asbestos in New York City Public School Buildings - Public Policy: Is There a Scientific Basis?" *Reg. Toxicol. Pharmacol.* 20:161-169 (1994).





Report / Law Engineering  
District No. 2

11/16/94  
Dust sample log  
Hatfield  
to Mrs (Longo) 11/21/94



Dust samples: 12x10 cm, 10x10 cm, n=2. TEM in Asb strand/cm<sup>2</sup>

1	-	lit fixture	0 > sum
2	1.6 x 10 <sup>6</sup>	ceiling tile	23 > sum
3	1.8 x 10 <sup>6</sup>	lit fixture	26 > sum

obtain N 33179 SAED (only plate available) \*

102 objects have distribution data available

AML  
Asbestos 1.6 x 0.474% = 0.77 x 10<sup>6</sup> f. > sum cm<sup>2</sup>

30 yrs. 365 days. 24 hrs. 60 min.  
[15.77 x 10<sup>6</sup> fibers/cm<sup>3</sup> min/cm<sup>3</sup> \* hrs: air]

AML:  
770,000 fb > sum  
25,667 f/yr (30)  
70 f/dy (24 hrs)  
23 f/8hrs  
Hang 1cm  
~ 3f/m<sup>3</sup> cm<sup>2</sup>

15,768,000 bac  
1440 min/dy

3f/305 cm<sup>3</sup> = ~ 0.01 f/cc

assume ceiling height  
10 ft = ~ 305 cm

on top of ceiling tile  
[mult floor]

3f/10 cm<sup>3</sup> = 0.3 f/cc  
see air data



LAW OFFICES  
STICH, ANGELL, KREIDLER & MUTH, P.A.  
THE CROSSINGS, SUITE 120  
280 SECOND AVENUE SOUTH  
MINNEAPOLIS, MINNESOTA 55401-2122  
TELEPHONE (612) 337-6251  
FACSIMILE #(612) 338-1940



ROBERT T. STICH  
JOHN F. ANGELL  
MICHAEL S. KREIDLER\*  
STEVEN J. MUTH  
ROBERT D. BROWNSON  
D. SCOTT BALLOU

ROBERT H. YAEGER  
THOMAS J. LINNEMAN  
SCOTT P. DRAWE\*  
JAMES D. KNUDSEN\*  
SUSAN M. HANSEN  
JOSEPH M. STOCOG  
GREGORY L. WRIGHT  
MICHAEL W. GAUGHAN, JR.  
LEO I. BRISBOIS  
LOUISE A. BEHRENDT  
JEFFREY A. MAGNUS

\*ALSO ADMITTED TO  
PRACTICE IN WISCONSIN

May 26, 1995

Daniel P. Albers, Esq.  
COFIELD, UNGARETTI & HARRIS  
3500 Three First National Plaza  
Chicago, IL 60602

VIA FAX


Re: *Chicago Board of Education, et al. v. Asbestospray, et al.*  
Our File No.: 12801/15230

Dear Mr. Albers:

Enclosed are copies of the reports prepared by Dr. Arthur Langer.

If you have any questions, please do not hesitate to contact me.

Very truly yours,

  
Lynnae I. Waskosky  
Legal Assistant

Enclosures

cc: Jonathan Miller, Esq. (w/ enclosures)  
Jeff Johnston, Esq. (w/ enclosures)

Table 1: Description of the sites and types of second air monitoring in South Shore High School.

HE8 IDENTIFICATION N°	FILTER SIZE AND TYPE OF MEMBRANE	TYPE OF SAMPLE	DURATION OF SAMPLING (MINUTES)	FLOW RATE (LPM)	VOLUME OF AIR SAMPLED (IN LITERS)	LOCATION OF SAMPLING
50282	0.45µm MCE	Area	674	2.5	1,702	East Mechanical Room
50284	0.45µm MCE	Area	746	2.6	1,900	Lobby
50286	0.45µm MCE	Area	753	2.5	1,865	Auditorium Rear
50288	0.45µm MCE	Area	758	2.5	1,904	Auditorium Front
50290	0.45µm MCE	Area	736	2.5	1,828	Stage
50292	0.45µm MCE	Personal	817	2.5	2,070	Personal
50294	0.45µm MCE			OPEN BLANK		
50296	0.45µm MCE			CLOSED BLANK		
50298	0.45µm MCE	Area	616	2.5	1,561	East Pair
50300	0.45µm MCE	Area	648	2.6	1,661	West Pair
50304	0.45µm MCE	Area	719	2.6	1,862	Southeast Single
50305	0.45µm MCE	Area	509	2.5	1,268	North Single
50306	0.45µm MCE	Area	707	2.5	1,792	Southwest Single

Table 2: Results of the analysis of the second set of membrane filters by transmission electron microscopy for asbestos in South Shore High School.

HES IDENTIFICATION N°	TOTAL VOLUME OF AIR SAMPLED (IN LITERS)	N° OF FIELDS EXAMINED	GRID AREA EXAMINED (IN $\mu\text{m}^2$ )*	ASBESTOS FIBERS DETECTED		VOLUME OF AIR SCANNED (IN ML)	AIRBORNE CONCENTRATION (F/M/L)
				$\geq 5\mu\text{m}$	$< 5\mu\text{m}$		
50282	1,702						
50284	1,900						
50286	1,885						
50288	1,904						
50290	1,828						
50292	2,070						
50294	OPEN BLANK						
50296	CLOSED BLANK						
50298	1,561						
50300	1,881						
50304	1,862						
50305	1,288						
50308	1,782						

\* Total area of grid  $385\text{mm}^2$

Table 1: Description of the sites and types of air monitoring in District 2 office.

HES IDENTIFICATION #	FILTER SIZE AND TYPE OF MEMBRANE	TYPE OF SAMPLE	DURATION OF SAMPLING (MINUTES)	FLOW RATE (LPM)	VOLUME OF AIR SAMPLED (IN LITERS)	LOCATION OF SAMPLING
50252	0.45µm MCE	Area	808	2.5	2,036	1st Floor, Room 18
50254	0.45µm MCE	Area	823	2.6	2,123	1st Floor, West Hallway
50258	0.45µm MCE	Area	849	2.5	2,130	1st Floor, Auditorium Bard Room 15
50259	0.45µm MCE	Area	782	2.5	1,928	1st Floor, Main Office
50260	0.45µm MCE	Area	848	2.5	2,082	2nd Floor, Room 256
50262	0.45µm MCE	Personal	830	2.5	2,087	Personal
50264	0.45µm MCE	OPEN BLANK				
50268	0.45µm MCE	CLOSED BLANK				
50268	0.45µm MCE	Area	742	2.6	1,953	West Pair
50270	0.45µm MCE	Area	608	2.5	1,986	East Pair
50274	0.45µm MCE	Area	760	2.5	1,989	2nd Floor, Room 256

Table 2: Results of the analysis of the membrane filters by transmission electron microscopy for asbestos in District 2 office.

HES IDENTIFICATION N°	TOTAL VOLUME OF AIR SAMPLED (IN LITERS)	N° OF FIELDS EXAMINED	GRID AREA EXAMINED (IN MM <sup>2</sup> )*	ASBESTOS FIBERS DETECTED		VOLUME OF AIR SCANNED (IN ML)	ARBORNE CONCENTRATION (F/ML)
				≥ 5µm	< 5µm		
50252	2,036						
50254	2,123						
50258	2,130						
50258	1,888						
50260	2,082						
50262	2,067						
50264	OPEN BLANK						
50266	CLOSED BLANK						
50268	1,953						
50270	1,986						
50274	1,888						

\* Total area of grid 385mm<sup>2</sup>

Table 1: Description of the sites and types of air monitoring in the Leaf Ericson Elementary School.

HES IDENTIFICATION N°	FILTER SIZE AND TYPE OF MEMBRANE	TYPE OF SAMPLE	DURATION OF SAMPLING (MINUTES)	FLOW RATE (LPM)	VOLUME OF AIR SAMPLED (IN LITERS)	LOCATION OF SAMPLING
50732	0.45µm MCE	Area	747	2.0	1,504	Front Office
50734	0.45µm MCE	Area	787	2.1	1,629	Lobby
50736	0.45µm MCE	Area	717	2.1	1,529	Cafeteria
50738	0.45µm MCE	Area	678	2.2	1,426	Teacher's Lounge
50740	0.45µm MCE	Area	781	2.1	1,607	Hallway
50742	0.45µm MCE	Personal	897	1.8	1,691	Personal
50744	0.45µm MCE			OPEN BLANK		
50746	0.45µm MCE			CLOSED BLANK		
50748	0.45µm MCE	Area	889	2.1	1,825	West Side Pair
50750	0.45µm MCE	Area	878	2.1	1,882	East Side Pair

Table 2: Results of the analysis of the membrane filters by transmission electron microscopy for asbestos in Leif Erickson Elementary School (Second).

HEB IDENTIFICATION N°	TOTAL VOLUME OF AIR SAMPLED (IN LITERS)	N° OF FIELDS EXAMINED	GRID AREA EXAMINED (IN MM²)*	CHRYSOTILE ASBESTOS FIBERS DETECTED		VOLUME OF AIR SCANNED (IN ML)	AIRBORNE CONCENTRATION (F/ML)
				≥ 5µm	< 5µm		
50732	1,504	20	0.242	0	0	845	0.0011
50734	1,829						
50736	1,529						
50739	1,426						
50740	1,007						
50742	1,691						
50744	OPEN BLANK						
50746	CLOSED BLANK						
50748	1,825						
50750	1,862						

\* Total area of grid 365mm²

Table 1: Description of the sites and types of air monitoring in the Leif Erickson Elementary School

HES IDENTIFICATION N°	FILTER SIZE AND TYPE OF MEMBRANE	TYPE OF SAMPLE	DURATION OF SAMPLING (MINUTES)	FLOW RATE (LPM)	VOLUME OF AIR SAMPLED (IN LITERS)	LOCATION OF SAMPLING	
50222	0.45µm MCE*	Area	808	2.4	1,916	Front Office	
50224	0.45µm MCE	Area	784	2.4	1,884	Lobby	
50226	0.45µm MCE	Area	830	2.4	1,988	Cafeteria	
50228	0.45µm MCE	Area	811	2.4	1,910	Teacher's Lounge	
50230	0.45µm MCE	Area	812	2.3	1,876	Hallway (near room 218)	
50232	0.45µm MCE	Personal	823	2.4	1,975	Personal	
50234	0.45µm MCE	OPEN BLANK					
50236	0.45µm MCE	CLOSED BLANK					
50238	0.45µm MCE	Area	784	2.4	1,884	East Double	
50240	0.45µm MCE	Area	788	2.5	1,962	West Double	

\* Methyl Cellulose Ester

Table 2: Results of the analysis of the membrane filters by transmission electron microscopy for asbestos in Leff Erickson Elementary School (Second).

HES IDENTIFICATION N°	TOTAL VOLUME OF AIR SAMPLED (IN LITERS)	N° OF FIELDS EXAMINED	GRID AREA EXAMINED (IN MM <sup>2</sup> )*	CHRYSOITILE ASBESTOS FIBERS DETECTED		VOLUME OF AIR SCANNED (IN ML)	AIRBORNE CONCENTRATION (F/ML)
				≥ 5µm	< 5µm		
50222	1,916						
50224	1,884						
50226	1,908						
50228	1,910						
50230	1,878						
50232	1,978						
50234	OPEN						
50236	CLOSED						
50238	1,894						
50240	1,962						

\* Total area of grid 385mm<sup>2</sup>



Table 2: Results of the analysis of the membrane filters by transmission electron microscopy for asbestos in District Office.

HEB IDENTIFICATION N°	TOTAL VOLUME OF AIR SAMPLED (IN LITERS)	N° OF FIELDS EXAMINED	GRID AREA EXAMINED (IN MM <sup>2</sup> )	CHRYSOPILE ASBESTOS FIBERS DETECTED		VOLUME OF AIR SCANNED (IN ML)	AIRBORNE CONCENTRATION (F/MML)
				≥ 5µm	< 5µm		
50842	1,806	20	0.242	0	0	1,135	< 0.0009
50844	1,832	30	0.363	0	0	1,822	< 0.0005
50846	1,828	20	0.242	0	0	1,212	< 0.0008
50848	1,774	20	0.242	0	0	1,115	< 0.0009
50850	1,122	28	0.351	0	0	1,023	< 0.0010
50852	2,188	20	0.242	0	0	1,383	< 0.0007
50854	OPEN	20	0.242	0	0		
50856	CLOSED	30	0.363	0	0		
50858	1,904	20	0.242	0	0	1,192	< 0.0008
50860	2,133	20	0.242	0	0	1,341	< 0.0007
50868	851	20	0.242	0	0	535	< 0.0019

\* Total area of grid 365mm<sup>2</sup>

Table 1: Description of the sites and types of air monitoring in South Shore.

HES IDENTIFICATION N°	FILTER SIZE AND TYPE OF MEMBRANE	TYPE OF SAMPLE	DURATION OF SAMPLING (MINUTES)	FLOW RATE (LPM)	VOLUME OF AIR SAMPLED (IN LITERS)	LOCATION OF SAMPLING
53462	0.45µm MCE	Area	858	2.50	2,148	Stage
53464	0.45µm MCE	Area	848	2.37	2,011	Auditorium Front
53466	0.45µm MCE	Area	783	2.40	1,902	Auditorium Rear
53468	0.45µm MCE	Area	824	2.43	2,001	East Mechanical Room
53470	0.45µm MCE	Area	830	2.43	2,019	Lobby
53472	0.45µm MCE	Personal	853	2.41	2,055	Personal
53474	0.45µm MCE			OPEN BLANK		
53476	0.45µm MCE			CLOSED BLANK		
53478	0.45µm MCE	Area	781	2.40	1,887	East Pair
53480	0.45µm MCE	Area	800	2.47	1,975	West Pair

Table 2: Results of the analysis of the membrane filters by transmission electron microscopy for asbestos in South Shore.

HES IDENTIFICATION #	TOTAL VOLUME OF AIR SAMPLED (IN LITERS)	# OF FIELDS EXAMINED	GRID AREA EXAMINED (IN NMAF)*	ASBESTOS FIBERS DETECTED		VOLUME OF AIR SCANNED (IN ML)	AIRBORNE CONCENTRATION (F/ML)
				≥ 5µm	< 5µm		
53462	2,148	20	0.242	0	0	1,350	< 0.0007
53464	2,011	20	0.242	0	0	1,264	< 0.0008
53466	1,802	20	0.242	0	0	1,186	< 0.0008
53468	2,001	20	0.242	0	0	1,278	< 0.0008
53470	2,019	20	0.242	0	0	1,289	< 0.0008
53472	2,055	20	0.242	0	0	1,282	< 0.0008
53474	OPEN BLANK	20	0.242	0	0		
53476	CLOSED BLANK	20	0.242	0	0		
53478	1,897	20	0.242	0	0	1,182	< 0.0008
53480	1,975	11	0.133	0	0	662	< 0.0015



# The asbestos panic attack

*How the feds got schools to spend billions on a problem that really didn't amount to much*

**W**hen school custodians in Oakland County, Mich., want to fix a leaky water valve, they don head-to-toe spacesuits. "They make you sweat like a pig," says facilities consultant Bill Lee. Then, they test the air near the leaky valve. Next, they wet the insulation surrounding the pipe, chip it off, seal it in a bag, seal that in another bag, then check the air again. Only after that can they strip off their spacesuits and actually replace the offending valve.

The reason for all the elaborate precautions: asbestos. A tough, heat-resistant mineral fiber associated with lung disease, asbestos has long had the reputation of a workplace hit man. The reputation has cost plenty. Across the nation, school districts that can't buy new library books are spending hundreds of thousands of dollars to deal with asbestos because they mistakenly believe their children are in great danger. In the fall of 1993, for instance, New York City

closed its public schools for two weeks and spent \$83 million on asbestos reinspection and removal because earlier asbestos inspections were shoddy. Total spending nationwide has been \$10 billion, the National School Boards Association told Congress earlier this month. Experts say it could reach \$30 billion.

Much of the money, though, is probably being spent in vain. There is no telling how much of the cleanup might have been necessary. No one has ever determined how much asbestos in the air is unsafe, and there is now broad consensus among scientists and physicians that asbestos in public buildings is not much of a threat to health. "A

phantom risk" is what Richard Wilson, a physics professor at Harvard University, calls it. A study soon to be released by the federal Office of Technology Assessment will say much the same thing.

**Paper-thin evidence.** How America's money-strapped schools could have so overreacted to the perceived threat from asbestos is an illuminating tale. One part, at least, is understandable: Parents and teachers pressed for drastic remedies for something they were told was a

**U.S. NEWS**  
**WORLD REPORT**



**Cleanup.** Many school districts like the one in New York City had costly asbestos-removal drives. No one is sure now if it was worth it.

## SCIENCE & SOCIETY

real danger. Less understandable is the role of government agencies, especially the federal Environmental Protection Agency, which created a public panic on the basis of paper-thin scientific information.

It's also a story about how the instinct to act overwhelms common sense. "When everybody's shouting 'Fire!' in a theater, the man who quietly stands in the corner and says, 'There's no fire,' is rarely heeded," observes Arthur Langer, director of the Environmental Sciences Laboratory at Brooklyn College in New York, who has served on numerous asbestos-study panels. Langer recalls sitting with other experts in the mid-1980s to draft EPA asbestos rules. The documents used terms like "hazard" and "emergency." "I said, 'Let's change the language of this; we are using emotive words,'" Langer said. "They just blew me out."

John Welch, president of an association of former manufacturers of asbestos products, told an EPA panel in 1984 that since asbestos was present in the air everywhere, the EPA should set standards for levels deemed permissible. "They didn't want to hear it," he says. "No safe level" was the foundation of their arguments.

**First warning.** The saga began in the 1950s when a brilliant, energetic physician named Irving Selikoff documented that workers in mines, shipbuilding and other asbestos-using industries had contracted lung cancer, asbestosis—a disease marked by stiffening of the lung tissues—and a rare lung cancer called mesothelioma. By the 1970s, Selikoff's research was the foundation for lawsuits against asbestos manufacturers. Many were driven out of business. (Others continue to pay. Last October 31, for instance, 10 large asbestos manufacturers settled with 15,000 school districts for \$200 million in damages.)

Selikoff's findings scared school leaders because many walls, floor and ceiling tiles, roofs and insulation materials contained asbestos fibers. If the surfaces were abraded, asbestos could float into the air and be inhaled. Parents feared their kids could get asbestosis.

That fear was misguided: Early studies concluded that asbestosis came only after long-term inhalation of large volumes of asbestos dust, as in dirty factories. A more likely risk to children was lung cancer. But again, early studies had



**Voice of reason.** Prof. Arthur Langer kept trying to warn policy makers they were overreacting.

seen a high coincidence between smoking and asbestos-linked lung cancer. More important, the risk of all these diseases seemed to be tied to the exposure level. How much was too much?

To help local officials, EPA published a "guidance" book in 1979. It had a bright-orange cover and was known thereafter as the Orange Book. But instead of declaring what levels of airborne asbestos were safe or unsafe for children, it issued directions on how to search for asbestos-containing materials. The only "permanent" solution, it said, was to take it out. Four years later, the EPA

issued its Blue Book, which said much the same thing: Removal was "always appropriate, never inappropriate."

Joseph Breen, an EPA official who worked on the Orange Book, recalls, "There was a cry to get something out, and the best available information was what had been done to date." Unfortunately, at the time, little work had been done on the health effects of low levels of asbestos in schoolroom air.

While the Orange and Blue books did not command that asbestos be torn out, their dire admonitions—plus the availability of federal funds for asbestos removal only—pushed schools into many needless removals. An asbestos-remediation industry sprang up overnight; it would gross \$4 billion to \$5 billion annually. Schools would pay up to \$1 billion a year; other building owners paid the rest.

**On second thought.** But by 1985, some notable environmental health scientists were backing off. New data were showing that levels of airborne asbestos in buildings with even flaking insulation could be as low, or nearly as low, as the air outdoors. Asbestos was everywhere: It came from auto-brake pads and building and roofing materials. People breathe in a million fibers a year, and nearly everyone has asbestos in his lungs, scientists would say.

The new thinking was that most asbestos in schools should be left alone; in most cases, painting, spray-coating or covering it up was the best and cheapest

### RISKY BUSINESS

*Many things expose people to a greater threat than exposure to asbestos*

Lifetime probability of premature death (per 100,000)

Being a pedestrian hit by car	290
Tobacco smoke	200
Diagnostic X-ray	75
Bicycling	75
Miami/New Orleans drinking water	7
Lightning	3
Hurricanes	3
Asbestos in school buildings	1

USNAWR - Basic Data: Energy and Environmental Policy  
Center of Harvard University

solution. In a nod to the new thinking, the EPA's 1985 Purple Book placed "managing asbestos" ahead of "removal" on some lists of options. But the shift was subtle, and it was hardly noticed. Opposing interests now had a stake in asbestos removal: They included labor unions who wanted it out of workplaces, parent-teacher groups fearful for children and a mushrooming asbestos-removal industry.

**Powerful convert.** Perhaps most important, Selikoff himself had drifted from the position of being a neutral research scientist to that of an anti-asbestos activist. He told a congressional panel in 1984 that the risk posed by asbestos in schools was intolerable. The subcommittee chairman, then Rep. Jim Florio of New Jersey, shepherded passage of a law called the Asbestos Hazard Emergency Response Act in 1986. Florio says he wanted to end the confusing stream of "guidances," put an end to the sloppy and corrupt asbestos-removal firms and make the EPA write clear rules for schools to follow. The EPA did some of that: It put asbestos inspectors, planners and even haulers under strict regulations. It ordered schools to do inspections and create asbestos-management plans. All that, of course, added millions of dollars to schools' costs. The EPA, however, later argued that Florio had fueled the asbestos alarm. Florio counters that the EPA dragged its feet and never set safety standards.

By 1990, however, a mass of new data showed the true levels of asbestos in schoolroom air around the nation were extremely low. Articles in the *New England Journal of Medicine* and *Science* magazine argued that the asbestos threat had been exaggerated. These caught the attention of John "Joe" Schwarz, a physician and Michigan state senator, who feared the reasons to fear asbestos had been overstated from the beginning. It took three years for him to win passage of a law requiring school districts to keep asbestos-laden materials in place unless unique conditions made removal wiser. Opposition came from the state's trial lawyers, who represented plaintiffs in asbestos cases, parental groups, labor unions and even, surprisingly, schools themselves. "What was particularly pernicious, a bureaucracy had grown up," Schwarz now says. "The schools all had asbestos-

### DON'T TAKE OUR WORD ON IT

*The EPA gave confusing advice over the years about the best way to handle asbestos:*



#### 1979 Orange Book

**"No safe level of exposure has been established. . . . Removal completely eliminates the source of exposure to asbestos and is, therefore, a permanent solution."**

#### 1990 Green Book

**"Based on available data, the average airborne levels in buildings seem to be very low. . . . Removal is often NOT a building owner's best course of action to reduce asbestos exposure."**

maintenance officers, and they had all submitted their [EPA required] plans and were hellbent to rip it out."

Some now regret it. Rick Simonson, the assistant superintendent for Oakland County schools north of Detroit, estimates his district spent nearly \$100 million tearing out 70 percent to 80 percent of the schools' asbestos. He now says they should have done just the reverse—taken out 20 to 30 percent and sealed up the rest. "We spent a ton of money removing that stuff when we didn't need to," he says.

In its 1990 Green Book, the EPA acknowledged that low levels of asbestos in



**Florio.** He wrote tough asbestos legislation.

school and office buildings meant low overall risk. It pointed out that the dust created by improper asbestos removal could actually increase the danger. Still, some schools were not getting the message. In May 1990, for instance, the Downers Grove school district near Chicago prepared to spend the last \$850,000 of a \$5 million asbestos-management project. But this time, it said, the work would be much harder because the asbestos was on pipes sealed inside the walls. That got the attention of then EPA Administrator William Reilly, who ordered the EPA to study how well it had advised the public on asbestos. The result, published in 1992, was a remarkable—and embarrassing—document. It found that the EPA had made matters worse by publishing confusing and shifting guidances.

In the absence of certainty at the federal level, six other states have debated proposals like Michigan's. None has been enacted because of trial lawyers' protests and because of state attorneys general who argue that such a law could affect their own litigation against manufacturers. Eleven states have set permissible asbestos-in-air standards for public buildings; up to nine states include schools. The level is about 10 times more stringent than the one just set by the federal Occupational Safety and Health Administration for industry.

But the EPA still refuses to say what levels are safe for schoolchildren to breathe. The reason? Robert Jordan, an environmental protection specialist at the EPA, says his agency fears that "people could be lulled into complacency" by taking infrequent air samples. If asbestos levels suddenly turned worse, school officials wouldn't know it, he argues.

So asbestos madness continues. For fear of asbestos, in 1993 New York City ripped out tons of plaster from its schools, only to find that just 25 percent of it contained asbestos. How much of that found its way into the air no one knows. With Congress and the EPA now considering regulations for lead and radon exposure, the 1992 EPA report on how it messed up its message on asbestos should be required reading. But that report is virtually impossible to find inside the EPA. Says one in-house expert, "I think it's been buried." ■

BY PETER CARY